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Abstract 
Human pluripotent stem cells (hPSCs) exhibit two unique characteristics: pluripotency and 
self-renewal. These properties are maintained by a series of complex signaling pathways, 
however, quantitative data for the respective proteins is lacking. Selected reaction monitoring 
(SRM) is a targeted, quantitative technique in mass spectrometry that is highly sensitive in 
peptide detection. In this thesis, an SRM protocol was developed in order to detect and 
quantify a defined set of proteins responsible for maintaining stem cell pluripotency. Two 
hESC differentiation protocols were validated for use as model systems within which to 
measure differential protein expression by SRM. SRM assays were generated for thirty-three 
proteins and tested on cell lysates. Wnt1 and β-catenin were shown to be upregulated during 
differentiation, while other proteins and peptides were detected but not quantifiable. The 
results of this study highlight the complexity of hPSC proteome and help further the 
understanding of the mechanisms responsible for pluripotency. 
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1 Introduction 
1.1 Human Pluripotent Stem Cells 
Human pluripotent stem cells (hPSCs), which include human embryonic stem cells 
(hESCs) and induced pluripotent stem cells (iPSCs) possess two unique characteristics. 
They are pluripotent, that is, capable of differentiating into any of the three primary germ 
layers of mesoderm, endoderm, and ectoderm. Secondly, they are capable of self-
renewal, meaning that they can proliferate indefinitely in culture while maintaining their 
pluripotency, provided the proper conditions are maintained.
1
 Because of these 
properties, hPSCs are highly valued as a research tool for modeling in vitro 
differentiation and early human development, as well as showing great promise for use in 
regenerative medicine. In addition, hPSCs could be used as a model system for disease 
and search for treatments. However, the mechanisms responsible for stem cell 
pluripotency and self-renewal are still poorly understood, particularly at the protein level. 
1.1.1 Human Embryonic Stem Cells 
hESCs were first derived by Thomson et al. in 1998 from donated embryos generated 
from in vitro fertilization
2
. The inner cell mass of the pre-implantation blastocyst was 
extracted and plated on a feeder layer of γ-irradiated mouse embryonic fibroblasts 
(MEFs), which release cytokines and growth factors that promote pluripotency, and 
allowed to expand. The derived cells exhibited characteristics such as a high nucleus to 
cytoplasm ratio, high telomerase activity, and cell surface markers characteristic of 
undifferentiated nonhuman ESCs.
3
 In addition, the colonies generated were not clonal 
expansions from a single cell, and were therefore heterogeneous while appearing 
uniform. Upon injection into severe combined immunodeficient (SCID) mice, hESCs 
generated teratomas, exhibiting the ability to generate mesoderm, endoderm and 
ectoderm. Since 1998, according to Fraga et al., more than 1200 hESC lines have been 
derived worldwide. 
4
 
hESCs differ from mouse embryonic stem cells (mESCs) in several different 
characteristics.
5
 While mESCs exhibit three-dimensional tightly packed colonies and a 
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doubling rate of 16 hours, hESCs colonies exhibit a flattened two-dimensional structure 
and a doubling time of about 36 hours.
6
 In addition, while leukemia inhibitory factor 
(LIF) and bone morphogenic protein 4 (BMP4) are required to maintain mESC 
pluripotency, they are not sufficient to maintain hESC pluripotency, and BMP4, in fact, 
directs hESCs towards differentiation. 
7
 Surface marker SSEA1, which signifies 
pluripotency in mESCs, instead marks differentiation in hESCs. hESC cultures are 
technically difficult to maintain, and prone to spontaneous differentiation. hESCs exhibit 
poor survival upon dissociation, and cannot be expanded from the single cell state in the 
absence of Rho-associated kinase (ROCK) inhibitor, and as such, must be passaged in 
small clumps.
8
 Basic fibroblast growth factor (bFGF) has been identified as a required 
factor in stem cell growth media. 
9, 10
 Typically, hESC culture media consists of a basal 
media such as DMEM, a protein source (KnockOut Serum Replacement) and self-
renewal factors such as the aforementioned bFGF.  
Due to the eventual push towards clinical use, there is a trend towards the use of hESC 
culture in defined and xeno-free conditions.
11
 hESCs are frequently maintained in feeder-
free conditions, in which instead of being plated on a MEF feeder layer, hESCs are plated 
on an alternate matrix. These matrices include products such as Matrigel® (BD) and 
Geltrex™ (Life Technologies), which are basement membranes derived from mouse 
Engelbreth-Holm-Swarm tumors. Consisting primarily of laminin, collagen IV and 
enactin, these basement membranes simulate the extracellular environment required to 
support these cells in tissues
12
. However, hPSC growth on these matrices require the use 
of either a defined medium such as mTeSR
™
, or hESC media conditioned on a MEF 
feeder layer in order to supply the growth factors required to maintain pluripotency. 
mTESR
™
 has been shown to maintain pluripotency in multiple hESC lines, including 
expression of factors such as Oct4, SSEA3, and SSEA4.
13
 
1.1.2 Stem Cell Signaling/Important Pathways 
Sox2, Oct4 and Nanog are transcription factors that are part of the core machinery of 
pluripotency in hESCs. 
14, 15
 These transcription factors both activate and repress target 
genes in vivo.
16
 Although Oct4 is a pluripotency factor, different expression levels in the 
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presence of BMP4 can direct differentiation towards mesoderm or endoderm
17
. Nanog 
has been shown to repress endoderm differentiation. All three factors have been shown to 
be regulated by phosphorylation.
18
 However, the network of proteins that control stem 
cell pluripotency and cell fate is markedly more complex, as seen in Figure 1.  
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Figure 1. Stem cell signaling pathways. Notch, Hedgehog, Wnt, and Activin/Nodal 
signaling pathways are among those that play a role in maintaining pluripotency and stem 
cell fate. Transcriptional targets and crosstalk between proteins connect these pathways in 
a complex network that is still being elucidated. Figure adapted from Novus Biologicals. 
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In addition to the core machinery of transcription factors, the canonical Wnt, 
Nodal/Activin, Hedgehog, and Notch signaling pathways all play a role in maintaining 
the balance of stem cell pluripotency, with cross-talk between pathways further 
complicating characterization.
19
 
The Wnt signaling pathway includes such proteins as Wnt1, Wnt2, Wnt3A, Wnt5A, 
Cerberus, WIF1, Frizzled, DKK1, Axin1, β-Catenin, APC, GSK3β, DVL1, Akt1, SFRP1, 
SFRP2 and FRAT1. Wnts are secreted developmental proteins that bind to Frizzled 
transmembrane receptors.
20
 They are highly conserved across species and involved in 
embryogenesis patterning. When canonical Wnt signaling is inactive, the β-catenin 
destruction complex forms, resulting in the phosphorylation, ubiquitination and 
degradation of β-catenin. In the presence of Wnt signaling, the β-catenin destruction 
complex is disrupted, and β-catenin levels are allowed to accumulate. β-catenin 
translocates to the nucleus and acts as a co-activator for TCF/LEF transcription factors, 
activating the transcription of Wnt responsive genes such as Myc and DKK1. 
The β-catenin destruction complex is made up of GSK3β, APC, Axin-1, PP2A, and CK1. 
GSK3β is a serine threonine protein kinase that is constitutively active.  APC is a large 
tumor suppressor protein that is part of the β-catenin destruction complex. It also plays a 
role in cell migration, adhesion, transcriptional activation and apoptosis. SFRP1, SFRP2, 
and WIF-1 are Wnt inhibitors, previously identified to be secreted by hESCs.
21
 DVL1 
and FRAT-1 are positive regulators of Wnt signaling that inhibit GSK3B phosphorylation 
of β-catenin. Akt1 is a serine-threonine protein kinase that suppresses apoptosis by 
phosphorylation. It inhibits GSK3B to increase cell proliferation. 
P53 is a tumor suppressor protein that plays many roles within cells, including acting as a 
cell cycle regulator and a role in cell division, differentiation or apoptosis.
22, 23
 It can 
promote differentiation by suppressing Nanog.
24
 CDKI1 aka p21 is a cyclin dependent 
kinase inhibitor controlled by P53 involved in regulation of the cell cycle at G1. 
NOTCH signaling plays a key role in cell fate, affecting implementation of 
differentiation, proliferation, and apoptosis.
25
  NOTCH is a transmembrane protein 
receptor for Jagged/Delta.  Upon interaction, NOTCH is cleaved, and the intracellular 
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domain of the protein translocates to the nucleus and promotes transcription of 
downstream factors. Hes1 and Hey1 are transcription factors downstream of Notch 
signaling. Hes1 plays a role in cell proliferation and differentiation.
26
  Hey1 plays a role 
in neuronal and cardiac differentiation. 
Activin/Nodal signaling has been shown to be vital for maintenance of pluripotency. 
27
 
Activin/Nodal signaling is required to maintain Nanog expression.
28
 Nodal is a secreted 
protein that is responsible for formation of mesoderm and axial structures in the early 
embryo. It is not expressed in adult cells, except in certain cancers.
29
 Lefty-1 is a member 
of the TGFβ family; it acts as an inhibitor of Nodal. Activin-A is a secreted homodimer 
that plays a role in cell fate and embryogenesis patterning. TDGF/Cripto-1 is a co-
receptor for Nodal, also required for self-renewal and pluripotency.
30, 31
  Cerberus is a 
secreted protein that acts as an inhibitor of the Wnt and Nodal pathways.
32
 
Sonic hedgehog (SHH) signaling  is involved in cell proliferation and  early embryo 
patterning, and plays a role in hPSC differentiation.
33
 Patched is a receptor for Sonic 
hedgehog that associates with and suppresses the activity of the protein Smoothened. 
Smoothened is a G-protein coupled receptor in tandem with Patched. SHH binding with 
Patched stops inhibition of Smoothened. GLI3 is a transcription factor that activates 
Patched expression during embryogenesis. It acts as both an activator and repressor of the 
Hedgehog signaling pathway. SUFU functions in concert with Sox2 and Oct4 in the 
Hedgehog pathway. It serves as a negative regulator of Sonic Hedgehog and β-catenin, 
and sequesters GLI3. 
Though these signaling pathways have been summarized, quantitative data at the protein 
level is lacking. The crosstalk and effect of each pathway is largely affected by protein 
expression levels, and many of these proteins are present at low abundance, resulting in 
difficult detection by methods such as mass spectrometry. Nodal, Cripto and Lefty have 
been shown to be highly expressed components of TGFβ signaling that support the 
pluripotent state
34
. Small changes in Activin/Nodal signaling have also been shown to 
direct cell fate towards cardiac differentiation
35
. Singh et al. have shown that Akt 
activation is important to hESC self-renewal through suppression of the canonical Wnt 
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signaling pathway
36
. Upon activation and dimerization through Nodal or Activin 
signaling, Smad2/3 has been shown to maintain the pluripotent state by regulation of 
Nanog expression, but its activity can be affected by the crosstalk between PI3K/Akt, 
Raf/Mek/Erk, Wnt and GSK3B signaling.
36
 In the absence of PI3K/Akt signaling, Wnt 
signaling is no longer suppressed and β-catenin can direct Smad2/3 to activate genes 
promoting differentiation, such as the mesendoderm marker MixL1. β-Catenin and Wnt 
signaling has been shown to be both antagonistic and key to maintenance of pluripotency, 
whereby large amounts of Wnt signaling results in high β-catenin expression promoting 
differentiation, though a basal level of β-catenin is necessary to sustain pluripotency.37 
1.1.3 Induced Pluripotent Stem Cells 
While hESCs proved to be a valuable tool, the requirement of human embryos in order to 
generate new cell lines has led to ethical questions and practical concerns that place limits 
on embryonic stem cell research. In 2006, the Yamanaka group identified four factors 
that enabled the reprogramming of fully differentiated somatic cells into the pluripotent 
state.
38
 By introducing the factors Sox2, Klf4, Oct4 and c-Myc via retroviral transduction, 
MEFs began to exhibit stem-cell like morphology and markers. In addition, injection into 
nude mice resulted in generation of tissues. These derived cells were named induced 
pluripotent stem cells (iPSCs). One year later, the first human iPSCs were generated 
using the same four factors, dubbed the “Yamanaka Factors”.39 For this research, Shinya 
Yamanaka was jointly awarded the 2012 Nobel Prize for Physiology or Medicine with 
John Gurdon for discovering that mature cells can be reprogrammed to pluripotency. 
Concurrently, the Thomson group also developed a method to generate iPSC lines using 
Oct4, Sox2, Nanog and Lin28 as their reprogramming factors.
40
 In addition to avoiding 
the need for destruction of human embryos to obtain new pluripotent cell lines, iPSCs 
present other research opportunities. The possibility of generating patient or disease 
specific cell lines could lead to more clinical relevance, and generating more genetically 
diverse lines would prove to be far simpler.
41, 42
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1.1.4 Variation among cell lines 
Due to the variation inherent in the process of hPSC derivation and the overall 
inefficiency in iPSC reprogramming, it is important that cell lines be well 
characterized.
43, 44
 Many studies have looked at characterization of cell lines, at 
transcriptional, epigenetic and proteomic levels. Bock et al. characterized 20 hESC and 
12 IPSC lines by DNA methylation and gene expression, finding that variation between 
cell lines can affect differentiation potential
45
. By characterizing gene expression or 
methylation sites that deviated from the reference distribution, the group was able to 
develop a score card predicting a cell line’s ability to differentiate into particular lineages. 
Similarly, a test set of iPSCs derived from different individuals was found to have 
differing capacities for neural differentiation
46
. Another study found that iPSCs and 
hESCs expressed highly similar proteomes, but some metabolic, antigen processing, and 
cell adhesion proteins were found to be differentially expressed.
47
 
Before any therapeutic use for hPSCs is developed, we must better understand the 
microenvironment surrounding them, as well as their individual properties and capacity 
for differentiation. Though hPSCs are pluripotent and able to differentiate into any cell in 
the body, harnessing that ability requires a profound understanding of the signaling 
pathways at play. For instance, treatment of hPSCs with BMP4 will lead to 
differentiation; however, time of exposure affects the type of differentiation that will 
occur. Short-term exposure to BMP4 promotes mesoderm progenitor development, but 
this also requires FGF and Nodal/Activin signaling.
48
 If that BMP4 signal is not 
inhibited, a feedback loop forms instead promoting the formation of trophoblast and 
extraembryonic endoderm.
49-51
 In contrast, Seguin et al. have developed a CA1 cell line 
expressing a Sox17/ERT2 transgene that, when induced with tamoxifen, will promote 
differentiation towards a stable definitive endoderm precursor state that maintains 
expression of pluripotency markers Oct4 and Nanog.
52, 53
 Differentiation protocols such 
as these would be aided by a tool that could elucidate subtle changes in protein 
expression that are occurring. 
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1.2 Mass Spectrometry 
Mass spectrometry (MS) is a method of determining quantity, structure and composition 
of compounds by measuring the mass-to-charge ratio (m/z) of ions. Mass spectrometers 
consist of three main parts: an ionization source, a mass analyzer, and a detector. The 
ionization source ionizes the analyte.  Two “soft” methods of ionization are commonly 
used in proteomic analysis, matrix-assisted laser desorption/ionisation (MALDI) and 
electrospray ionization (ESI). MALDI involves sample spotted on a plate and crystallized 
in a matrix, and ionized using a laser. Typically, this results in singly charged ions with a 
mass of [M+H]. Proteins can be identified by a technique known as Peptide Mass 
Fingerprinting (PMF), in which peptides generated from an enzymatic, typically trypsin, 
digest are detected and compared to a database. In the case of ESI, the analyte is sprayed 
out of an electrically charged tip in droplets, which are desolvated and sent into the mass 
analyzer. Compared to MALDI, ESI typically results in multiply charged ions, usually 
doubly or triply charged in the case of peptides. One particular benefit of ESI is that it 
can be easily integrated (i.e. on-line) with High Performance Liquid Chromatography 
(HPLC), allowing for chromatographic separation and more effective analysis of protein 
samples, as well as easier automation of protocols. The mass analyzer separates ions 
according to their m/z ratio, and the abundance of ions is measured by the detector. There 
are many types of mass analyzers, including Time-Of-Flight (TOF), Quadrupole (Q), Ion 
Trap (IT), and Orbitrap. Multiple mass analyzers can be combined to form a hybrid 
instrument that allows for tandem mass spectrometry (MS/MS). MS/MS allows for 
sequence data to be obtained from peptides by introducing a fragmentation step between 
multiple levels of MS scans. The fragmentation produces m/z peaks in the MS/MS scan 
that correspond to the difference in amino acid residues, from which the peptide sequence 
can be obtained. The data obtained is commonly analyzed using bioinformatics software, 
including search databases such as MASCOT and OMSSA, which use predictive 
algorithms to match MS data against a protein database in order to identify proteins in the 
sample.
54, 55
 PEAKS is a de novo sequencing and database searching suite, with the 
unique feature of being able to combine searches from different tools.
56
 It relies heavily 
on mass accuracy, resolution, and spectral quality. The Trans-Proteomic Pipeline 
provides a number of tools for working with MS/MS data, including the ability to convert 
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vendor specific files to the open mzXML or mzML format, as well as validation, 
identification and quantification analysis of the data set.
57, 58
 Despite the power of LC –
MS/MS, it has several shortcomings. Sequencing speed limits the amount of peptides that 
can be identified in each run, and sample complexity may cause abundant peptides to 
mask detection of less abundant peptides. 
1.2.1 Selected Reaction Monitoring 
Selected reaction monitoring (SRM) is a targeted, quantitative technique used in mass 
spectrometry, possible only on triple quadrupole mass spectrometers, such as the 4000 
QTRAP
®
  (AB SCIEX, Framingham, MA).
59
 Also known as multiple reaction 
monitoring (MRM), SRM has been used in drug identification and analysis of 
metabolites, and is increasingly being used in proteomics. 
60, 61
 It involves the use of 
peptide precursor and fragment ion pairs known as “transitions” to identify peptides and 
thus proteins. By monitoring multiple transitions per peptide and multiple peptides per 
protein, SRM can serve to identify proteins with a great deal of specificity and selectivity.  
Indeed, the technique is able to obtain quantitative data over a range of five levels of 
magnitude, with a limit of detection between 10-50 attomoles under optimal conditions, 
as opposed to low femtomole levels for other instruments.
61, 62
 A schematic of the 
mechanism of SRM can be seen in Figure 2. The first quadrupole is set to filter for the 
precursor peptide ion at a defined m/z, while the second quadrupole serves as a collision 
cell where collision induced dissociation (CID) occurs. The third quadrupole is set to 
filter for the fragment ion generated at a defined m/z. The chromatograph of each 
transition, including retention time and signal intensity is recorded. At its simplest, SRM 
can be considered a double filter method, capable of focusing on the analyte of interest, 
cutting through a more complex sample.
63
 It differs from other mass spectrometry 
techniques in that it is a targeted rather than a scanning technique. Whereas other MS 
techniques perform survey scans, selecting the top N most abundant ions for MS/MS, 
SRM detects solely the ions corresponding to the list of transitions input into the method. 
No full MS spectrum is taken. As a result, it scans for only the targets listed, and is 
typically used in a hypothesis-driven approach where only certain defined peptides and 
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proteins are monitored. Post-translational modifications that may change the m/z ratio of 
the transitions will not be detected unless specifically accounted for. 
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Figure 2.  Schematic of SRM. A tryptic digest of protein sample is loaded and subjected 
to reverse-phase chromatography on a coupled HPLC system and ionized via 
electrospray ionization. The instrument scans for and detects peptide transitions based on 
a preloaded list of transitions. Precursor masses are selected in Q1, collision-induced 
dissociation occurs in Q2, while Q3 selects for the fragment mass. Intensity and retention 
time are recorded by the software. Figure adapted from Gstaiger and Aebersold, 2009.
64
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A proper SRM assay relies heavily upon reproducible chromatography. Numerous factors 
can affect the quality of chromatography, including changes in mobile phase, flow 
restriction, and the column temperature. Well-defined chromatographic peaks require a 
minimum of eight data points collected over the elution time. Effectiveness of an SRM 
assay therefore relies heavily upon the optimization of several factors. The dwell time 
refers to the time the instrument spends scanning for the individual transition, and as 
such, a higher dwell time correlates with a higher sensitivity. The cycle time refers to the 
time spent cycling through the entire list of transitions. If a given peptide has a 
chromatographic peak width of thirty seconds, in order to properly detect that peak, cycle 
time is limited to about 3.75 seconds in order to gather enough data points for a 
quantifiable peak. Thus, the maximum number of transitions that can be scanned at any 
given time are limited by both the cycle time and the dwell time.
65
 Rather than cycle 
through the preset list of transitions throughout the entire sample run, a scheduled method 
may also be used. In a scheduled SRM method, each transition is associated with a 
predicted LC elution time, and as such is only scanned for in a pre-specified window 
around that time point. By doing this, transitions being scanned for concurrently are 
decreased, dwell time and thus sensitivity can increase, and more total transitions can be 
included in a single method, making more efficient use of instrument time. However, 
total number of transitions is also limited by the instrument itself. For the 4000 QTRAP
®
, 
a maximum of 1000 transitions can be included within a single scheduled method. 
Retention times can be predicted using software, or preferentially acquired manually 
through use of synthetic peptide standards.
66
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Figure 3.  Potential fragment ions generated from peptide fragmentation.  a,b,c ions 
refer to N-terminal fragments, while x,y,z refer to C-terminal fragments. In Collision 
Induced Dissociation (CID), b and y ions are typically observed. 
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When selecting peptide targets for SRM assays, several key criteria are necessary.
60
  
Most importantly, peptides should be “proteotypic,” that is, both specific to the protein 
target and confidently and consistently identified by mass spectrometry. These peptides 
should reproducibly be obtained from the protease digest. Peptides should be kept to a 
residue length of between eight and twenty-five amino acids, and residues prone to 
oxidation such as methionine and tryptophan should be avoided. Doubly-charged 
precursors are preferred, unless there is a histidine present in the peptide sequence, 
making a triply-charged precursor more likely. CID usually results in peptides 
fragmenting at the peptide bond, generating y and b ions, as seen in Figure 3. Online 
repositories such as the Global Proteome Machine Database (GPMDB) and SRMAtlas 
contain libraries of both experimentally-derived and predicted transitions for peptides, 
serving as a helpful resource.
67, 68
 However, due to the variation between instruments, it is 
best to select SRM targets based on own empirical data. In addition, many peptide 
fragmentation spectra deposited are for ion-trap instruments, which may differ from triple 
quadrupole fragmentation. Pure in silico predictions for protein and peptide targets may 
not be appropriate for SRM assays, as the given protein or peptide may not properly 
solubilize, ionize, or even be present after a tryptic digestion. Stergachis et al. developed 
a method where optimal proteotypic peptides are discovered through digestion of full-
length proteins generated in vitro by cDNA clones
69
. This method could prove beneficial 
for generating assays for proteins present at low abundance that have not been observed 
via shotgun proteomics. 
There are a variety of online tools that can be used in developing SRM assays, as 
reviewed by Cham et al.
70
 Skyline is a publicly available program developed by the 
MacCoss lab of the University of Washington capable of generating, visualizing, and 
optimizing SRM protocols.
71
 Transitions can be selected from spectral libraries obtained 
from sources such as Peptide Atlas, the Global Proteome Machine (GPM), and the 
National Institute of Standards and Technology (NIST), or from MS/MS data generated 
from the protein of interest. Methods can be refined by importing previously acquired 
SRM data and optimizing for collision energy. Collision energy optimization has been 
shown to significantly increase SRM signal.
72
 SRM data such as retention time and peak 
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areas can also be exported for downstream analysis. Though SRM is limited to detecting 
the pre-selected transitions rather than discovering novel results and requires extensive 
optimization, it remains a powerful tool in hypothesis-driven research.  
Because of the targeted nature of SRM and being a method of protein detection and 
quantification that does not require antibodies, proteomic studies using SRM are 
becoming more commonplace, in particular within yeast cells, mammalian cells, and 
human body fluids.
73
  In 2009, Picotti et al. were able to characterize the full dynamic 
range of the proteome of S. cerevisiae using SRM, to the point of detecting proteins as 
low as 50 copies per cell.
74
 Within an unfractionated yeast digest they were able to 
characterize a range of proteins covering 4.5 orders of magnitude. In addition, they were 
able to detect proteins that were previously unobserved in other proteomics experiments. 
In 2010, SRM was used by Murphy et al. to identify glycolytic proteins in cancer cells.
75
 
In 2010, Lopez et al. used SRM to verify putative protein biomarkers for Trisomy 21 in 
serum.
76
 Lange et al. identified a set of virulence factors from Streptococcus pyogenes 
via SRM.
77
 
Chen et al. used SRM to screen for members of the Wnt/ β-Catenin pathway in colon 
tissue samples and colon cancer cell lines, as the pathway is disregulated in this cancer.
78
 
Compared to results from Western blotting, differences in protein expression were easier 
to discern using SRM, with certain proteins, such as β-catenin, being capable of being 
detected in as few as 100 cells. 
Apart from detection, SRM can also be used as a quantification tool. In order to estimate 
protein abundance in the microbe Leptospira interrogans, SRM was used.
79
 Under what 
is known as the “best flyer” hypothesis, the most intense tryptic peptides for a protein 
should be constant throughout a whole proteome. As such, anchor point proteins were 
identified to generate a calibration curve. In an unfractionated, unlabeled sample, protein 
abundance changes were found for 39 proteins upon treatment with antibiotics. Bisson et 
al. combined SRM with affinity purification in order to characterize the signaling 
pathway surrounding the GRB2 adaptor protein within HEK293T cells.
80
 Upon 
identifying GRB2-interacting proteins, SRM assays were generated. 90 of 108 GRB2-
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associated proteins were detected by SRM. These SRM assays were later used to identify 
which proteins preferentially bound GRB2 SH2 or SH3 domains under various stimuli, 
thus greatly increasing the knowledge of the signaling dynamics surrounding the GRB2 
adaptor. An SRM-based study was also performed quantifying the temporal 
phosphorylation profiles of the EGFR signaling network, taking advantage of SRM’s 
reproducibility.
81
 Due to its sensitivity and selectivity, SRM can be used in a wide variety 
of studies, and it would be particularly useful in characterizing a targeted list of signaling 
proteins within a complex background, such as a cell lysate.  
1.2.2 Parallel Reaction Monitoring 
An technique analogous to SRM known as parallel reaction monitoring (PRM), or 
targeted MS/MS, has recently been described for the high-resolution/high mass accuracy 
instrument the Q Exactive™ (Thermo). In place of the third quadrupole, an orbitrap mass 
analyzer is used.
82
 Similar to SRM, pre-input targets are listed in the method, however, 
the orbitrap is capable of detecting all MS/MS fragments at once, thus eliminating the 
time consuming step of transition optimization. The Domon group was able to detect and 
quantify 770 yeast peptides in a single 60-minute experiment using this technique. 
83
 
Using a synthetic peptide cocktail, the Coon group has shown that PRM provides 
comparable or, at times, better than SRM.
84
 Though SRM is theoretically more sensitive 
than PRM due to a faster scan speed, the ability of PRM to obtain high-resolution data 
eliminates the chance of interfering ions confounding target detection.
85
 
1.2.3 Quantitative Proteomics 
The ultimate goal of SRM is quantitation. Although label-free quantification methods are 
widely used, reproducibility can be a concern, and without some sort of reference, 
comparison across sample acquisitions can be difficult.
86
 Methods such as stable isotope 
labeling in with amino acids in cell culture (SILAC) and isobaric tag for relative and 
absolute quantitation (iTRAQ) are commonly used; however, these methods are 
examples of relative quantitation.
87-89
  Each method has both advantages and 
disadvantages. An advantage of SILAC is that the label is incorporated upon protein 
synthesis, thus minimizing error further downstream in the workflow. However, it can 
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only be incorporated at the cellular level, it is expensive, and a great deal of optimization 
must take place in order to ensure 100% label incorporation.  Methods such as iTRAQ 
are incorporated at the peptide level after a proteolytic digestion, and can allow for 
analysis of up to eight samples simultaneously.
89
  
 In order to achieve absolute quantitation, a known standard must be used.  The  absolute 
quantitation, or AQUA method involves synthesizing an isotopically labeled version of 
the target peptide, and spiking a known amount into the sample.
90
 Typically the label is 
13
C or 
15
N, as these labels do not result in a shift in chromatographic retention time, 
unlike deuterium and 
18
O containing compounds. Because of this, the synthetic peptide 
mimics the endogenous peptide in both retention time and fragmentation pattern, but 
differs in mass. The absolute amount of the target peptide can be obtained from the 
relative intensity of light to heavy transitions.  The Gygi group confirmed the use of this 
method by quantifying a K-48 polyubiqitinated peptide. Using this method, the copy 
number per cell can be determined. Though effective, the synthesis of isotopically labeled 
peptides can become expensive if high amounts are required. 
Alternately, there has been success using dimethyl labeling as a method of relative 
quantitation, as outlined in Figure 4.
91
 Key advantages of this method are its ability to be 
incorporated post-digest, thus being compatible with all protein samples, its quick 
reaction time, and that it is inexpensive compared to other labeling techniques. A 
disadvantage is a slight shift in retention time compared to unlabeled peptides. Samples 
are treated with formaldehyde and sodium cyanoborohydride which introduces a 
dimethyl label to primary amines in a peptide, typically at the N- terminus and on the 
lysine side-chain. Using different isotopes of formaldehyde and sodium 
cyanoborohydride resulting in labels of varying masses, typically allowing for a light 
(+28 Da), medium (+32 Da), and heavy (+36 Da) label. By mixing these in a 1:1 ratio, up 
to three samples could be analyzed in a single mass spectrometry experiment.
92
 Using 
this method, the Pinto lab was able to characterize the glycolytic proteome in MCF-7 
breast cancer cells.
75
 SRM assays specific to dimethyl-labeled targets were used to 
monitor changes in protein expression in both insulin-growth factor-1 stimulated MCF-7 
cells, as well as across lung tumors of different levels of differentiation. 
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Figure 4. Dimethyl labeling of peptides. After tryptic digestion, peptides are treated 
with formaldehyde followed by incubation with sodium cyanoborohydride, introducing a 
dimethyl label to all primary amine groups present. Different isotopes of formaldehyde 
and sodium cyanoborohydride alter the size of the mass label introduced. 
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1.3 Proteomics and Stem Cells 
The proteome is the full protein complement of a cell under a set of given conditions. 
Many studies investigating the transcriptome of hPSCs have been performed; however, 
protein expression is not always directly correlated to the level of transcript, due to post-
transcriptional levels of regulation such as mRNA stability, protein degradation, protein 
processing, alternative splicing, and rates of translation.
93
 Since proteins are the effectors 
of cellular processes, monitoring protein expression in addition to transcript is also 
important. A major advantage of the proteomic approach is the ability to identify and 
study many proteins with relatively little sample. Proteomic studies are frequently 
performed using a “bottom-up” or “shotgun” approach, in which proteins are 
enzymatically degraded to peptides, commonly using trypsin, and then analyzed by mass 
spectrometry. Alternately, “top-down” proteomics involves the study of whole intact 
protein mixtures by mass spectrometry. Due to the complexity of sample, there are 
usually additional fractionation techniques ahead of LC-MS, including strong cation 
exchange (SCX) or 1-D SDS-PAGE.
94
 SCX fractionation followed by reverse-phase LC-
MS is known as Multi-Dimensional Protein Identification Technology (MuDPIT).
95
 
Increasing the number of fractions often results in more protein identifications, however, 
it significantly increases instrument time. Using multiple fractionation techniques is 
complementary, and often results in increased protein coverage. Indeed, additional 
fractionation has been shown to be more effective than repeated analyses in terms of total 
number of proteins identified. 
94, 96, 97
 Ultra-long LC gradients have also been shown to 
increase identifications.  Kocher et al. demonstrated the ability to detect 2761 proteins 
from an unfractionated HeLa cell lysate over the course of a single-run 10 hour 
gradient.
98
 Longer gradient and column lengths generally increase peptide identification, 
but they generally reach a point of diminishing returns.
99
 
Due to the complex nature of regulation and wide variety of proteins involved, proteomic 
studies of hPSCs have become increasingly common. Many levels of regulation are 
present, so studies targeting the hESC membrane, the extracellular matrix and secreted 
proteins have been conducted. The regulatory pathways and growth factors that govern 
hESC self-renewal and pluripotency are poorly defined, so Bendall et al. used a mass 
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spectrometry technique known as iterative exclusion in order to analyze MEF and hESC 
conditioned media.
100
 Iterative exclusion involves injecting the same sample numerous 
times, but including all previous identifications on an exclusion list, thus making it more 
likely that low abundance proteins are identified on later injections. A large number of 
previously undetected secreted growth factors were identified, including Activin A, 
Lefty, and TGFβ, using this method.  
Phosphorylation pathways have been shown to be important in hESC maintenance and 
critical in cell signaling.
101
 Van Hoof et al. determined that the pluripotency-associated 
protein SOX2 becomes SUMOylated due to phosphorylation, suggesting that 
phosphorylation may play a role in regulation.
18
 Rigbolt et al. conducted a temporal study 
characterizing the hESC phosphoproteome during differentiation.
102
 Two methods of 
differentiation were used, treatment with phorbol 12-myristate 13 acetate (PMA) and 
culture in non-MEF-conditioned medium, in order to control for events specific to the 
treatment and those caused by cell differentiation.  Using a combined quantitative 
proteomic and phosphoproteomic approach involving SCX, SILAC, and titanium dioxide 
phosphopeptide enrichment, 6521 proteins and 23 522 phosphorylation sites were 
profiled. It was found that numerous kinases, DNA methyltransferases and transcription 
factors relating to differentiation were regulated by phosphorylation, notably the 
transcriptional elongation complex PAF1, which binds to promoters of genes encoding 
Oct4 and Nanog. Given the complexity of the network of factors promoting pluripotency, 
a proteomics approach may be the best way to understand the interactions taking place. 
Few hPSC studies involving SRM have been conducted. Yocum et al. used SRM to 
verify and quantify early markers of neural differentiation such as collapsin response 
mediator proteins 2 and 4 within hESCs grown in feeder-free conditions.
103
 Protein 
markers such as cytokeratin-8 identified in earlier global experiments as well as proteins 
of significance such as Oct4 had SRM assays generated. Eight target proteins and 25 
peptides were detected, though many targets that had not been detected in global 
experiments were also left undetected in SRM analysis, suggesting that the target 
selection and validation for SRM are highly important. This study also indicated that 
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SRM is a sensitive technique for detection of target proteins within hESCs. That 
sensitivity could be applied to obtain quantitative data for such targets. 
1.4 Thesis Objectives and Rationale 
Because of the complexity of the networks and mechanisms responsible for hPSC 
pluripotency, it would be beneficial to develop a targeted method capable of detecting 
and quantifying a defined set of stem cell signaling proteins simultaneously. 
Transcriptome studies have been performed, RNA transcript does not directly correspond 
to protein expression, therefore it is important to analyze the proteome as well. Many of 
these proteins have not been detected or quantified by conventional MS analysis. The 
dynamic range and sensitivity of SRM might be able to overcome the sensitivity or 
detection issues responsible for this. 
 In this thesis, an SRM protocol is developed with the intent of detecting and quantifying 
the proteins and cell signaling factors responsible for maintenance of stem cell 
pluripotency. This will provide a method capable of characterizing the “protein 
fingerprint” of stem cell cultures, and serve as a starting point to analyze changes in 
protein expression upon differentiation. We hypothesize this SRM protocol will provide 
quantitative information on the expression of a curated set of pluripotency-related 
proteins upon differentiation. 
 
The objectives of this thesis are as follows. Firstly, two cell differentiation models within 
which protein expression changes could be analyzed were characterized. These systems 
included a BMP4-driven differentiation of H9 hESCs and a tamoxifen-induced 
differentiation of CA1 Sox17/ER
T2 
hESCs towards definitive endoderm precursors. 
Secondly, SRM assays for proteins primarily from the NOTCH, Hedgehog, Wnt, and 
Activin/Nodal signaling pathways were developed. Finally, quantitative protein 
expression data was obtained through use of a consolidated scheduled SRM protocol for 
analysis of differentiated and undifferentiated stem cell lysates. 
By obtaining quantitative data in order to characterize the stem cell signaling networks 
responsible for promoting pluripotency and the exit from pluripotency, this research will 
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help improve understanding of the signaling networks and, in turn, the development of 
defined media for optimal cell culture conditions, more effective conditions for cell-
differentiation protocols, leading to more effective stem cell research. 
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2 Methods 
2.1 SRM Assay Development  
Thirty-three initial protein targets were selected through a literature search, including 
members of the canonical Wnt signaling pathway, the Activin/Nodal signaling pathway, 
Hedgehog signaling pathway, and Notch signaling pathway. Protein sequences were 
obtained from Uniprot and loaded into the SRM assay development software Skyline. 
Proteins were digested in silico with trypsin, cleaving at arginine and lysine. Human 
spectral libraries from GPMDB and NIST were loaded into Skyline. Peptides predicted to 
be proteotypic were selected through use of several online applications, and through use 
of criteria outlined by Lange et al.
60
 Briefly, peptides selected had no missed cleavages, 
were 8-25 residues in length, were neither extremely hydrophilic or hydrophobic, and 
lacked residues susceptible to oxidation like tryptophan and methionine. When 
unavoidable, methionine oxidation was taken into account in transition mass. 
PeptideCutter was used to predict efficiency of tryptic digestion, while the GPMDB was 
used to identify whether target peptides were previously observed. Finally, target peptide 
sequences were submitted to Protein BLAST by NCBI to confirm specificity for the 
target protein.  
2.2 Peptide Synthesis 
Peptides were synthesized in-house on the MultiPepRS peptide synthesizer (Intavis) at 
the 5-µmol level using the FMOC protocol on WANG Resin. Offline, arginine or lysine 
residues were coupled to the resin before being used on the synthesizer. 
Wang resin was suspended in a peptide synthesis vessel in dichloromethane (DCM), and 
washed three times with DCM. The amino acid to be coupled was dissolved in DCM with 
2,6-dichlorobenzoyl chloride and pyridine base, and allowed to mix for five minutes. The 
activated amino acid solution was added to the peptide synthesis vessel and was allowed 
to react with the resin for 4-6 hours, or overnight. Following coupling, resin was washed 
six times with DCM. Resin coupling was quantitated using UV-Vis spectroscopy, if 
substitution was less than desired (<0.3mmol/g), amino acid coupling was repeated. 
Resin was capped with acetic anhydride/disisopropylethylamine solution in DCM to 
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deactivate hydroxyl groups on the resin. Resin was washed six times with DCM and 
stored in a vacuum desiccator until use. After synthesis was complete, peptides were 
dried and cleaved from resin with cleavage cocktail (95% trifluoroacetic acid, 2.5% 
ddH2O, 2.5% triisopropylsilane) and precipitated by dropwise addition to cold diethyl 
ether. Precipitated peptides were pelleted, solublized in 10%  glacial acetic acid (GAA) in 
ddH2O, and lyophilized. Lyophilized crude peptide was stored at -80°C. 1 nmol/mL stock 
solutions of each peptide were made. Serial dilution was performed to create working 
solutions of 100 fmol/µL. Peptide cocktails were injected into the 4000 QTRAP
®
 to 
obtain MS/MS spectra. Briefly, an SRM-triggered DDA protocol was developed for each 
peptide, to obtain both SRM transition and MS/MS sequence data, confirming peptide 
identity. Y and b fragment ions were targeted for the doubly and triply charged 
precursors of each target peptide. The top five transitions for each peptide were pooled 
into a general SRM protocol for use on cell lysates to confirm endogenous detection.  
2.3 Cell Culture 
Unless otherwise stated, all cell culture reagents were obtained from Life Technologies. 
Human embryonic stem cell lines H9 (WiCell) and CA1 were obtained from Dr. Cheryle 
Seguin of The University of Western Ontario.
2, 43, 52
 hESCs were cultured and propagated 
on gamma-irradiated MEFs (CF-1 (GlobalStem), 0.5 M per 6 well plate, or 4DR), and fed 
daily with hESC media (DMEM/F12, 20% KOSR, 1% NEAA, L-Glutamine, β-
mercaptoethanol (Fisher), and 4 ng/mL bFGF). 0.5M MEFs were plated on 6-well culture 
plates coated with a 0.1% solution of gelatin. Cultures were incubated at 37°C and 5% 
CO2. To prevent differentiation, at confluency, cells were passaged either mechanically 
or using trypsin. Mechanical passaging was performed using a Pasteur pipette that was 
heated and pulled into a picking tool. This pick was used to separate cell colonies into 
small clumps, which were later plated on a new cell culture plate. For enzymatic 
passaging, cells were washed twice with PBS, and treated with 0.5 mL 0.25% trypsin per 
well for 2-3 minutes. Colonies were broken up with vigorous pipetting, collected, and 
trypsin was deactivated with 1.5 mL hESC media. Colonies were passaged onto a fresh 
culture plate. 
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Excess cells were suspended in cryopreservation media (50% hESC media, 45% KOSR, 
5% DMSO) and stored in liquid nitrogen for future use. Fresh cultures were started by 
thawing a vial of previously frozen hESCs obtained from liquid nitrogen storage. Vials 
were thawed in a 37°C water bath until a single ice crystal remained. Vials were 
disinfected with 70% ethanol. Thawed cells were diluted in 4 ml of hESC media and 
plated into one well of a 6-well plate containing a MEF feeder layer. Media was changed 
daily. Upon colony formation (up to two weeks), cells were passaged and expanded. 
Before experiments, cells were passaged and cultured on the feeder-free basement 
membrane Geltrex
®
. 6-well plates were coated with 30 µL/mL Geltrex
®
 solution, and 
stored at 37°C for at least 1 hour for polymerization to occur. Control cells were fed with 
MEF-conditioned hESC media. To create MEF-CM, hESC media was conditioned on 
MEFs for 48 hours, collected, filtered and aliquoted into 36 mL fractions and frozen at -
20°C until needed for cell culture. Fresh hESC media was added to frozen aliquots to 
create a 70/30 hESC/MEF-CM media mixture which was used for feeder-free cell 
culture.  Differentiation media was identical to hESC media, except lacking bFGF and 
instead containing either 0.1nM 4-OHT or 10 ng/mL rhBMP4 (R&D Systems). CA1 
Sox17-ERT2 Clone K cell media was also supplemented with 0.6 ug/mL puromycin.  
Cells were differentiated for 96 hours. 
2.4 Protein Extraction 
Adherent cells were washed twice with 2 mL of cold PBS (Life Technologies). Cells 
were detached by incubating with 0.25% trypsin for 1-2 minutes, which was deactivated 
with hESC media. Cells were washed with DPBS. Cells were lysed in urea cell lysis 
buffer (8M urea, 50 mM ammonium bicarbonate, 1x HALT
™
 protease inhibitor cocktail 
(Thermo Scientific)) and incubated for 20 minutes on ice, with occasional vortex mixing. 
To shear genomic DNA, ensure membrane lysis, and lower sample viscosity, cell lysates 
were briefly sonicated. Samples were centrifuged at 10 000 × g for 10 minutes to remove 
debris, aliquoted and stored at -80°C for future analysis. 
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2.5 Bradford Assay 
Protein samples were quantified by a modified Bradford assay. 
104, 105
 10 µL of sample 
was diluted to 80 µL using ddH2O. A 1 mg/mL solution of bovine serum albumin (BSA) 
was used as a standard. A serial dilution scheme was performed on a 96-well plate as 
illustrated in Figure 5. Varying amounts of sample was added to each well along with a 
diluent matching the make-up of the diluted sample.  200 µL of Coomassie Protein Assay 
Reagent (Thermo Scientific) was added to each well and allowed to react for five 
minutes. Absorbance at 595 nm was measured using a Victor
3
V 1420 Multilabel Counter 
(Perkin Elmer). Protein concentration was determined from the equation generated from 
the BSA standard dilution curve. 
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Figure 5. Bradford Assay setup. A serial dilution of BSA protein standard and samples 
were resuspended to a total of 10 µL per well with diluent bringing lysis buffer 
concentrations to acceptable levels for assay. 200 µL of Coomassie Protein Assay 
Reagent was added to each well and allowed to react for 5 minutes. 
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2.6 Flow Cytometry 
Cells cultured on Geltrex
® 
were dissociated to a single-cell state with 1 mL of 0.25% 
trypsin-EDTA solution. Trypsin was deactivated by adding it 1:1 to trypsin neutralizer 
(Life Technologies). Cells were passed through a cell strainer, washed, and pelleted. Cell 
count was determined by taking a 10 µL aliquot for use with a hemacytometer. Cells 
were resuspended in FACS Buffer (PBS, 10% FBS) and divided equally among FACS 
tubes. Cells were washed and pelleted. Cells were treated with aqua LIVE/DEAD
®
 
Fixable Dead Cell Stain (Invitrogen), incubated, washed and pelleted. Cells were treated 
with surface marker conjugated-antibodies for Alexa Fluor
®
 647-SSEA1 and PE-SSEA3 
(eBioscience), incubated for 20 minutes, then washed and pelleted. SSEA1 is a surface 
marker of differentiation, while SSEA3 is a surface marker of pluripotency. Cells were 
fixed with 200 µL 4% paraformaldehyde (PFA) solution for 10 minutes, washed, then 
permeablized with 200 µL 0.1% Triton X-100 for 10 minutes and washed. Cells were 
treated with antibodies for intracellular pluripotency marker Alexa Fluor
® 
488-Oct4 
(eBioscience), incubated for 20 minutes, and then washed. Cells were analyzed using an 
LSRII flow cytometer (BD Biosciences). For establishment of instrument parameters, 
compensation controls, and fluorescence intensities, singly-stained compensation beads 
(BD Biosciences) were used as well as unstained fixed and permeablized hESCs. 
Fluorescence Minus One (FMO) controls were also analyzed, to help discriminate 
between positive and negative signals. At least 20 000 events were acquired for fully 
stained samples. Differentiated and undifferentiated samples were paired and run on the 
same day. Flow cytometry data was analyzed in software FlowJo. All analysis was 
performed on the gated live cell population, designated as being negative for aqua 
LIVE/DEAD
®
 fluorescence. Experiments were conducted in duplicate. 
2.7 Immunofluorescence 
Cells cultured on Geltrex were washed twice with PBS and incubated in fixing solution 
(4% paraformaldehyde, 10% sucrose in PBS) at room temperature for 20 minutes. Cells 
were washed with PBS. Cells being stained for intracellular markers were treated with 
permeablization solution (0.1% Triton X-100 in PBS) and incubated for 10 minutes at 
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room temperature. Cells were washed with PBS, and treated with DAKO Protein Block 
to eliminate nonspecific staining. Primary antibodies for Oct-4, SSEA4 and SSEA1 
(Millipore) were added at a 2 µg/mL concentration in 0.1% BSA solution and rocked for 
1 hour. Plates were sealed with Parafilm and incubated at 4°C overnight.  Primary 
antibody solution was removed, secondary antibody solution was added at a 1 µg/mL 
concentration in 0.1% BSA solution, and rocked for 30 minutes to 1 hour. Secondary 
antibodies used were Alexa Fluor
®
 488 goat anti-mouse IgG and Alexa Fluor
®
 568 goat 
anti-mouse IgM (Invitrogen). Secondary antibody solution was collected, cells were 
rinsed with PBS. Cells were treated with 0.3 nM DAPI for nuclear staining, washed, and 
then imaged by fluorescent microscopy with the Leica STP6000 at 10X magnification. 
2.8 Localization of SOX17 
CA1 Sox17/ERT2 Clone K cells were manually passaged onto Geltrex-coated glass 
coverslips and allowed to attach for 24-hours. Cells were treated for 2 hours with 0.1 uM 
4-OHT, washed, fixed, permeablized, treated with DAKO protein block and stained with 
SOX17 mouse anti-human Alexa Fluor
®
 488-conjugated antibody (BD Pharmigen) for 
one hour. Cells were treated with DAPI for nuclear staining. Immunofluorescence 
confocal microscopy was conducted on the LSM510 Meta Confocal Microscope (Zeiss). 
2.9 RT-PCR 
Total RNA was extracted from cells through use of 5-Prime PerfectPure RNA Extraction 
Kit. 400 µL of lysis solution was added per well of confluent cells, and plates were 
incubated and rocked for five minutes at room temperature. Lysis solution was pipetted 
vigorously, and added to the RNA purification column. Purification columns were 
centrifuged at 13 000 g for 1 minute and collection tubes were replaced after each step. 
RNA was washed once with 400 µL Wash 1 solution, twice with 200 µL Wash 2 
solution, and eluted with 50 µL of Elution solution. Total RNA was quantified by using 
either a Nanodrop or plate reader. Absorbance ratios of 260 nm/280 nm and 
260nm/230nm were monitored for sample quality. After quantification, RNA samples 
were stored at -80°C until further use. 
 cDNA was synthesized using the high capacity cDNA Reverse Transcription Kit 
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(Applied Biosystems). 2 μg of RNA sample was mixed with 10 µL of master mix (2.0 µL 
10X RT buffer, 0.8 µL 25X dNTP, 2.0 µL 10X RT random primers, 1.0 µL reverse 
transcriptase, 4.2 µL nuclease-free H2O) and brought up to 20 µL with ddH2O. The 
mixed samples were placed in a thermocycler set at 25°C for 10 minutes, 37°C for 120 
minutes, 85°C for 5 minutes and kept at 4°C. 1:100 dilutions of synthesized cDNA were 
used in RT-PCR reactions. SYBR Green Master Mix (Bio Rad) was used. Samples were 
incubated at 95°C for 3 minutes. Samples were then amplified at 95°C for ten seconds 
followed by annealing at 60°C for forty cycles. Melt curve data was obtained by 
increasing temperature from 65°C to 95°C in 0.5°C increments. Primers for targets can be 
seen in Table 1. Markers of endoderm Cerberus, CXCR4, DLX5, GATA4 and GATA6 
were used to confirm endoderm formation in CA1K differentiation system. Sox17 was 
monitored to confirm constitutive expression of the transcript across differentiation. 
Pluripotency markers Oct4, Nanog and Nodal were used to monitor loss of pluripotency 
in both H9 and CA1K differentiation systems. All samples were normalized to GusB 
expression. Each biological replicate was run in triplicate for each target. RT-PCR data 
was analyzed using the ∆∆CT method.106 
 
 
 
 
 
 
 
 
 
32 
 
 
 
 
 
 
 
 
Table 1. List of Real-Time RT-PCR Primers. 
Gene 
Gene Accession 
No. Forward Primer Reverse Primer 
TBP NM_003194 TGTGCACAGGAGCCAAGAGT ATTTTCTTGCTGCCAGTCTGG 
CER1 NM_005454 ACAGTGCCCTTCAGCCAGACT  ACAACTACTTTTTCACAGCCTTCGT  
CXCR4 NP_001008540 CACCGCATCTGGAGAACCA  GCCCATTTCCTCGGTGTAGTT  
DLX5 NM_005221 CGCCTCGCTGGGATTG CTTGATCTTGGATCTTTTGTTCTGAA  
GATA4 NM_002052 TCCAAACCAGAAAACGGAAGC GCCCGTAGTGAGATGACAGG 
GATA6 NM_005257 GCGGGCTCTACAGCAAGATG ACAGTTGGCACAGGACAATCC  
NANOG NM_024865 TGATTTGTGGGCCTGAAGAAA GAGGCATCTCAGCAGAAGACA 
OCT4 NM_002701 TGGGCTCGAGAAGGATGTG GCATAGTCGCTGCTTGATCG 
SOX17 NM_022454 GGCGCAGCAGAATCCAGA CCACGACTTGCCCAGCAT 
NODAL NP_060525 TGACTTCTCCTTCCTGAGCC GGGACAAAGTGACAGTGAATAG 
GUSB NP_000172 ACGCAGAAAATATGTGGTTGGA GCACTCTCGTCGGTGACTGTT 
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2.10 Dimethyl Labeling 
Subsequent to tryptic digestion, peptides were labeled by isotopic dimethyl labeling for 
quantification purposes.
107
 Samples were treated with formaldehyde or deuterated-
formaldehyde (Sigma), vortexed, and incubated for five minutes. Sodium 
cyanoborohydride was added to the samples, which were allowed to incubate for two 
hours. Undifferentiated samples were given the “light” label, and differentiated samples 
were given the “heavy”.  After labeling, reactions were quenched by the addition of 10% 
formic acid, and samples were mixed 1:1 and desalted as previously described. Combined 
samples were brought to dryness in a vacuum centrifuge and reconstituted in 10% formic 
acid for MS analysis. 
2.11 Gel Electrophoresis 
Samples were separated by 1D gel electrophoresis. 100 ug of protein lysate was diluted 
1:2 with 2X loading buffer (4% SDS, 20% glycerol, 120 mM Tris-Cl pH 6.8, 200 mM 
DTT, 0.1% bromophenol blue) and loaded onto a 1.5 mm 12% SDS-PAGE gel. 2 µL of 
PrecisionPlus DualColour Protein Standard (Bio-Rad) was added to provide a molecular 
weight ladder. Gels were run at a constant voltage of 200V. Finished gels were fixed for 
one hour or overnight in fixing solution (50% methanol, 10% glacial acetic acid in 
water), stained in Coomassie stain solution (50% methanol, 10% glacial acetic acid, 0.1% 
Brilliant Blue R-250 in water) for 25-40 minutes, and destained in destain solution (45% 
methanol, 10% glacial acetic acid, in water) until background was clear. Gel was 
scanned, imaged, and stored in 5% glacial acetic acid at 4°C until use. 
2.12 In-gel Tryptic Digestion 
Gel lanes were cut into fractions, which were cut into  ~2 mm cubes, put in 
microcentrifuge tubes and destained with alternating washes with destaining solution (1 
M ammonium bicarbonate/20% acetonitrile in ddH2O) and washing solution (50% 
methanol/5% acetic acid in ddH2O). Once gel pieces were completely destained, they 
were dehydrated with acetonitrile. Gel pieces were then rehydrated with 
dithiothreitol (DTT) solution (10mM DTT in 100mM ammonium bicarbonate) and 
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allowed to reduce for 30 minutes. Excess DTT solution was removed, and iodoacetamide 
solution (100mM IAA in 100mM ammonium bicarbonate) was added, and gel pieces 
were allowed to reduce for 30 minutes. IAA solution was removed, and gel pieces were 
dehydrated with acetonitrile, allowed to rehydrate with 100 mM ammonium bicarbonate, 
then dehydrated once more with acetonitrile. Gel pieces were completely dried in a 
vacuum centrifuge.  Gel pieces were fully rehydrated with trypsin (Fisher) solution (20 
ug/mL trypsin in 50 mM ammonium bicarbonate), and allowed to incubate on ice for 10 
minutes. Excess trypsin solution was removed, gel pieces were covered in 50 mM 
ammonium bicarbonate and allowed to digest overnight at 37°C, for at least 18 hours. 
Supernatants were collected, followed by two extractions with 10% formic acid, and a 
final extraction with acetonitrile. Supernatants were pooled and volume was reduced in a 
vacuum centrifuge. Prior to MS analysis, samples were reconstituted in 10% formic acid. 
2.13 In-Solution Tryptic Digestion 
100 ug of protein lysate was resuspended up to 100 µL in 50 mM ammonium 
bicarbonate. The sample was reduced with 5 µL of DTT solution (200 mM DTT in 
100mM ammonium bicarbonate) at room temperature for 45 minutes, vortexing 
occasionally.. Samples were centrifuged at 5000xg for 30 seconds. Sample was alkylated 
with 20 µL IAA solution (200 mM iodoacetamide in 100 mM ammonium bicarbonate) at 
room temperature for 45 minutes, vortexing occasionally. Excess IAA was neutralized by 
adding 10 µL of DTT solution, and left to incubate for 45 minutes at room temperature. 
Sample was diluted with 50 mM ammonium bicarbonate to bring buffers to levels 
acceptable for a trypsin digest. Trypsin solution was added to sample (1:25 trypsin to 
protein) and sample was left to digest overnight for at least 18 hours at 37°C. Tryptic 
samples were acidified 1:2 with 10% formic acid and desalted using 1 mL C-18 SPE 
columns (Phenomenex). Columns were primed with 3×1 mL aliquots of Buffer B 
(acetonitrile + 0.1% formic acid), and washed with 3×1 mL aliquots of Buffer A (ddH2O 
+ 0.1% formic acid). Sample was loaded and washed with 3×1 mL aliquots of Buffer A. 
Sample was eluted with 400 µL Buffer C (50% Buffer A, 50% Buffer B).  Eluent was 
brought to dryness using a vacuum centrifuge and reconstituted in 10% formic acid 
before mass spectrometry analysis. 
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2.14 Mass Spectrometry 
SRM experiments were performed on the 4000 QTRAP
®
 mass spectrometer (AB SCIEX) 
coupled to a nanoAcquity HPLC system, operating in nanospray mode. The HPLC 
system was equipped with a 2 mm X 180 um inner diameter trap column packed with 
C18 beads (5 um, SymmetryC18, Waters nanoAcquity) ahead of a 20 cm X 75 um inner 
diameter C18  analytical column (1.7 µm BEH130 C18, Waters) and a PicoTip silica tip 
emitter (New Objective). Samples were run on a 2-hour linear gradient at 0.3 µL/min 
from 95-40% solvent A (Solvent A: ddH2O + 0.1% formic acid, Solvent B: acetonitrile + 
0.1% formic acid) followed by a column reequilibration step (10 minutes 40-5% solvent 
A, 15 minutes 5% solvent A, 25 minutes 95% solvent A). A scheduled SRM protocol 
pooling the optimized transitions was used, with a 2 second scan time, and 4 minute 
acquisition window. 
The mass spectrometer was operated in positive ion mode, with IonSpray voltage of 
2300V, interface heater temperature of 120°C, curtain gas of 20, ion source gas of 25, 
entrance potential of 10, collision cell exit potential of 10, and medium collision gas 
pressure. Initial transition collision energies were calculated using Skyline default 
settings for 4000 QTRAP
®
, using the formula CE = 0.057(m/z) – 4.265 for doubly 
charged precursor ions, and CE = 0.031(m/z) +7.082 for triply charged precursors.  
Collision energy was optimized for each precursor by using the Skyline CE optimization 
method. Synthetic peptide was injected into the instrument, while the voltage was altered 
stepwise by +/- 5 V. The optimum voltage was identified from the maximum peak area 
and used for all subsequent analyses. 
2.15 MS Data Analysis 
Instrument specific .wiff data files were converted to mzML through use of MSConvert, 
and SRM data was imported into Skyline software for visualization and further 
downstream analysis.
71
 Savitzky-Golay smoothing was applied to chromatograms, and 
peaks were assessed to assure software’s automatic peak picking was successful. Peaks 
were selected manually. A report was exported from Skyline containing information on 
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peak areas and retention times for further processing. Statistical analysis was performed 
as described by Bisson et al., using formulae seen in Figure 6.
80
 By using weighted 
averages and discriminatory values, outlier transitions can be disregarded in calculating 
overall fold change. The transition response   
  for each sample was calculated from a 
weighted average of technical replicates in triplicate as seen in equation 1. The weighted 
value wi was based on the signal-to-noise (S/N) ratio, in which transitions with S/N < 5 
were assigned a weight of 0, S/N > 20 were assigned a weight of 1, and intermediate 
values S/N values were assigned based on a sigmoidal curve. Transitional fold change Ft 
was determined using equation 2. The weight for transitional fold change wt is 
determined with equations 3 and 4, favouring changes with low standard deviation and 
high absolute difference. Peptide fold change weight wp is calculated by equation 5, while 
peptide fold change Fp is calculated by equation 6 for all transitions with the same 
behaviour (i.e. up or down) as the peptide. Protein fold change is calculated by equation 7 
while the protein discriminating factor or average weight value wpr was calculated by 
equation 8. Bisson et al. showed a weight value of 0.7 to be equivalent to a p-value of 
0.05. This value was used for determination of significance in protein fold change for the 
purposes of this study. 
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Figure 6. Equations for statistical analysis of SRM transitions .
80
 Based on the signal-
to-noise ratio of the measurement, each transition is assigned a value from 0 to 1, with a 
S/N < 5 = 0, a S/N >20 = 1, and intermediate values determined by a sigmoidal curve. 
Transition fold changes are calculated and weighted, and combined into peptide and then 
protein fold changes. Using this method, outlier measurements are removed from the 
analysis. 
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3 Results 
3.1 Cell Line Differentiation and Characterization 
Two model systems were used to model protein expression changes that occur as human 
embryonic stem cells (hESC) differentiate. Specifically, two human embryonic stem cell 
lines were chosen, H9, derived by the Wisconsin stem cell group led by Jamie Thomson, 
and CA1, derived by Andras Nagy at the University of Toronto. 
2, 43, 52
 Figure 7 
illustrates the two differentiation schemes. By treating H9 cells with recombinant human 
Bone Morphogenic Protein-4 (rhBMP4) over the course of 96 hours, cells would be 
driven towards a more differentiated phenotype, that of trophoblast or mesoderm
108
. The 
CA1 line contains a transgene that constitutively expresses a Sox17/Estrogen Receptor 
(ERT2) fusion protein that is localized to the cytoplasm under non-induced conditions. 
Upon induction with 4-hydroxytamoxifen (4-OHT) the protein translocates to the nucleus 
and directs differentiation of the cells towards a definitive endoderm precursor state. 
Specifically, the line used was CA1 Sox17/ERT2 Puro Clone K (CA1K), obtained from 
Dr. Cheryle Seguin.
53
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Figure 7.  hESC differentiation models. A. H9 differentiation protocol. H9 cells are 
treated for 96 hours with hESC media containing rhBMP4.  B. CA1K differentiation 
protocol. CA1K cells are treated for 96 hours with hESC media containing 4-OHT. C.  
Transgene responsible for constituitive Sox17/ERT2 protein expression, including 
expression of a puromycin resistance gene for selection. pCAGG – strong promoter. ERT2 
- human estrogen receptor. IRES – Internal ribosome entry site.  
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These two hESC differentiation methods provide two distinct systems within which to 
monitor protein changes. The H9 differentiation is more apparent, providing a model 
expected to manifest large changes in protein expression. The CA1K differentiation 
offers a model expected to provide more subtle changes, as the differentiated cells still 
retain some aspects of pluripotency. In addition, the CA1K differentiation process is 
more directed, leading to a less heterogeneous cell population. 
 As seen by phase contrast microscopy in Figure 8, the phenotypic change can be 
confirmed visually. Prior to differentiation, cell colonies consist of round, tightly packed 
cells with defined borders. H9 BMP4 differentiation tends to result in fewer, smaller 
colonies containing cells with extended morphology, while CA1 differentiation results in 
cells with a more cobblestone-like appearance, while still maintaining dense colonies. To 
validate both of these approaches and confirm successful differentiation, several 
techniques were used, including immunofluorescence, RT-PCR, and flow cytometry.  
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Figure 8. Changes in hESC morphology after exposure to differentiation factors. 
hESCs were passaged and plated on Geltrex basement membrane matrix. H9s were 
treated with differentiation media containing 10 ng/μL rhBMP4 to induce differentiation, 
or cultured in MEF-CM as a control. CA1K cells were treated with differentiation media 
containing 0.1 nM 4-OHT or cultured in MEF-CM. Media was changed daily, and phase 
contrast micrographs at 10X magnification were taken at 24 hour intervals to monitor 
changes in morphology. H9 differentiation led to colony disruption and elongated cells, 
CA1K differentiation kept colony structure, with slightly more cobblestone-like cells. 
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3.1.1 Immunofluorescence 
To confirm the change in phenotype and a loss of pluripotency, immunofluorescence 
experiments were performed. hESC cells in feeder-free culture were treated with BMP4 
or 4-OHT for 96 hours, fixed and stained for several factors of interest. These factors 
included Oct4, a nuclear transcription factor required for pluripotency, SSEA4, a cell 
surface marker of pluripotency, SSEA1, a cell surface marker of differentiation, and 
DAPI for nuclear staining. Figure 9 illustrates the results of the immunofluorescence 
experiments. During H9 differentiation, bright green fluorescence localized at the nucleus 
and cell membrane is very pronounced in undifferentiated samples, indicating high Oct4 
and SSEA4 expression. In differentiated samples, SSEA1 expression is more 
pronounced, as seen in red-yellow patches.  
 Undifferentiated CA1Ks show bright green fluorescence localized to the nucleus, 
indicative of high Oct4 expression. Upon differentiation, nuclear staining is reduced and 
red surface staining is increased, indicative of increased SSEA1 expression. Likewise, 
strong SSEA4 fluorescence is seen in the undifferentiated cells, while the red 
fluorescence of SSEA1 expression becomes more prominent in the differentiated cells. 
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Figure 9.  Immunofluorescence of Differentiated Cells. Immunofluorescence staining 
was performed on undifferentiated and differentiated cell lines. Cells were allowed to 
differentiate for 96 hours under treatment with 0.1 nM 4-hydroxytamoxifen (4-OHT) or 
10ng/mL rhBMP4. Cells were stained for pluripotency markers Oct4 (intracellular) and 
SSEA4 (surface), and surface differentiation marker SSEA1. DAPI nuclear staining was 
also used. Three biological replicates were performed for each differentiation protocol. 
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3.1.2 Confocal Microscopy of Sox17/ERT2 Translocation 
To ensure that the tamoxifen-inducible Sox17/ERT2 system successfully results in the 
fusion protein being translocated to the nucleus, immunofluorescence experiments 
combined with confocal microscopy were performed. CA1 Sox17/ERT2 clone K cells 
were cultured on Geltrex-coated coverslips for 24 hours, then treated with tamoxifen for 
two hours, then fixed and stained with a conjugated Alexa Fluor
®
488 Sox17 antibody. As 
shown by the green staining in Figure 10, in uninduced cells, the fusion protein is spread 
out across the cytoplasm and fluorescence is diffuse. Upon two hours of treatment, the 
green fluorescence becomes more concentrated and co-localizes with the blue DAPI 
nuclear stain, showing the fusion protein does translocate to the nucleus. 
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Figure 10. Confocal Microscopy of Sox17 Nuclear Localization. CA1 Sox17ERT2 
Puro Clone K cells were grown on Geltrex coated coverslips for 24 hours. Cells were 
treated with 0.1 nM 4-OHT for 2 hours, then mounted, stained for Sox17 and DAPI, and 
imaged using a confocal microscope. A single biological replicate was performed. 
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3.1.3 Real-Time RT-PCR Analysis of hESC Differentiation 
To confirm that cell differentiation was occurring at the transcription level, RT-PCR 
experiments were performed. H9 or CA1K cells were again seeded onto Geltrex, and 
treated with BMP4 or tamoxifen, or kept as a control for 96 hours. RNA was extracted, 
and cDNA was synthesized. As the CA1K line was being differentiated towards 
definitive endoderm, expression of endodermal markers including  Cerberus, CXCR4, 
DLX5, GATA4, and GATA6 were analyzed, along with pluripotency markers Nodal, 
Oct4, and Nanog. Constitutively expressed proteins β-glucuronidase (GusB) and TATA-
binding protein (TBP) were used as loading controls. The -ΔΔCt method was used for 
quantitation.
106
 All expression levels were normalized to GusB expression, as it is a 
housekeeping gene expected to remain stable across differentiation. Fold change of 
mRNA expression was expressed relative to the undifferentiated sample. As H9 BMP4 
differentiation was a less directed method of differentiation, only the pluripotency 
markers Oct4, Nanog, and Nodal were monitored.  
Figure 11A illustrates expression changes in H9 BMP4 differentiation with an N = 6. 
Oct4 expression was decreased by 50%, while Nanog expression dropped by 75%. 
Previous RT-PCR analyses have shown that BMP4 treatment results in decreased 
expression of Oct4 and Nanog over a 96-hour time course. 
50, 109
 
Figure 11B illustrates expression changes in tamoxifen-induced differentiation of CA1K 
cells with N=9. Endoderm markers Cerberus, CXCR4, DLX5, GATA4 and GATA6 were 
all seen to be upregulated, while Oct4, Nanog and Nodal remained stable or slightly 
decreased in expression, consistent with the gene expression results for the stable SOX17 
overexpressing cell line generated by Seguin et al.
53
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Figure 11.  Real-Time RT-PCR Data for Cell Differentiation. Real-time RT-PCR 
experiments were performed on cDNA obtained from differentiated A. H9 and B. CA1 
Sox17/Ert2 Puro Clone K cell lines, differentiated for 96 hours upon treatment with 0.1 
nM 4-OHT or 10 ng/mL rhBMP4 respectively. Data was normalized to GusB expression.         
-ΔΔCt method was used for quantitation. Bars represent fold change of expression 
relative to undifferentiated sample, error bars represent standard error of the mean. 
Changes found to be significant according to a two-tailed t-test with p <0.05 were marked 
with *. 9 biological replicates were performed for CA1K differentiation. 6 biological 
replicates were performed for H9 differentiation. 
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3.1.4 Flow Cytometry Analysis of Differentiated hESC Populations 
To confirm that cell differentiation was occurring at the cellular protein level, flow 
cytometry experiments were performed. hESCs cultured on Geltrex™ were dissociated 
and labelled with conjugated antibodies for pluripotency markers Oct4 and SSEA3, and 
differentiation marker SSEA1. Fixation is required to analyze Oct4, which kills the entire 
cell population. To ensure analysis was performed on live cells, an Aqua viability dye 
was first used in order to gate on the live population. The viability dye binds to exposed 
membrane, hence dead cells will exhibit greater overall fluorescence. All analysis was 
performed on the live population, which exhibits lower fluorescence. 
Each treatment was performed in biological duplicate, and a single representative 
replicate has been presented. hESCs survive poorly when dissociated to the single-cell 
state, becoming prone to apoptosis and differentiation.
110
 Thus, only 20-50% live cells 
were available for analysis, as seen in Figure 12B and 12C. Histograms showing the 
change in fluorescence for each marker can be seen in Figure 12D-F. 
For Oct4 expression in H9s, cells exhibited a 2.3-fold decrease in median fluorescence 
upon differentiation, which is significantly lower for p < 0.05. For SSEA1 expression, 
exhibited a 37-fold increase in median fluorescence upon differentiation. For SSEA3 
expression, exhibited a 2.2-fold decrease in median fluorescence upon differentiation. 
Dot plots comparing multiple proteins in Figure12G-I confirm that the differentiated and 
undifferentiated cells form two distinct populations. 
Figure 13 illustrates flow cytometry data for CA1K differentiation. For Oct4 expression 
in CA1K cells exhibited a 1.3-fold increase in median fluorescence upon differentiation. 
As expected, the differentiated CA1K cells still express Oct4.
53
 For SSEA1 expression 
exhibited a 1.5-fold increase in median fluorescence upon differentiation. For SSEA3 
expression exhibited a 1.08-fold decrease in median fluorescence upon differentiation. 
The dot plots also signify that the populations of these differentiated and undifferentiated 
cells are far less distinct than the H9 cells in terms of these pluripotency markers. These 
cells cannot definitively be called differentiated taking only flow cytometry data into 
account. 
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Taking the immunofluorescence, RT-PCR, and flow cytometry experiments together, we 
can confirm that we have two distinct, but equally valid differentiation models with 
which to detect protein changes that occur during differentiation:  the H9 differentiation 
model to illustrate drastic changes, and the more subtle CA1K differentiation model.  
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Figure 12. Flow cytometry of H9 Differentiation. H9 cells were differentiated for 96 
hours in 10 ng/mL rhBMP4. Cells were dissociated to the single cell state, stained with 
AqVi LIVE/DEAD
®
 dye, fixed, then stained with SSEA1, SSEA3, and Oct4 conjugated 
antibodies. All analysis was conducted on the gated live cell population.  Fluorescence is 
on the log scale. Red = differentiated. Blue = undifferentiated. Green = Fluorescence 
minus One (FMO) A. Forward scatter vs. side scatter for fully stained H9 cells. B-C. 
Aqua viability dye fluorescence vs.  Forward scatter for fully stained BMP4 treated and 
untreated cells. D-F. Histograms for Oct4, SSEA1 and SSEA3 expression. Fluorescence 
is on the log scale. G-I. Dot plots for undifferentiated and differentiated cell populations. 
Two biological replicates were performed. 
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Figure 13. Flow cytometry of CA1K Differentiation. CA1K cells were differentiated 
for 96 hours in 0.1 nM 4-OHT.  Cells were dissociated to the single cell state, stained 
with Aqua LIVE/DEAD
® 
viability dye, fixed, then stained with SSEA1, SSEA3, and 
Oct4 conjugated antibodies. All analysis was conducted on the gated live cell population. 
Red = differentiated. Blue = undifferentiated.  Green = Fluorescence minus One (FMO) 
negative control. A. Forward scatter vs. side scatter for fully stained CA1K cells. B-C. 
Aqua viability dye fluorescence vs.  forward scatter for fully stained 4-OHT treated and 
untreated cells. D-F. Histograms for Oct4, SSEA1 and SSEA3 expression. Fluorescence 
is on the log scale. G-I. Dot plots for undifferentiated and differentiated cell populations. 
Two biological replicates were performed. 
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3.2 SRM Assay Development 
Stem cell pluripotency is controlled by a complex network of signaling pathways and 
proteins. Potential SRM targets were selected through an extensive literature search for 
notable proteins responsible for pluripotency maintenance, with an emphasis on proteins 
from the Notch, Hedgehog, Wnt, and Activin/Nodal signaling pathways. Thirty-three 
initial protein targets were selected, and are listed with Uniprot accession numbers and 
corresponding peptides in Table 2. Thirty-three preliminary targets were initially chosen 
in order to fill a 96-well peptide synthesis plate, with the potential for more targets in 
future studies.  
 
Two or three tryptic peptides corresponding to each target protein were chosen for 
synthesis. Protein sequences were obtained from the online database Uniprot and loaded 
into the SRM assay development software Skyline. The protein sequences were subjected 
to an in silico trypsin digest, preferentially cleaving at arginine and lysine residues, 
except for when followed by a proline residue. Human protein spectral libraries were 
downloaded from the Global Proteome Machine Database (GPMDB) and the National 
Institute of Standards and Technology and loaded into Skyline. Peptides that were 
previously observed experimentally were given preference in the selection process. 
However, many target proteins were not present in the library. Criteria set out by Lange 
et al. for SRM target selection were followed and input into the filter function in 
Skyline.
60
 Peptides were limited to 8-25 residues in length, residues prone to oxidation 
such as methionine and tryptophan were excluded, and Skyline generated a list of 
peptides matching either the library or filter. Certain protein sequences were unable to 
provide peptides meeting these criteria due to a large amount of methionine in the 
sequence, Nodal, in particular. In these cases, methionine was accepted and oxidation 
was accounted for. Peptides were checked for protein specificity using protein BLAST.
111
  
PeptideCutter was used to assess probability of tryptic cleavage for the target peptides
112
. 
Target peptides were synthesized in-house at the 5 µmol level using the FMOC protocol 
on an Intavis multiple peptide synthesizer. 
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Table 2. List of target proteins and peptides.
 
 
Protein Accession Peptide Protein Accession Peptide
Wnt1 P04628 QNPGILHSVSGGLQSAVR SUFU Q9UMX1 VHEFTGTDGPSGFGFELTFR
ETAFIFAITSAGVTHSVAR GIETDGSNLSGVSAK
ACNSSSPALDGCELLCCGR GLEINSKPVLPPINPQR
DVL-1 O14640 NVLSNRPVHAYK Frizzled-1 Q9UP38 FPVHGAGELCVGQNTSDK
LSSSTEQSTSSR GGFPGGAGASER
SQASATAPGLPPPHPTTK VPSYLNYHFLGEK
AXIN-1 O15169 SDIYLEYTR WIF-1 Q9Y5W5 VLIGFEEDILIVSEGK
DAHEENPESILDEHVQR ASVVQVGFPCLGK
TCQQAECPGGCR
Lefty-1 O75610 LPPNSELVQAVLR Nodal Q96S42 VPSTCCAPVK
QPLLLQVSVQR TKPLSMLYVDNGR
EHLGPLASGAHK GQPSSPSPLAYMLSLYR
DKK1 O94907 NGICVSSDQNHFR POUF51 Q01860 LEQNPEESQDIK
SSDCASGLCCAR FEALQLSFK
DHHQASNSSR WVEEADNNENLQEICK
Cerberus O95813 TVPFSQTITHEGCEK Patched Q13635 TYVEVVHQSVAQNSTQK
VVVQNNLCFGK TEYDPHTHVYYTTAEPR
TPASQGVILPIK LPTPSPEPPPSVVR
P53 P04637 LGFLHSGTAK Sonic 
Hedgehog
Q15465 ELTPNYNPDIIFK
SVTCTYSPALNK SGGCFPGSATVHLEQGGTK
RPILTIITLEDSSGNLLGR LAHALLAALAPAR
Wnt2 P09544 ESAFVYAISSAGVVFAITR FRAT-1 Q92837 APGPLAAAVPADK
CHGVSGSCTLR LLQQLVLSGNLIK
CQDCLEALDVHTCK
GLI3 P10071 TSPNSLVTILNNSR Smoothened Q99835 GAASSGNATGPGPR
IKPDEDLPSPGAR FNSSGQCEVPLVR
GQQEQPEGTTLVK DYVLCQANVTIGLPTK
APC P25054 NVSSLIATNEDHR Wnt3a P56704 IGIQECQHQFR
SAEDPVSEVPAVSQHPR ESAFVHAIASAGVAFAVTR
NDSLSSLDFDDDDVDLSR SCAEGTAAICGCSSR
Akt1 P31749 TFHVETPEER Wnt5a P41221 ETAFTYAVSAAGVVNAMSR
FYGAEIVSALDYLHSEK FNSPTTQDLVYIDPSPDYCVR
TFCGTPEYLAPEVLEDNDYGR NESTGSLGTQGR
Beta-
Catenin
P35222 HAVVNLINYQDDAELATR Activin-A 
(homodimer, 
beta A chain)
P08476 EGSDLSVVER
LLNDEDQVVVNK HPQGSLDTGEEAEEVGLK
NEGVATYAAAVLFR SELLLSEK
CDKI1 
Aka p21
P38936 DCDALMAGCIQEAR TDGF/Cripto-1 P13385 FSYSVIWIMAISK
WNFDFVTETPLEGDFAWER DDSIWPQEEPAIRPR
TPELPPSAR
NOTCH1 P46531 NGGTCDLLTLTEYK Hes1 Q14469 NSSSPVAATPASVNTTPDKPK
GSIVYLEIDNR FLSTCEGVNTEVR
FEEPVVLPDLDDQTDHR LGSQAGEAAK
GSK3-Beta P49841 VIGNGSFGVVYQAK Hey1 Q9Y5J3 YLSIIEGLDASDPLR
DIKPQNLLLDPDTAVLK LVSHLNNYASQR
IQAAASTPTNATAASDANTGDR LGSAHPEAPALR
SFRP-1 Q8N474 FYTKPPQCVDIPADLR SRFP-2 Q96HF1 LPNLLGHETMK
SEAIIEHLCASEFALR EVLEQAGAWIPLVMK
SQYLLTAIHK DSLQCTCEEMNDINAPYLVMGQK
Nanog Q9H9S0 TVFSSTQLCVLNDR
YLSLQQMQELSNILNLSYK
NSNGVTQK
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Upon synthesis, peptides were cleaved, precipitated, lyophilized and stored at -80°C until 
use. A small aliquot was taken and injected directly into a Quattro Micro triple 
quadrupole mass spectrometer (Waters) to confirm the theoretical peptide mass was 
present. In all cases, the most abundant ions corresponded to the theoretical peptide mass, 
with an estimated 80% purity, and thus crude peptide was used without further 
purification.
66
 Synthetic peptides were serially diluted to a 100 fmol/µL working solution, 
and MS/MS data was obtained for each generated peptide on the 4000 QTRAP
®
. SRM-
triggered DDA methods were generated for each peptide, looking specifically for y and b 
ions generated by doubly and triply charged precursors. The doubly charged precursor 
was selected in most cases, unless the target peptide contained a histidine residue or a 
lysine/arginine residue followed by proline, in which case the triply charged precursor 
was preferred. Five of the top transitions were collected and compiled in a general SRM 
protocol. Transitions were prioritized by having fragment m/z greater than the precursor 
m/z, overall intensity, and favouring y-ions. Retention times were noted and reacquired 
when the LC gradient was altered. SRM chromatograms showing the five transitions 
chosen along with corresponding MS/MS data for each target peptide can be seen in 
Figures 14-46. Multiple co-eluting transitions as seen in the chromatograms serve to 
identify the target peptide, while the area under the curve of each transition can be 
integrated to obtain quantitative information about peptide abundance. Though peptides 
can be identified solely by multiple transitions, MS/MS sequence data was also obtained 
in order to confirm the target sequence. 
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Figure 14. SRM and MS/MS data for protein Dishevelled. SRM-triggered MS/MS 
spectra were obtained for synthetic peptide targets. Top five SRM transitions are shown 
in a chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. SQASATAPGLPPPHPTTK (m/z=879.46
++
) B. LSSSTEQSTSSR 
(m/z=635.30
++
) C. NVLSNRPVHAYK (m/z=466.59
+++
) 
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Figure 15. SRM and MS/MS data for protein Nanog. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. YLSLQQMQELSNILNLSYK (m/z=1143.10
++
) B. NSNGVTQK  
(m/z=424.22
++
) C. TVFSSTQLCVLNDR(m/z=820.41
++
) 
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Figure 16. SRM and MS/MS data for protein WIF1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. VLIGFEEDILIVSEGK (m/z=880.99
++
) B. ASVVQVGFPCLGK  
(m/z=681.37
++
) C. TCQQAECPGGCR (m/z=712.28
++
) 
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Figure 17. SRM and MS/MS data for protein Activin A. SRM-triggered MS/MS 
spectra were obtained for synthetic peptide targets. Top five SRM transitions are shown 
in a chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. HPQGSLDTGEEAEEVGLK (m/z=632.64
+++
) B. SELLLSEK  
(m/z=459.46
++
) C. EGSDLSVVER (m/z=545.77
++
) 
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Figure 18. SRM and MS/MS data for protein Frizzled1. SRM-triggered MS/MS 
spectra were obtained for synthetic peptide targets. Top five SRM transitions are shown 
in a chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. FPVHGAGELCVGQNTSDK (m/z=639.30
+++
) B. VPSYLNYHFLGEK 
(m/z=522.94
++
) C. GGFPGGAGASER (m/z=531.75
++
) 
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Figure 19. SRM and MS/MS data for protein Oct4. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. WVEEADNNENLQEICK (m/z=995.94
++
) B. LEQNPEESQDIK 
(m/z=715.34
++
) C. FEALQLSFK (m/z=541.79
++
) 
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Figure 20. SRM and MS/MS data for protein Akt1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. FYGAEIVSALDYLHSEK (m/z=647.99
+++
) B. 
TFCGTPEYLAPEVLEDNDYGR (m/z=1223.55
++
) C. TFHVETPEER (m/z=415.54
+++
) 
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Figure 21. SRM and MS/MS data for protein Patched. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. TYVEVVHQSVAQNSTQK (m/z=639.99
+++
) B. TEYDPHTHVYYTTAEPR 
(m/z=693.99
+++
) C. LPTPSPEPPPSVVR (m/z=736.91
++
) 
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Figure 22. SRM and MS/MS data for protein SFRP2. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. DSLQCTCEEMNDINAPYLVMGQK (m/z=906.06
+++
) B. 
EVLEQAGAWIPLVMK (m/z=842.46
++
) C. LPNLLGHETMK (m/z=418.23
+++
) 
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Figure 23. SRM and MS/MS data for protein Wnt5a. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. FNSPTTQDLVYIDPSPDYCVR (m/z=829.72
+++
)  B. 
ETAFTYAVSAAGVVNAMSR (m/z=972.98
++
)  C. NESTGSLGTQGR (m/z=603.79
++
) 
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Figure 24. SRM and MS/MS data for protein Sonic hedgehog. SRM-triggered 
MS/MS spectra were obtained for synthetic peptide targets. Top five SRM transitions are 
shown in a chromatogram (left). Sequence information can be confirmed with MS/MS 
spectra (right). A. SGGCFPGSATVHLEQGGTK (m/z=630.63
+++
) B. ELTPNYNPDIIFK 
(m/z=782.41
++
) C. LAHALLAALAPAR (m/z=429.93
+++
) 
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Figure 25. SRM and MS/MS data for protein HES1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. NSSSPVAATPASVNTTPDKPK (m/z=1035.03
++
) B. LGSQAGEAAK 
(m/z=466.25
++
) C. FLSTCEGVNTEVR (m/z=756.36
++
) 
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Figure 26. SRM and MS/MS data for protein GSK3β. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. DIKPQNLLLDPDTAVLK (m/z=631.69
+++
) B. VIGNGSFGVVYQAK 
(m/z=719.89
++
) C. IQAAASTPTNATAASDANTGDR (m/z=1052.50
++
) 
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Figure 27. SRM and MS/MS data for protein Smoothened. SRM-triggered MS/MS 
spectra were obtained for synthetic peptide targets. Top five SRM transitions are shown 
in a chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. DYVLCQANVTIGLPTK (m/z=896.47
++
) B. GAASSGNATGPGPR 
(m/z=600.29
++
) C. FNSSGQCEVPLVR (m/z=746.86
++
) 
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Figure 28. SRM and MS/MS data for protein SUFU. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. GIETDGSNLSGVSAK (m/z=478.91
+++
) B. VHEFTGTDGPSGFGFELTFR 
(m/z=734.35
++
) C. GLEINSKPVLPPINPQR (m/z=624.69
+++
) 
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Figure 29. SRM and MS/MS data for protein Cerberus. SRM-triggered MS/MS 
spectra were obtained for synthetic peptide targets. Top five SRM transitions are shown 
in a chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. TVPFSQTITHEGCEK (m/z=578.61
+++
) B. TPASQGVILPIK (m/z=408.58
+++
) 
C. VVVQNNLCFGK (m/z=639.33
++
) 
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Figure 30. SRM and MS/MS data for protein p53. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. RPILTIITLEDSSGNLLGR (m/z=690.06
+++
) B. SVTCTYSPALNK 
(m/z=670.83
++
) C. LGFLHSGTAK (m/z=344.19
+++
) 
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Figure 31. SRM and MS/MS data for protein Wnt2. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. CQDCLEALDVHTCK (m/z=583.58
+++
) B. ESAFVYAISSAGVVFAITR 
(m/z=994.53
++
) C. CHGVSGSCTLR (m/z=411.85
+++
) 
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Figure 32. SRM and MS/MS data for protein Gli3. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. GQQEQPEGTTLVK (m/z=707.86
++
) B. TSPNSLVTILNNSR (m/z=758.41
++
) 
C. IKPDEDLPSPGAR (m/z=465.58
+++
) 
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Figure 33. SRM and MS/MS data for protein FRAT1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. APGPLAAAVPADK (m/z=589.33
++
) B. LLQQLVLSGNLIK (m/z=719.95
++
)  
 
75 
 
 
 
 
Figure 34. SRM and MS/MS data for protein Cripto-1. SRM-triggered MS/MS 
spectra were obtained for synthetic peptide targets. Top five SRM transitions are shown 
in a chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. FSYSVIWIMAISK (m/z=772.91
++
) B. DDSIWPQEEPAIRPR 
(m/z=603.64
+++
) C. TPELPPSAR (m/z=484.26
++
) 
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Figure 35. SRM and MS/MS data for protein Lefty1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. EHLGPLASGAHK (m/z=406.22
+++
) B. LPPNSELVQAVLR (m/z=718.41
++
) 
C. QPLLLQVSVQR (m/z=640.89
++
) 
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Figure 36. SRM and MS/MS data for protein DKK1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. NGICVSSDQNHFR (m/z=511.90
+++
) B. SSDCASGLCCAR (m/z=672.26
++
) 
C. DHHQASNSSR (m/z=380.17
+++
) 
78 
 
 
 
 
Figure 37. SRM and MS/MS data for protein SFRP1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. SQYLLTAIHK (m/z=391.89
+++
) B. FYTKPPQCVDIPADLR (m/z=640.66
+++
) 
C. SEAIIEHLCASEFALR (m/z=615.98
+++
) 
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Figure 38. SRM and MS/MS data for protein Nodal. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. VPSTCCAPVK (m/z=559.77
++
) B. GQPSSPSPLAYMLSLYR 
(m/z=933.97
++
) C. TKPLSMLYVDNGR (m/z=498.60
+++
) 
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Figure 39. SRM and MS/MS data for protein β-Catenin. SRM-triggered MS/MS 
spectra were obtained for synthetic peptide targets. Top five SRM transitions are shown 
in a chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. LLNDEDQVVVNK (m/z=693.37
++
) B. HAVVNLINYQDDAELATR 
(m/z=681.35
+++
) C. NEGVATYAAAVLFR (m/z=741.39
++
) 
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Figure 40. SRM and MS/MS data for protein Axin1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. DAHEENPESILDEHVQR (m/z=673.31
++
) B. SDIYLEYTR (m/z=580.29
++
) 
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Figure 41. SRM and MS/MS data for protein Wnt1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. ETAFIFAITSAGVTHSVAR (m/z=660.18
+++
) B. 
ACNSSSPALDGCELLCCGR (m/z=1063.94
++
) C. QNPGILHSVSGGLQSAVR 
(m/z=607.33
+++
) 
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Figure 42. SRM and MS/MS data for protein CDKI1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. WNFDFVTETPLEGDFAWER (m/z=1180.04
++
) B. DCDALMAGCIQEAR 
(m/z=805.34
++
) 
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Figure 43. SRM and MS/MS data for protein Wnt3A. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. ESAFVHAIASAGVAFAVTR (m/z=635.34
+++
) B. SCAEGTAAICGCSSR 
(m/z=793.82
++
) C. IGIQECQHQFR (m/z=472.57
+++
) 
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Figure 44. SRM and MS/MS data for protein APC. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. NDSLSSLDFDDDDVDLSR (m/z=1014.44
++
) B. SAEDPVSEVPAVSQHPR 
(m/z=762.30
+++
) C. NVSSLIATNEDHR (m/z=485.91
+++
) 
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Figure 45. SRM and MS/MS data for protein Hey1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions are shown in a 
chromatogram (left). Sequence information can be confirmed with MS/MS spectra 
(right). A. YLSIIEGLDASDPLR (m/z=831.44
++
) B. LVSHLNNYASQR 
(m/z=467.91
+++
) C. LGSAHPEAPALR (m/z=406.89
+++
) 
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Figure 46. SRM and MS/MS data for protein Notch1. SRM-triggered MS/MS spectra 
were obtained for synthetic peptide targets. Top five SRM transitions  are shown in a 
chromatogram(left). Sequence information can be confirmed with MS/MS spectra 
(right).A. NGGTCDLLTLTEYK (m/z=792.88
++
) B. FEEPVVLPDLDDQTDHR 
(m/z=675.66
+++
) C. GSIVYLEIDNR (m/z=639.84
++
) 
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To ensure optimal transition signal, each peptide was subjected to the collision energy 
optimization feature in Skyline. Collision energy voltage was changed stepwise by +/- 5 
V. The voltage giving the maximum peak area was used for all subsequent analyses. 
In order to confirm that target peptides could be detected endogenously, the SRM 
protocols were tested on tryptic digests of CA1K cell lysates. A great deal of 
optimization took place. Multiple HPLC gradients were used before finalizing a 170 
minute gradient consisting of a 120 minute gradient of 5-40% acetonitrile, followed by a 
50 minute re-equilibration step. Sample injection varied from 2-10 µL or 2-12.5 µg of 
peptides to determine optimal signal while retaining enough sample for multiple 
replicates. Dwell time was tested from 20-45 ms. Transitions were sorted into three 
protocols by protein mass range, with a high (311 kDa - 53 kDa) middle (49kDa - 39kDa) 
and low (38 kDa - 18kDa). The general SRM protocol was split into three methods 
containing 160 transitions each, with a dwell time of 20 ms. 5 µL injections of 10 µg of 
peptide sample were used. To improve cycle time, an SRM-triggered MS/MS scan was 
not included. Peptides were confirmed to be detected when 4 or more SRM transitions 
co-eluted. Table 3 shows the target peptides identified in SRM analyses of tryptic digests 
of unfractionated CA1K cell lysates, 66% of targets were identified. Target peptides that 
were identified were eluting at a reproducible time point with similar chromatographic 
activity, as seen in sample chromatograms in Figure 47. Since peptides were being 
successfully detected, a quantitative labeling technique was introduced in order to 
monitor changes between differentiated and undifferentiated samples. 
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Table 3.Target Peptides Detected via SRM in Unlabeled Cell CA1K Lysates. 
 
Protein
Peptide CA1K
CA1K 
Diff
Protein
Peptide CA1K
CA1K 
Diff
QNPGILHSVSGGLQSAVR   VHEFTGTDGPSGFGFELTFR  
ETAFIFAITSAGVTHSVAR   GIETDGSNLSGVSAK  
ACNSSSPALDGCELLCCGR   GLEINSKPVLPPINPQR
NVLSNRPVHAYK  FPVHGAGELCVGQNTSDK  
LSSSTEQSTSSR   GGFPGGAGASER  
SQASATAPGLPPPHPTTK   VPSYLNYHFLGEK  
SDIYLEYTR   VLIGFEEDILIVSEGK
DAHEENPESILDEHVQR   ASVVQVGFPCLGK  
TCQQAECPGGCR  
LPPNSELVQAVLR   VPSTCCAPVK 
QPLLLQVSVQR   TKPLSMLYVDNGR  
EHLGPLASGAHK  GQPSSPSPLAYMLSLYR  
NGICVSSDQNHFR LEQNPEESQDIK
SSDCASGLCCAR FEALQLSFK  
DHHQASNSSR   WVEEADNNENLQEICK  
TVPFSQTITHEGCEK   TYVEVVHQSVAQNSTQK  
VVVQNNLCFGK TEYDPHTHVYYTTAEPR
TPASQGVILPIK   LPTPSPEPPPSVVR
LGFLHSGTAK ELTPNYNPDIIFK  
SVTCTYSPALNK  SGGCFPGSATVHLEQGGTK 
RPILTIITLEDSSGNLLGR   LAHALLAALAPAR  
ESAFVYAISSAGVVFAITR  APGPLAAAVPADK  
CHGVSGSCTLR   LLQQLVLSGNLIK  
CQDCLEALDVHTCK
TSPNSLVTILNNSR   GAASSGNATGPGPR  
IKPDEDLPSPGAR  FNSSGQCEVPLVR 
GQQEQPEGTTLVK DYVLCQANVTIGLPTK  
NVSSLIATNEDHR   IGIQECQHQFR  
SAEDPVSEVPAVSQHPR   ESAFVHAIASAGVAFAVTR
NDSLSSLDFDDDDVDLSR SCAEGTAAICGCSSR
TFHVETPEER ETAFTYAVSAAGVVNAMSR
FYGAEIVSALDYLHSEK   FNSPTTQDLVYIDPSPDYCVR
TFCGTPEYLAPEVLEDNDYGR   NESTGSLGTQGR  
HAVVNLINYQDDAELATR   EGSDLSVVER 
LLNDEDQVVVNK   HPQGSLDTGEEAEEVGLK
NEGVATYAAAVLFR   SELLLSEK  
DCDALMAGCIQEAR   FSYSVIWIMAISK
WNFDFVTETPLEGDFAWER  DDSIWPQEEPAIRPR
TPELPPSAR
NOTCH1 NGGTCDLLTLTEYK   NSSSPVAATPASVNTTPDKPK 
GSIVYLEIDNR FLSTCEGVNTEVR 
FEEPVVLPDLDDQTDHR   LGSQAGEAAK
GSK3-Beta VIGNGSFGVVYQAK   YLSIIEGLDASDPLR 
DIKPQNLLLDPDTAVLK   LVSHLNNYASQR
IQAAASTPTNATAASDANTGDR   LGSAHPEAPALR
SFRP-1 FYTKPPQCVDIPADLR   SRFP-2 LPNLLGHETMK
SEAIIEHLCASEFALR EVLEQAGAWIPLVMK 
SQYLLTAIHK  DSLQCTCEEMNDINAPYLVMGQK
Nanog TVFSSTQLCVLNDR   Beta-Actin VAPEEHPVLLTEAPLNPK  
YLSLQQMQELSNILNLSYK   GYSFTTTAER  
NSNGVTQK  SYELPDGQVITIGNER  
Beta-
Catenin
Activin-A 
(homodimer, 
beta A chain)
CDKI1 
Aka p21
TDGF/Cripto
-1
Hes1
Hey1
GLI3 Smoothened
APC Wnt3a
Akt1 Wnt5a
Cerberus Patched
P53 Sonic 
Hedgehog
Wnt2 FRAT-1
AXIN-1 WIF-1
Lefty-1 Nodal
DKK1 POUF51
Wnt1 SUFU
DVL-1 Frizzled-1
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Figure 47. Target peptides were detected in tryptic digests of undifferentiated CA1K 
cell lysate. Sample SRM data for A. β-catenin peptide NEGVATYAAAVLFR. B. Oct4 
peptide FEALQLSFK, imaged in Skyline software.  Each graph represents an 
independent biological replicate with similar retention times and intensities upon repeated 
injections. Each peak represents a single transition for the respective peptide. 
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3.3 Dimethyl Label Incorporation  
In order to quantify the protein changes between differentiated and undifferentiated cell 
populations, dimethyl labeling was chosen as a labeling technique. With the benefits of 
being added at the peptide level and being relatively inexpensive, if could be used with 
already harvested protein sample. To ensure the dimethyl labeling protocol was 
functioning properly, the target peptide HPQGSLDTGEEAEEVGLK was subjected to 
both the light and heavy labeling process, as seen in Figure 4. Dimethyl labeling 
occurred at primary amines, which include the N-terminus and the lysine side chain. 
SRM assays were generated for the light, heavy, and unlabeled versions of the peptide, 
and each treatment of the peptide was analyzed for the presence of each transition. As 
seen in Figure 48, in each treatment, the expected transitions are detected. The light 
labeled peptide is uniquely detected in the light dimethyl label treatment, and the heavy 
labeled peptide is uniquely detected in the heavy dimethyl label treatment. The light and 
heavy treatments retain some unlabeled peptide, however, this amounts to less than 0.1% 
of the total signal. The intensity of the labeled peptide is greater than 10
6
 cps, suggesting 
nearly 100% incorporation. The labeled transitions are unique to their respective 
treatments. In addition, the retention times do not differ substantially between treatments. 
As the dimethyl label causes peptides to become slightly more hydrophobic, the retention 
time is expected to increase slightly. 
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 As seen in Figure 47, for this sample peptide the 
retention time increases slightly from 19.9 minutes to 20.2 minutes. In addition, the 
MS/MS fragmentation and transition intensities are nearly identical between labeling 
techniques.  To determine whether the labeling could accurately quantify samples in an 
SRM assay, a BSA tryptic digest was dimethyl-labeled and mixed in 1:2, 1:1, and 2:1 
light-to-heavy ratios. Acquired SRM intensities matched those values. 
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Figure 48. Efficiency of dimethyl labeling of peptides. Target peptide 
HPQGSLDTGEEAEEVGLK was treated with both the heavy and light dimethyl labels 
and left unlabeled.  Peptide was subjected to LC-SRM analysis. Transitions for the 
unlabeled, light, and heavy labeled peptides were monitored for each treatment. The 
chromatograms depict the intensities and retention times of the detected transitions. 
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3.4 Quantitation and Scheduled Method 
Because the protein expression changes were expected to be more drastic, the H9 
differentiation line was used. H9 cell lysates treated with BMP4 were subjected to in-
solution trypsin digests and subjected to dimethyl labeling. Undifferentiated cells were 
treated with the light label, while differentiated cells were treated with the heavy label. 
The samples were mixed in a 1:1 ratio, desalted, dried, and resuspended in 10% formic 
acid. However, by introducing the heavy and light label within one sample, the number of 
transitions requiring detection has doubled, requiring six unscheduled instrument runs of 
160 transitions each. Because this consumed a great deal of sample, limiting the 
availability for technical replicates, as well as being an inefficient use of instrument time, 
a scheduled  SRM method was developed. Within a scheduled SRM method, transitions 
are only scanned for within a given window of their retention times, allowing for more 
efficient instrument usage and more transitions to be detected in each run. Cycle time 
determines the amount of time it takes to cycle through concurrently measured 
transitions. Retention times were obtained for synthetic heavy and light dimethyl labeled 
peptides, and transitions were reconfirmed. Some b ions were enhanced in dimethyl 
labeled peptides and were added to the protocol if they exceeded y ion intensities. To 
ensure maximum sensitivity, retention time windows of 1 to 4 minutes were tested, along 
with cycle times of 1 to 3 seconds, as seen in Figure 49. Ideal chromatographic peaks 
were well defined by multiple data points over the course of elution and easily separated 
from the noise, and completely within the retention time window. It was determined that 
a cycle time of 2 seconds led to the best peak shapes and a 4 minute retention time 
window accounted for any variation in chromatography. A single protocol encompassing 
990 transitions was created. A table summarizing the SRM method containing each 
transition targeted, including collision energy, declustering potential, and retention time 
can be seen in Appendix A. 
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Figure 49. Optimization of scheduled SRM method settings. Scheduled SRM method 
settings for retention time windows and cycle times were tested on dimethyl-labeled H9 
lysate. Depicted are SRM chromatograms for β-actin peptide GYSFTTTAER under 
varying acquisition conditions.  A. 1 minute window, 1 second scan time B. 2 minute 
window, 1 second scan time C. 2 minute window, 2 second scan time D. 2 minute 
window, 3 second scan time E. 3 minute window, 1 second scan time F. 3 minute 
window, 2 second scan time G. 4 minute window, 1 second scan time. 
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 H9 cells differentiated through treatment with BMP4 and undifferentiated controls were 
harvested, lysed, and subjected to an in-solution tryptic digest. Upon digestion, samples 
were dimethyl labeled and mixed 1:1 ahead of SRM analysis. Differentiated sample was 
heavy labeled, undifferentiated sample was light labeled. Four biological samples were 
injected in triplicate using the scheduled SRM protocol. Sample SRM chromatograms 
from the can be seen in Figure 50. Three proteins were found to be reproducibly 
detectable for all three peptides for each target within both differentiated and 
undifferentiated H9 cells and thus capable of quantitation: β-catenin, Wnt1, and β-actin. 
The peak areas for each peptide’s transitions were used for quantitation. All three were 
subjected to statistical analysis as described by Bisson et al.
80
  Briefly, transitions were 
scored based on their signal-to-noise ratio to limit the influence of outlier data, and 
transition, peptide, and protein fold changes were calculated from weighted transition 
peak areas. Fold change expression upon differentiation can be seen in Figure 51. β-
catenin expression was shown to increase by 11-fold during H9 differentiation, while 
Wnt1 expression was shown to increase 3.4-fold. Β-actin expression decreased by 1.5 
fold. None of these changes were found to be statistically significant by the protein 
weight threshold cut-off described in the analysis, but under a less stringent 
quantification method of summing all transitions for each peptide of a protein, beta-
catenin differential expression was found to be significant for p <0.05.  Other Wnt 
signalling pathway-related proteins seemed to be preferentially detected in the 
differentiated sample, however, under this analysis, no other proteins were found to be 
quantifiable, as peptides were either not present, or lost in the noise of a complex sample. 
Table 4 outlines some of the targets that have and have not been detected. Lefty and 
Hey1 appeared to by preferentially detected in differentiated samples. Detection was 
defined by the presence of two or more coeluting transitions, quantification require more 
stringent criteria.  For some that have been detected, SRM signal varied considerably 
between technical replicates, excluding them from statistical analysis. For others, such as 
the SFRP2 targets, intensities were too low to separate from the background. Other 
peptide targets experienced poor chromatography resulting in peaks eluting outside the 
set retention window. Other targets exhibited detection of one or two transitions, or a 
single peptide, not enough to confirm target identity. Interference from co-eluting 
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peptides may also be responsible for causing much of the noise preventing proper 
detection. Mean peak areas and standard deviation for each transition in the scheduled 
SRM protocol can be seen in Appendix B. 
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Figure 50. Scheduled SRM data for dimethyl labeled H9 lysate. Chromatograms 
represent the sum of all transitions for the given peptide. Blue represents undifferentiated 
sample, red represents differentiated sample.  A.  β-catenin. - NEGVATYAAAVLFR  B. 
Wnt1 - QNPGILHSVSGGLQSAVR  C. Actin - GYSFTTTAER 
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Figure 51.  Protein fold change for H9 BMP4-driven differentiation. 100 µg of H9 
and H9BMP4 cell lysates were tryptically digested, dimethyl labelled, and mixed 1:1. 
Samples were run on the scheduled SRM method. Peak areas for transitions were 
integrated and subjected to statistical analysis and expressed as protein fold change of 
differentiated cells relative to undifferentiated cells. Error bars are the weighted standard 
error of each protein’s peptide fold change values. Four biological replicates were used. 
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Table 4. Peptide targets detected in dimethyl labelled H9 cell lysates. 
 
 
Sample 1 Sample 2 Sample 3 Sample 4
Protein Peptide Light Heavy Light Heavy Light Heavy Light Heavy
QNPGILHSVSGGLQSAVR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
ETAFIFAITSAGVTHSVAR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
ACNSSSPALDGCELLCCGR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
LPPNSELVQAVLR ✓ ✓ ✓ ✓
QPLLLQVSVQR ✓ ✓ ✓ ✓
EHLGPLASGAHK ✓ ✓ ✓ ✓
NGICVSSDQNHFR
SSDCASGLCCAR
DHHQASNSSR ✓ ✓ ✓ ✓
TVPFSQTITHEGCEK ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
VVVQNNLCFGK ✓ ✓ ✓ ✓
TPASQGVILPIK ✓ ✓ ✓ ✓
TSPNSLVTILNNSR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
IKPDEDLPSPGAR ✓ ✓ ✓ ✓
GQQEQPEGTTLVK
TFHVETPEER ✓ ✓ ✓ ✓
FYGAEIVSALDYLHSEK ✓ ✓ ✓ ✓
TFCGTPEYLAPEVLEDNDYGR ✓ ✓ ✓ ✓
HAVVNLINYQDDAELATR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
LLNDEDQVVVNK ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
NEGVATYAAAVLFR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
GSK3-Beta VIGNGSFGVVYQAK ✓ ✓ ✓ ✓
DIKPQNLLLDPDTAVLK ✓ ✓ ✓ ✓
IQAAASTPTNATAASDANTGDR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
SFRP-1 FYTKPPQCVDIPADLR ✓ ✓ ✓ ✓
SEAIIEHLCASEFALR ✓ ✓ ✓ ✓
SQYLLTAIHK ✓ ✓ ✓ ✓
Nanog TVFSSTQLCVLNDR ✓ ✓ ✓ ✓
YLSLQQMQELSNILNLSYK ✓ ✓ ✓ ✓ ✓
NSNGVTQK ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
VLIGFEEDILIVSEGK ✓ ✓
ASVVQVGFPCLGK ✓ ✓ ✓ ✓
TCQQAECPGGCR ✓ ✓ ✓ ✓
VPSTCCAPVK ✓ ✓ ✓ ✓
TKPLSMLYVDNGR ✓ ✓ ✓ ✓
GQPSSPSPLAYMLSLYR
LEQNPEESQDIK
FEALQLSFK ✓ ✓ ✓ ✓
WVEEADNNENLQEICK
ELTPNYNPDIIFK ✓ ✓ ✓ ✓
SGGCFPGSATVHLEQGGTK ✓ ✓ ✓ ✓
LAHALLAALAPAR ✓ ✓ ✓ ✓
APGPLAAAVPADK ✓ ✓ ✓ ✓
LLQQLVLSGNLIK
FSYSVIWIMAISK ✓
DDSIWPQEEPAIRPR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
TPELPPSAR
NSSSPVAATPASVNTTPDKPK ✓ ✓ ✓ ✓
FLSTCEGVNTEVR
LGSQAGEAAK
YLSIIEGLDASDPLR ✓ ✓ ✓ ✓
LVSHLNNYASQR ✓ ✓ ✓ ✓
LGSAHPEAPALR ✓ ✓ ✓ ✓
SRFP-2 LPNLLGHETMK ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
EVLEQAGAWIPLVMK ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
DSLQCTCEEMNDINAPYLVMGQK ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Beta-Actin VAPEEHPVLLTEAPLNPK ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
GYSFTTTAER ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
SYELPDGQVITIGNER ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
TDGF/Cripto-1
Hes1
Hey1
Sonic Hedgehog
FRAT-1
WIF-1
Nodal
POUF51
GLI3
Akt1
Beta-Catenin
Wnt1
Lefty-1
DKK1
Cerberus
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Due to the lack of reproducibility and inability to reliably detect many of the initial 
targets, several steps were taken in order to overcome the problem. The non-fractionated 
dimethyl-labelled cell lysate may have been too complex to identify many of the target 
proteins, the peptide targets may be being masked by more abundant species, the peptides 
may be below the limit of detection, or alternately, the predicted proteotypic peptides 
were not being generated by tryptic digests.  
3.5 Single Protein Digests 
To empirically confirm whether the peptides identified were in fact proteotypic and 
appearing in tryptic digests, single protein digests were performed on a set of four 
purified recombinant human proteins: Nodal, Activin-A, Lefty, and Cripto. 1 ug aliquots 
of each were run on a 12% SDS PAGE Gel, and subjected to in-gel tryptic digestion. 
SRM assays corresponding to all possible tryptic fragments for the specified protein were 
generated, including fragments with oxidized methionine. To observe exactly which 
peptides were being produced by the digest, the sample was also subjected to Top 12 
MS/MS analysis on the Q Exactive™. MS data was uploaded to PEAKS for de novo 
sequencing and database searching. As seen in Figure 52, upwards of 90% protein 
coverage was observed for Nodal, with similar results for the other protein digests. 34 
unique peptides were observed for Nodal, 48 unique peptides were observed for Activin 
A, 11 unique peptides were observed for Cripto, and 23 unique peptides were observed 
for Lefty. The peptides previously selected for the SRM protocol were also observed, 
with the exception of Activin-A. Activin-A is heavily processed before secretion, and the 
Uniprot sequence did not reflect that, leading to SRM target selection for peptides that 
should not be present in the mature protein. Those peptide targets were replaced for 
future analyses. SRM analysis of the single protein digests on the 4000 QTRAP
®
 led to 
considerably less peptide identification. For Cripto, 3/12 potential peptides were 
identified via SRM. For Activin A, 2/3 peptides were identified via SRM. For Lefty, 8/18 
potential peptides were identified. For Nodal, 1/11 potential peptides were identified. An 
equivalent amount of sample was injected on both instruments, with the Q Exactive™ 
identifying far more potential peptide targets than the 4000 QTRAP
®
. 
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Figure 52. Sequence coverage for Nodal digest.  A tryptic digest was performed on 
rHNodal, and was subjected to LC-MS/MS on the Q Exactive™. Blue lines represent 
identified peptide sequences, in order of PEAKS peptide score, while coloured squares 
represent post-translational modifications carbamidomethylation, deamidation, and 
oxidation. Mature nodal consists only of residues 238-347.  
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3.6 Fractionation Experiments 
The dimethyl scheduled SRM protocol contained 990 transitions. The 4000 QTRAP
®
 is 
limited to detecting a maximum of 1000 transitions in a single method, so the method 
may have been too close to the upper optimal limit. 
To solve this issue, the scheduled method was divided in two, splitting the transitions by 
proteins in a high (>50 kDa) and a low (<50kDa) fraction. In order to simplify the sample 
complexity in the same manner, lysates were run on a 12% SDS-PAGE gel and 
fractionated into the high and low fractions as seen in Figure 53A. A sample SDS-PAGE 
gel can be seen in Figure 54. An in-gel tryptic digest was performed, and samples were 
subjected to LC-MS. Peptide targets found in the high fraction included those from 
Axin1, β-Catenin, β-Actin and Akt1, while those found in the low fraction included 
peptides from WIF1, Cerberus, DKK1, HES1 and FRAT1. Representative samples can 
be seen in Figure 55. A fair amount of noise still surrounds the peaks identified. 
Another fractionation was performed by cutting an SDS-PAGE gel into five fractions, as 
seen in Figure 53B. However, few peptide identifications were made beyond the most 
abundant, such as β-catenin and β-actin. Figure 56A illustrates that background noise 
was cut substantially, as the β-catenin peptide peak is very distinct. In Figure 56B-C, a 
single target transition was observed in the absence of co-eluting peaks, suggesting the 
presence of the target, but not confirming the identity. Further studies into fractionation 
could improve target detection by simplifying sample complexity, reducing noise and co-
eluting peptides or interferences. 
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Figure 53. 1D SDS-PAGE fractionation schemes. To lower sample complexity, 
samples were loaded on 1D SDS-PAGE gels. Two fractionation schemes were used: A. 
Greater than 50 kDA and lower than 50 kDA. B. Five fractions of  > 150 kDa, 150-75 
kDA, 75 – 37 kDa, 37-20 kDa, <20 kDA. 
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Figure 54. Sample SDS-PAGE Gel. 100 ug of hESC lysate was loaded in each lane. 2 
uL of PrecisionPlus DualColour Protein Standard was loaded in leftmost lane as a 
molecular weight ladder. Gel was run at 200V until dye front was removed. Gel was 
fixed, stained with Coomassie Brilliant Blue R-250, destained, and imaged.  
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Figure 55. SRM chromatograms for peptide targets detected after SDS-PAGE 
fractionation. Unlabeled H9 cell lysate was loaded onto a 12% SDS-PAGE gel. The lane 
was cut into two fractions: > 50kDa and < 50kDa. Lowered sample complexity led to 
improved detection of certain peptide targets. A. β-catenin – LLNDEDQVVVNK B. 
Frat1 – LLQQLVLSGNLIK C. Akt1  - FYGAEIVSALDYLHSEK D. WIF1– 
ASVVQVGFPCLGK E. Axin1 - SDIYLEYTR F. Oct4 – FEALQLSFK. 
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Figure 56. Five-piece SDS-PAGE fractionation of H9 lysate. To decrease sample 
complexity, H9 lysate underwent SDS-PAGE, and the gel lane was fractionated into five 
fractions. Following an in-gel tryptic digest, samples underwent SRM analysis. A. SRM 
chromatogram for β-catenin peptide LLNDEDQVVVNK, zoomed out to full gradient 
(left) and zoomed in on eluted peak (right). B. SRM chromatogram for Wnt2 peptide 
CQDCLEALDVHTCK. C. SRM chromatogram for DKK1 peptide DHHQASNSSR. 
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4 Discussion 
Because of the complex network of signaling factors and proteins responsible for 
maintaining stem cell pluripotency, as well as SRM’s ability to filter through complex 
samples to identify low abundance proteins, SRM was posited as a technique that could 
detect and quantify a defined set of proteins simultaneously, allowing the characterization 
of a cell line’s “protein fingerprint,” thereby providing another tool in stem cell 
characterization. In this study, two distinct models of differentiation were characterized 
for use as a model system to test SRM’s capability to detect and quantify protein changes 
within hPSCs. Successful detection would serve as a proof of principle that SRM is a 
valid method of proteome characterization that could be further applied to more directed 
analyses of secreted, deposited, and membrane proteins.  
4.1 Cell Line Differentiation and Characterization 
Two distinct models of hESC differentiation were characterized in this study. The BMP4-
directed differentiation of H9 cells served as a drastic differentiation method that resulted 
in visibly apparent differentiation. The Sox17/ERT2 tamoxifen inducible CA1 cell line 
served as a more nuanced model of differentiation. Cells in which Sox17 was active were 
expected to maintain some capacity for multipotency, as they have previously been 
shown to be capable of endoderm and mesoderm generation, but not ectoderm.
53
 In 
addition, this directed differentiation method was expected to generate a more 
homogeneous culture of differentiated cells. Through phase contrast microscopy, the 
difference between the two systems was apparent. While tamoxifen-induced CA1K 
differentiation resulted in colonies with a slight cobblestone structure, BMP4-driven 
differentiation of H9s resulted in a breakdown of colony structure, as cells attained a 
flattened and elongated morphology. In order to validate these approaches and confirm 
differentiation was occurring, immunofluorescence, RT-PCR and flow cytometry 
experiments were conducted. 
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4.1.1 Immunofluorescence 
Immunofluorescence staining for pluripotency and differentiation markers allowed for 
visualization of their presence in cell colonies in culture. Both the undifferentiated H9 
and CA1K lines exhibited strong nuc Oct4 and SSEA4 expression. Some slight SSEA1 
expression can be seen in the outer edges of the H9 colonies, likely caused by 
spontaneous differentiation. Oct4 expression is clearly intracellular and nuclear, as 
expected for a transcription factor, while SSEA4 expression is on the surface membrane. 
Upon differentiation, CA1Ks exhibit a decrease in overall Oct4 and SSEA4 expression, 
while SSEA1 expression becomes more prominent. For H9 differentiation, the red-yellow 
patches of fluorescence indicate increased levels of SSEA1 expression coinciding with 
expression of the pluripotency markers. Oct4 expression is expected to decrease upon 
BMP4 differentiation, as is SSEA4. Here, the staining is less prominent but still present. 
As the Oct4 staining appears more diffuse, it may be a cross-excitation between the two 
antibodies, as Alexa Fluor
®
 488 and Alexa Fluor
®
 568 share a slight overlap in 
excitiation wavelengths. The aforementioned flattened morphology is also present in the 
differentiated H9 cells. Thus, at the culture level, protein markers indicate differentiation 
is occurring. 
Immunofluorescence and confocal microscopy confirmed that the Sox17/ERT2 fusion 
protein successfully translocated to the nucleus upon tamoxifen induction. Within two 
hours of tamoxifen treatment, Sox17 clearly colocalizes with nuclear staining and can 
promote the transcription of endoderm specific genes. 
4.1.2 RT-PCR 
Within the CA1K line, real-time RT-PCR analysis shows that endoderm markers 
Cerberus, CXCR4, DLX5, GATA4 and GATA6 are being upregulated and transcribed at 
the RNA level upon induction and translocation of the SOX17/ERT2 fusion protein. Oct4 
and Nanog transcription were still maintained, as previously described by Seguin et al.
53
 
Of the markers analyzed, only the increase in CXCR4 expression was found to be 
significant with p<0.05. This may be due to the variation inherent in cell culture, as 
Cerberus expression in particular varied considerably between samples. Though the 
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changes are subtle and not immediately apparent by the protein immunofluorescence, the 
process is working as described and a definitive endoderm precursor was being produced, 
as the changes in transcript levels agreed with those in previously described SOX17 
overexpressing CA1s.
53
 The system is typically used for further downstream 
differentiation. Sox17 positive cells have been shown to express markers of liver, 
pancreas and intestinal epithelium upon further differentiation.
113
 The purpose for this 
study was to provide a subtle systemic change in protein expression rather than a more 
terminal differentiation process. 
Real-time RT-PCR analysis of H9 differentiation showed that the expression of the 
pluripotency factors Oct4 and Nanog were downregulated by approximately 50 and 75% 
respectively, which is to be expected as these cells should have far less differentiation 
potential. The decrease in expression of these factors has also been confirmed in 
literature.
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4.1.3 Flow Cytometry 
Flow cytometry experiments showed the differentiated populations are distinct from the 
undifferentiated hESC populations. Prior to use of the viability dye, analyses were 
confounded by autofluorescence of the dead cells. Being able to gate on the live cell 
population ensured that the marker expression was valid. The negative control included 
on the histograms was Fluorescence Minus One (FMO). The FMO was fully stained for 
all markers except for the one it serves as a negative control for. Rather than simply using 
a fully unstained control, it can account for any cross-reaction between the other 
antibodies that might interfere with the target fluorescence.  For the H9 differentiation 
protocol, both differentiated and undifferentiated cells were positive for Oct4 expression 
compared to the negative control, however, Oct4 expression is reduced 2.3-fold upon 
differentiation. The undifferentiated population stained primarily negative for SSEA1 
expression. The 37-fold increase in median fluorescence upon differentiation indicates a 
large shift in the population of the cells toward the differentiated state. SSEA3 expression 
also decreases 2.2-fold upon differentiation. As seen in the histogram, the level SSEA3 
expression is variable among the undifferentiated population, but upon differentiation it 
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greatly decreases. SSEA3 expression has been shown to decrease more rapidly than 
SSEA4 upon differentiation, perhaps the varied expression represents a subpopulation of 
cells ready to make the transition away from pluripotency.
114
 SSEA3 is similar to SSEA4 
in that they are both glycosphingolipids and cell surface markers of pluripotency. Neither 
SSEA3 nor SSEA4 is essential for hESC pluripotency, but loss of expression of either is 
usually an effect of differentiation.
115
  
As expected, CA1K differentiation was far more subtle, and most pluripotency markers 
were maintained. Oct4 expression was slightly increased and SSEA3 expression was 
mostly maintained. Median SSEA1 expression is decreased, but the histogram shows that 
part of the population has increased expression. The dot plots in particular make it 
difficult to consider that the tamoxifen-induced cells are in fact differentiating. Taken 
alone, tamoxifen-induced differentiation showed no significant changes by flow 
cytometry.  
Taking the three validation methods together, it has been established that the two model 
systems of differentiation have been well characterized using standard methods. 
Tamoxifen induction of the Sox17 was confirmed by the localization experiment, while 
definitive endoderm production was confirmed by the upregulation of the markers 
CXCR4, Cerberus, DLX5, GATA4 and GATA6 as shown by RT-PCR analysis. Hence, 
they could be used to determine if SRM-based techniques can be used to similarly detect 
alterations in hESC differentiation. 
4.2 SRM Assay Development 
A key benefit of SRM is the ability to identify and quantify protein expression without 
the use of antibodies. Antibodies may not be available for desired targets, development 
costs are large, and cross-reactivity can be an issue. With SRM, target design involves the 
analysis and synthesis of peptides, which can be produced inexpensively with modern 
synthesizers. Any protein can be enzymatically digested to generate peptide targets. 
Unlike some antibodies where the epitope is unknown, SRM is more specific in that the 
target is always a known peptide.
116
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Protein targets were identified through a literature search and the peptides corresponding 
to them were chosen primarily through use of various SRM tools available online. The 
actual peptides chosen were often limited by the protein sequence itself. Lange et al.’s 
guidelines such as not including methionine or tryptophan weren’t feasible for certain 
proteins.
60
 In the case of Nodal, there was a single peptide candidate in the tryptic digest 
that did not contain a methionine residue. As SRM is a targeted technique, post-
translational modifications that are not included in the list of transitions will not be 
detected due to the change in m/z. Including these modifications greatly increases the 
amount of transitions required for an SRM method, so it is often best to avoid the 
residues if possible. Glutamine and asparagine residues are also prone to deamidation 
which could also cause problems with SRM detection. Protein sequences obtained from 
Uniprot were tryptically digested in silico in Skyline and target peptides were selected 
from the list. To ensure protein specificity, each sequence was submitted to a protein 
BLAST search, and tryptic efficiency for each peptide was calculated using 
PeptideCutter. The GPMDB and SRMAtlas served as potential sources of SRM targets; 
however, the majority of their SRM peptides were theoretical rather than based on 
empirical observation.
68, 117
 Many of the target proteins did not have corresponding 
peptides in either of those databases. This indicates that they were never detected, 
possibly due to their low abundance. Because of this, synthetic peptides were generated 
in-house and optimal transitions were determined from acquired MS/MS data with the aid 
of Skyline. 
Though all these tools exist to aid in selecting “proteotypic” peptides, basing target 
selection on theoretical peptides and in silico digestions rather than previous observations 
has its pitfalls. Some proteins are heavily modified and cleaved from their transcribed 
protein sequence. This led to some selected targets that should not be present in the 
mature protein, thus explaining difficulty in identification, particularly secreted proteins. 
For example, several of the peptides originally chosen for Activin A were not present in 
the active protein, necessitating the selection of new target peptides.  
Transition selection was accomplished by subjecting synthetic peptides to LC-MS/MS. 
Specifically SRM-triggered data-dependent acquisition scans, in which detection of a 
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transition triggers the 4000 QTRAP
®
 to acquire MS/MS data, were used in order to 
obtain both optimal transitions in terms of chromatography and intensity, as well as 
sequence information to validate the peptide’s identity. The top five transitions for each 
given peptide and corresponding MS/MS data can be seen in Figures 14-46. Each 
coloured line in the chromatogram represents a fragment ion of the precursor mass, or 
one of the peaks in the MS/MS spectrum. Transition selection was primarily based on 
intensity, but also giving preference to fragment ions greater in m/z than the precursor. 
These transitions were selected and consolidated in a general protocol for cell lysates. 
The protocol was optimized for numerous instrument parameters, including collision 
energy, dwell time, sample injection amounts, and varying chromatographic gradients. 
4.3 Detection in Cell Lysates 
The general SRM protocol was tested on CA1K lysates to confirm endogenous detection, 
and roughly 65% of target peptides were identified in samples repeatedly. Proteins such 
as β-catenin and Oct4 were detected reproducibly, as seen in Figure 47. Dimethyl 
labeling was introduced as a method of relative quantitation so protein expression levels 
could be compared between differentiated and undifferentiated cells.
75
 Dimethyl labeling 
has previously been shown to couple effectively with SRM on the 4000 QTRAP
®
 by Aye 
et al.
118
 The label was shown to be well incorporated when tested on a synthetic peptide, 
and tests proceeded on H9 lysates. To account for the doubling in transitions when 
including both heavy and light-labeled peptides in the same sample, a scheduled method 
was developed in order to maximize the amount of transitions in each method. The 
labeling didn’t appear to drastically affect peptide fragmentation, however, transition 
selections were reconfirmed on labeled synthetic peptides. New transitions were 
incorporated where signal intensities improved upon original selections, as some peptides 
had enriched b ions after the labeling. 
4.4 Wnt Signaling Pathway Upregulated in BMP4 
Induced Differentiation 
The canonical Wnt signaling pathway plays a key and controversial role in hPSC 
signaling. Sumi et al. claim Wnt signaling has a biphasic role in maintenance of self-
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renewal and differentiation of hPSCs based on β-catenin expression.119 Basal levels of β -
catenin appear to maintain self-renewal, while inhibition of GSK3β promotes 
accumulation of β-catenin, which drives cells to a differentiated state.36 A study by 
Davidson et al. refutes this by showing that Wnt and β-catenin signaling are actively 
repressed by Oct4 expression in the pluripotent state through siRNA knockdown of 
Oct4.
120
 In either case, Wnt signaling appears to play a role in determining stem cell 
pluripotency. Two components of the Wnt signaling pathway, Wnt1 and β-catenin, were 
detected and found to be upregulated upon BMP4-driven H9 differentiation using the 
scheduled SRM method, which both agrees and disagrees with the literature. Activin 
A/BMP4 treatment of hESCs was shown to induce expression of canonical Wnt 
signaling, while BMP4 has also been shown to be an antagonist of the Wnt signaling 
pathway through inhibition of Akt signaling, further cementing the complexity of the 
network surrounding hPSCs.
121, 122
  However, due to sensitivity and detection issues, 
quantitation information could not be determined for other targets. In particular, if the 
expression change in β-catenin was that drastic, members of the β-catenin destruction 
complex such as Axin, GSK3β, and APC would have been expected to be detected. Axin 
in particular has been shown to be the concentration-limiting factor in formation of the β-
catenin destruction complex, so lowered expression would correspond to increased β-
catenin levels. 
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4.5 Detection and Sensitivity Issues 
Detection and sensitivity issues were a factor in being unable to obtain quantitative data 
for many targets. While many protein targets were previously detected by antibody-based 
techniques such as Western blotting, many of these targets have been rarely detected by 
mass spectrometry, as signified by their absence in online spectral libraries. To maximize 
instrument efficiency and the number of proteins quantified per run, a scheduled SRM 
protocol was used.  One limitation of using the scheduled method is the loss of control of 
dwell time. In a scheduled method, only cycle time is determined directly, therefore the 
dwell time will be a function of how many concurrent transitions are being detected.
75, 124
 
If many transitions are co-eluting or being scanned for during the same time period, low 
abundance peptides in particular may not experience a long enough dwell time, and 
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sensitivity could suffer. In addition, use of a scheduled method requires the use of 
retention times, and a recurring problem was the shifting of peptide retention times from 
run-to-run, necessitating the four minute acquisition window. Week-to-week and month-
to-month variability in the instrument itself will affect measurements.
94
 A smaller 
retention time window would lead to fewer transitions being detected at one time, but 
could miss the target altogether if it elutes outside of that narrow range. Using a different 
mass spectrometer and software platform, the Domon group developed a technique 
known as intelligent SRM (iSRM). 
62
 In this method, detection of a set of two primary 
transitions triggered the acquisition of six secondary transitions from which sequence 
data could be simulated. A dynamic range of 10 amol – 100 fmol was shown against a 
complex background, with a method exceeding 6000 transitions per 60 minutes.  In 
contrast, the 4000 QTRAP
®
 is limited to detecting 1000 scheduled transitions at a time, 
and exhibited a much higher limit of detection. 
The dimethyl labeling protocol as a quantitation method may also be reconsidered. 
Though incorporation was strong and near-complete, it’s still ultimately a relative 
quantitation method. Use of the AQUA method of spiking isotopically-labeled synthetic 
peptides of a known amount could have simplified matters on some levels.
90
 Firstly, the 
labeled peptide would be assured of being present in the sample, thus the endogenous 
peptide could be confirmed as being either below the limit of detection or not present in 
the sample. With dimethyl labeling, if the target is not detected in either sample, that 
confirmation could not be made. Secondly, the labeled peptide would serve as an internal 
standard, allowing for the direct quantitation of how much endogenous peptide is present 
in the sample. This would enable one to clearly establish the limit of detection and 
provide a better idea of how abundant the target protein is in relation to the total amount 
of sample injected. However, the cost of this approach would be substantially more than 
dimethyl labeling.  
Another concern with dimethyl labeling is the relatively small minimum mass difference 
of 4 Da, which may cause overlapping spectra to occur.
125
  This may have caused issues 
with co-isolation of both the heavy and light species at Q1, leading to poor detection by 
the instrument. Both Q1 and Q3 are set to unit resolution, meaning they can only 
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distinguish between species with a difference of 1 m/z. This problem could be averted by 
preferentially selecting lysine containing peptides, selecting doubly charged precursors, 
or incorporating a heavier dimethyl label by using deuterated sodium cyanoborohydride 
in addition to deuterated formaldehyde. Stable isotope labeling in cell culture, or SILAC, 
incorporates a higher mass label as well, and by incorporating the label during cell 
culture growth, it could minimize the amount of downstream variation during sample 
preparation.
88
 SILAC has been coupled with SRM in an analysis seeking to identify 
secreted biomarkers.
126
 
Comparing the sequence coverage of recombinant human proteins obtained from the top 
12 method on the Q Exactive™ and the SRM scans on the 4000 QTRAP®, it is clear 
there are confounding factors causing the difference in detection. Firstly, as observed in 
Figure 52, many of the observed peptides contain post-translational modifications such 
as oxidation or deamidation, as well as non-specific cleavages. As stated previously, 
SRM is a targeted method, and unless these PTMs are accounted for, they will not be 
detected.
60
 However, by including these modified peptides in the analysis, experimental 
time is increased considerably. An alternate method would be to exclude the residues 
prone to deamidation, namely glutamine and asparagine, however, after already 
excluding methionine and tryptophan, excluding one-fifth of potential residues severely 
limits the amount of peptide candidates, and many proteins may not possess sequences 
compatible with those criteria. In either case, the presence of PTM peptides, particularly 
the oxidized or deamidated versions, will affect quantitation of the unmodified peptide. 
Hence changes in post-translational modifications that may occur during differentiation 
could confound results by appearing as alterations in expression. This may particularly 
affect secreted proteins, such as Wnts, which undergo extensive modifications.
127, 128
  
Much of the problem with methionine oxidation in proteomics is that it occurs 
incompletely. Partial oxidation complicates MS analysis by creating multiple species and 
spreading out the total signal among them.  It occurs readily when methionine is exposed 
to air, as well as during storage. To work around this problem, Pesavento et al. 
selectively oxidized all methionine and cysteine residues through treatment with 
performic acid within their sample.
129
 In doing so, they were able to analyze the true 
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abundance ratios of histones as well as identify novel PTMs. However, the caveat is that 
side reactions such as formylation of lysine and nonspecific cleavage of asparagine or 
tryptophan can occur upon treatment with performic acid, leading to a more complex 
sample.
130
 Other PTMs that were not considered in this study but may play a factor in 
peptide detection include glycosylation, phosphorylation, and lipidation. Many targets in 
the study are secreted, including proteins such as Wnt1and Nodal, which are heavily 
modified and processed prior to secretion.
127, 128
 Glycosylation of Nodal improves its 
stability.
131
 Glycosylation and lipidation can interfere with proteolytic enzymes’ ability to 
cleave the protein backbone. Glycosidase treatment can increase total peptide 
identification. 
132
 Delipidation can be performed by protein precipitation in 
acetone/methanol or chloroform/methanol, though this did not appear to aid in improving 
protein sequence coverage of plasma membrane associated proteins of hESCs.
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4.6 Sample Preparation 
Unfractionated in-solution digests may have also been a poor choice in sample workup, 
considering the complexity of the sample, particularly after combining two lysates in the 
dimethyl labeling protocol.  More than 100,000 detectable peptide species elute from a 
cell lysate sample during shotgun proteomic analysis, with sensitivity and sequencing 
speed being  limitations in actual peptide identification.
134
  Interference by the sheer 
amount of peptide species may be preventing low abundance peptides from being 
detected. Undersampling of data is an issue that results from the complexity of proteomes 
and protein digests.
97
 Co-fragmentation of peptides is a concern in shotgun proteomics, 
however, the Q3 filter of SRM makes it less likely that peptides will co-fragment.
135
 
There has been a growing movement towards using unfractionated samples, for instance, 
making use of the filter-assisted sample preparation (FASP) method popularized by 
Matthias Mann.
136
 In this method, cell lysates are reduced, alkylated and trypsinized on a 
membrane, even in the presence of high concentrations of detergent. Reagents and 
detergents are removed through repeated washes with an 8 M urea solution, which is in 
turn removed through washes with ammonium bicarbonate followed by centrifugation. 
The method allows for the benefits of detergent use without requiring protein 
precipitation, improving sample preparation and recovery. However, these were also 
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coupled with ultralong analytical HPLC columns, as well as long separation gradients.
98
 
Sample throughput suffers but identifications may increase. A two-hour gradient may not 
have been sufficient to properly separate the lysate sample within the SRM studies. 
Retention times for peptide targets were frequently overlapping, leading to a large 
amount of concurrently detected transitions and a lowered sensitivity due to the decreased 
dwell time. A longer or gradient could have more effectively separated the targets and 
potentially increased sensitivity. However, it could also have led to peak broadening and 
less defined signals.
99
 
 
The lysis buffer used was urea-based, and commonly used in proteomic samples. 
However, urea-based buffers have been shown to cause carbamylation in proteins when 
heated for extended periods of time.
137
 The effect is more drastic at higher 
concentrations, but as all in-solution digests of cell lysates were performed at urea 
concentrations of less than 2 M, the effects should be minimal. Still, an alternate lysis 
buffer was tested, M-PER Mammalian Protein Extraction Reagent (Thermo), composed 
of a proprietary detergent in 25 mM bicine buffer. In-solution digests using either M-PER 
or urea lysis buffer were performed and run on a Top 12 method on the Orbitrap Elite, 
with urea buffer resulting in a superior number of protein identifications. The M-PER 
buffer could solublize proteins that might be missed with the urea buffer, such as 
membrane proteins like Frizzled or Smoothened, potentially presenting itself as a 
complementary procedure.  
The SDS-PAGE fractionation methods described slightly improved peptide detection; 
however, SRM intensities were still fairly low, and particularly noisy. This suggests that 
there are still unresolved issues taking place. These could have involved deficiencies with 
sample preparation or with the instrument. Depletion of abundant proteins or subcellular 
fractionation prior to sample workup could improve signal and detection of low 
abundance targets. The issues with reproducibility may also be a product of the 
differentiation process. The mixture of cells becomes markedly more complex going 
from the pluripotent to the differentiated state, introducing more variability in protein 
expression. 
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Issues with instrument sensitivity itself may also be a factor. In order to judge signal 
intensity and for tuning and calibration purposes, a commercially available peptide 
standard was used. Glu-1-Fibrinopeptide B (Glu-Fib, Sigma) has a sequence of 
EGVNDNEEGFFSAR and produces characteristic ions of m/z 1570.6
+
 and 785.8
++
. A 1 
pmol/uL solution was infused into the instrument for initial tuning, while 200 fmol was 
typically injected on a simple gradient to assess SRM signal. A 200 fmol injection 
typically resulted in a signal intensity of 10
4
-10
5
 counts per second (cps) under optimal 
conditions. At peak performance, the 4000 QTRAP
®
 should be capable of detecting 
peptides at a sub-femtomole level, with 50 attomoles given as a lower limit of detection.
66
 
Upon serial dilution of Glu-Fib standard, the limit of detection was typically between 1-
10 fmol of peptide. This presents an issue when the stated goal of the study is detecting 
proteins of low abundance. HPLC columns, both trapping and analytical, were replaced, 
as was the emitter tip, suggesting the issue may be with the 4000 QTRAP
® 
instrument. 
4.7 Future Experiments 
Future studies should explore more extensive fractionation of protein samples to 
overcome issues of sensitivity. Methods such as strong cation exchange (SCX) may be 
able to simplify the complexity of the sample to improve detection of low abundance 
factors. Alternately, the amount of biological sample used could be scaled up in order to 
see more of the less abundant species. Many of the protein targets were secreted or 
membrane proteins. It would be worthwhile to enrich these fractions using subcellular 
fractionation techniques or by collecting conditioned media and performing fraction-
specific SRM assays, rather than analyzing whole cell lysates, simplifying the complexity 
of the assay. 
Further studies into parallel reaction monitoring are also suggested. With the Q 
Exactive™’s ability to monitor all potential transitions of a peptide at once, in addition to 
quicker assay development, each measurement could be validated with MS/MS spectra. 
Adding an Enhanced Product Ion (EPI) scan to an SRM method to acquire MS/MS data 
for sequencing on the 4000 QTRAP
®
 increases cycle time substantially, potentially 
leading to a loss of sensitivity. The Q Exactive™’s ability to acquire MS/MS data 
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simultaneously eliminates that problem. The sequence information obtained would 
prevent falsely identifying a peptide in the case of multiple peaks with co-eluting 
transitions. 
Once a method is optimized, analysis and characterization of multiple hESC as well as 
iPSC lines should be performed. Variations between cell lines affecting differentiation 
potentials have been previously documented, therefore, the more cell lines that are 
profiled, the better the understanding of stem cell signaling. In addition, monitoring the 
changes in protein expression during reprogramming of somatic cells to iPSCs could help 
us better understand the process by which pluripotency is regained from terminally 
differentiated cells. Currently, iPSC generation is a very inefficient process and better 
characterization of the pathways responsible could result in more effective derivation.
138
 
A successful SRM protocol could also be applied to time-course differentiation assays. 
Again, many of the factors monitored are transient and dose-dependent in their action, so 
by monitoring the protein changes over various time-points as cells differentiate, a better 
understanding of the mechanisms responsible for altering cell fate could be elucidated. 
4.8 Conclusion 
SRM is a sensitive and selective technique; however, as with any other proteomic 
technique, it is highly dependent on sample preparation and instrument optimization. In 
this thesis, we validated two distinct hESC differentiation models within which protein 
expression changes could be monitored. While some protein and peptide targets 
responsible for hESC pluripotency have been identified and quantified, the network of 
proteins responsible for maintaining stem cell pluripotency must still be fully 
characterized quantitatively, which could be accomplished through improvements in the 
SRM method. A better understanding of these complex pathways would lead to better 
stem cell culture conditions, more effective differentiation protocols, and ultimately act 
as a contribution to hPSCs role in regenerative medicine.  
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Appendices 
Appendix A: List of SRM transitions. 
Precursor 
m/z 
Fragment 
m/z 
RT 
(min) Target Protein, Peptide, Fragment Ion, Label 
DP 
(V) CE (V) 
582.795 476.246 29.1 ACTB.GYSFTTTAER.+2y4. (Heavy) 72.4 28 
580.783 476.246 29.1 ACTB.GYSFTTTAER.+2y4. (Light) 72.4 28 
582.795 577.294 29.1 ACTB.GYSFTTTAER.+2y5. (Heavy) 72.4 28 
580.783 577.294 29.1 ACTB.GYSFTTTAER.+2y5. (Light) 72.4 28 
582.795 678.342 29.1 ACTB.GYSFTTTAER.+2y6. (Heavy) 72.4 28 
580.783 678.342 29.1 ACTB.GYSFTTTAER.+2y6. (Light) 72.4 28 
582.795 825.41 29.1 ACTB.GYSFTTTAER.+2y7. (Heavy) 72.4 28 
580.783 825.41 29.1 ACTB.GYSFTTTAER.+2y7. (Light) 72.4 28 
582.795 912.442 29.1 ACTB.GYSFTTTAER.+2y8. (Heavy) 72.4 28 
580.783 912.442 29.1 ACTB.GYSFTTTAER.+2y8. (Light) 72.4 28 
911.978 1298.67 47.1 ACTB.SYELPDGQVITIGNER.+2y12. (Heavy) 96.4 46.8 
909.965 1298.67 47.1 ACTB.SYELPDGQVITIGNER.+2y12. (Light) 96.4 46.8 
911.978 649.839 47.1 ACTB.SYELPDGQVITIGNER.+2y12+2. (Heavy) 96.4 46.8 
909.965 649.839 47.1 ACTB.SYELPDGQVITIGNER.+2y12+2. (Light) 96.4 46.8 
911.978 706.381 47.1 ACTB.SYELPDGQVITIGNER.+2y13+2. (Heavy) 96.4 46.8 
909.965 706.381 47.1 ACTB.SYELPDGQVITIGNER.+2y13+2. (Light) 96.4 46.8 
911.978 475.226 47.1 ACTB.SYELPDGQVITIGNER.+2y4. (Heavy) 96.4 46.8 
909.965 475.226 47.1 ACTB.SYELPDGQVITIGNER.+2y4. (Light) 96.4 46.8 
911.978 689.358 47.1 ACTB.SYELPDGQVITIGNER.+2y6. (Heavy) 96.4 46.8 
909.965 689.358 47.1 ACTB.SYELPDGQVITIGNER.+2y6. (Light) 96.4 46.8 
1009.592 1323.818 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y12. (Heavy) 102.4 51.5 
1005.567 1319.793 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y12. (Light) 102.4 51.5 
1009.592 908.511 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y16+2. (Heavy) 102.4 51.5 
1005.567 906.499 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y16+2. (Light) 102.4 51.5 
1009.592 600.402 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y5. (Heavy) 102.4 51.5 
1005.567 596.377 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y5. (Light) 102.4 51.5 
1009.592 671.439 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y6. (Heavy) 102.4 51.5 
1005.567 667.414 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y6. (Light) 102.4 51.5 
1009.592 901.529 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y8. (Heavy) 102.4 51.5 
1005.567 897.504 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y8. (Light) 102.4 51.5 
669.362 914.459 53.2 AKT1.FYGAEIVSALDYLHSEK.+3b16+2. (Heavy) 78.4 26.2 
666.679 912.446 53.2 AKT1.FYGAEIVSALDYLHSEK.+3b16+2. (Light) 78.4 26.2 
669.362 1194.63 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y10. (Heavy) 78.4 31.2 
666.679 1190.605 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y10. (Light) 78.4 31.2 
669.362 1293.699 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y11. (Heavy) 78.4 31.2 
666.679 1289.674 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y11. (Light) 78.4 31.2 
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669.362 832.446 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y15+2. (Heavy) 78.4 25.2 
666.679 830.433 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y15+2. (Light) 78.4 25.2 
669.362 913.977 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y16+2. (Heavy) 78.4 26.2 
666.679 911.965 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y16+2. (Light) 78.4 26.2 
1239.575 1209.538 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y10. (Heavy) 120.3 60.5 
1237.563 1209.538 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y10. (Light) 120.3 60.5 
1239.575 1306.591 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y11. (Heavy) 120.3 60.5 
1237.563 1306.591 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y11. (Light) 120.3 60.5 
1239.575 1377.628 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y12. (Heavy) 120.3 60.5 
1237.563 1377.628 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y12. (Light) 120.3 60.5 
1239.575 1490.712 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y13. (Heavy) 120.3 60.5 
1237.563 1490.712 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y13. (Light) 120.3 60.5 
1239.575 1080.496 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y9. (Heavy) 120.3 60.5 
1237.563 1080.496 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y9. (Light) 120.3 60.5 
426.221 646.35 27.6 AKT1.TFHVETPEER.+3b5. (Heavy) 61.4 21 
424.879 642.325 27.6 AKT1.TFHVETPEER.+3b5. (Light) 61.4 21 
426.221 747.397 27.6 AKT1.TFHVETPEER.+3b6. (Heavy) 61.4 18 
424.879 743.372 27.6 AKT1.TFHVETPEER.+3b6. (Light) 61.4 18 
426.221 433.204 27.6 AKT1.TFHVETPEER.+3y3. (Heavy) 61.4 24 
424.879 433.204 27.6 AKT1.TFHVETPEER.+3y3. (Light) 61.4 24 
426.221 530.257 27.6 AKT1.TFHVETPEER.+3y4. (Heavy) 61.4 21 
424.879 530.257 27.6 AKT1.TFHVETPEER.+3y4. (Light) 61.4 21 
426.221 631.305 27.6 AKT1.TFHVETPEER.+3y5. (Heavy) 61.4 20 
424.879 631.305 27.6 AKT1.TFHVETPEER.+3y5. (Light) 61.4 20 
1030.466 1196.507 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y10. (Heavy) 105.1 48.6 
1028.453 1196.507 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y10. (Light) 105.1 48.6 
1030.466 1311.534 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y11. (Heavy) 105.1 48.6 
1028.453 1311.534 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y11. (Light) 105.1 48.6 
1030.466 1424.618 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y12. (Heavy) 105.1 48.6 
1028.453 1424.618 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y12. (Light) 105.1 48.6 
1030.466 934.411 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y8. (Heavy) 105.1 48.6 
1028.453 934.411 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y8. (Light) 105.1 48.6 
1030.466 1049.438 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y9. (Heavy) 105.1 48.6 
1028.453 1049.438 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y9. (Light) 105.1 48.6 
496.597 578.291 31.5 APC.NVSSLIATNEDHR.+3y10+2. (Heavy) 66.5 19.1 
495.255 578.291 31.5 APC.NVSSLIATNEDHR.+3y10+2. (Light) 66.5 19.1 
496.597 621.807 31.5 APC.NVSSLIATNEDHR.+3y11+2. (Heavy) 66.5 18.1 
495.255 621.807 31.5 APC.NVSSLIATNEDHR.+3y11+2. (Light) 66.5 18.1 
496.597 771.338 31.5 APC.NVSSLIATNEDHR.+3y6. (Heavy) 66.5 25.1 
495.255 771.338 31.5 APC.NVSSLIATNEDHR.+3y6. (Light) 66.5 25.1 
496.597 842.375 31.5 APC.NVSSLIATNEDHR.+3y7. (Heavy) 66.5 26.1 
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495.255 842.375 31.5 APC.NVSSLIATNEDHR.+3y7. (Light) 66.5 26.1 
496.597 955.459 31.5 APC.NVSSLIATNEDHR.+3y8. (Heavy) 66.5 25.1 
495.255 955.459 31.5 APC.NVSSLIATNEDHR.+3y8. (Light) 66.5 25.1 
612.984 1206.623 28.7 APC.SAEDPVSEVPAVSQHPR.+3y11. (Heavy) 75 30.8 
611.643 1206.623 28.7 APC.SAEDPVSEVPAVSQHPR.+3y11. (Light) 75 30.8 
612.984 701.875 28.7 APC.SAEDPVSEVPAVSQHPR.+3y13+2. (Heavy) 75 24.8 
611.643 701.875 28.7 APC.SAEDPVSEVPAVSQHPR.+3y13+2. (Light) 75 24.8 
612.984 759.389 28.7 APC.SAEDPVSEVPAVSQHPR.+3y14+2. (Heavy) 75 23.8 
611.643 759.389 28.7 APC.SAEDPVSEVPAVSQHPR.+3y14+2. (Light) 75 23.8 
612.984 823.91 28.7 APC.SAEDPVSEVPAVSQHPR.+3y15+2. (Heavy) 75 23.8 
611.643 823.91 28.7 APC.SAEDPVSEVPAVSQHPR.+3y15+2. (Light) 75 23.8 
612.984 891.48 28.7 APC.SAEDPVSEVPAVSQHPR.+3y8. (Heavy) 75 30.8 
611.643 891.48 28.7 APC.SAEDPVSEVPAVSQHPR.+3y8. (Light) 75 30.8 
683.997 783.381 33.1 AXN1.DAHEENPESILDEHVQR.+3y13+2. (Heavy) 80.2 33 
682.656 783.381 33.1 AXN1.DAHEENPESILDEHVQR.+3y13+2. (Light) 80.2 33 
683.997 783.374 33.1 AXN1.DAHEENPESILDEHVQR.+3y6. (Heavy) 80.2 32 
682.656 783.374 33.1 AXN1.DAHEENPESILDEHVQR.+3y6. (Light) 80.2 32 
683.997 896.458 33.1 AXN1.DAHEENPESILDEHVQR.+3y7. (Heavy) 80.2 33 
682.656 896.458 33.1 AXN1.DAHEENPESILDEHVQR.+3y7. (Light) 80.2 33 
683.997 1009.543 33.1 AXN1.DAHEENPESILDEHVQR.+3y8. (Heavy) 80.2 33 
682.656 1009.543 33.1 AXN1.DAHEENPESILDEHVQR.+3y8. (Light) 80.2 33 
683.997 1096.575 33.1 AXN1.DAHEENPESILDEHVQR.+3y9. (Heavy) 80.2 33 
682.656 1096.575 33.1 AXN1.DAHEENPESILDEHVQR.+3y9. (Light) 80.2 33 
596.313 624.354 33.6 AXN1.SDIYLEYTR.+2b5. (Heavy) 73.4 23.8 
594.301 620.329 33.6 AXN1.SDIYLEYTR.+2b5. (Light) 73.4 23.8 
596.313 568.273 33.6 AXN1.SDIYLEYTR.+2y4. (Heavy) 73.4 23.8 
594.301 568.273 33.6 AXN1.SDIYLEYTR.+2y4. (Light) 73.4 23.8 
596.313 681.357 33.6 AXN1.SDIYLEYTR.+2y5. (Heavy) 73.4 29.8 
594.301 681.357 33.6 AXN1.SDIYLEYTR.+2y5. (Light) 73.4 29.8 
596.313 844.42 33.6 AXN1.SDIYLEYTR.+2y6. (Heavy) 73.4 24.8 
594.301 844.42 33.6 AXN1.SDIYLEYTR.+2y6. (Light) 73.4 24.8 
596.313 957.504 33.6 AXN1.SDIYLEYTR.+2y7. (Heavy) 73.4 24.8 
594.301 957.504 33.6 AXN1.SDIYLEYTR.+2y7. (Light) 73.4 24.8 
829.368 1164.55 29.4 CDN1A.DCDALMAGCIQEAR.+2y10. (Heavy) 90.4 39.6 
827.355 1164.55 29.4 CDN1A.DCDALMAGCIQEAR.+2y10. (Light) 90.4 39.6 
829.368 1235.587 29.4 CDN1A.DCDALMAGCIQEAR.+2y11. (Heavy) 90.4 41.6 
827.355 1235.587 29.4 CDN1A.DCDALMAGCIQEAR.+2y11. (Light) 90.4 41.6 
829.368 833.393 29.4 CDN1A.DCDALMAGCIQEAR.+2y7. (Heavy) 90.4 36.6 
827.355 833.393 29.4 CDN1A.DCDALMAGCIQEAR.+2y7. (Light) 90.4 36.6 
829.368 904.431 29.4 CDN1A.DCDALMAGCIQEAR.+2y8. (Heavy) 90.4 36.6 
827.355 904.431 29.4 CDN1A.DCDALMAGCIQEAR.+2y8. (Light) 90.4 36.6 
134 
 
 
 
829.368 1051.466 29.4 CDN1A.DCDALMAGCIQEAR.+2y9. (Heavy) 90.4 36.6 
827.355 1051.466 29.4 CDN1A.DCDALMAGCIQEAR.+2y9. (Light) 90.4 36.6 
1196.065 1219.574 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y10. (Heavy) 117.1 58 
1194.053 1219.574 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y10. (Light) 117.1 58 
1196.065 1320.622 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y11. (Heavy) 117.1 59 
1194.053 1320.622 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y11. (Light) 117.1 59 
1196.065 1449.664 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y12. (Heavy) 117.1 58 
1194.053 1449.664 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y12. (Light) 117.1 58 
1196.065 1009.437 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y8. (Heavy) 117.1 60 
1194.053 1009.437 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y8. (Light) 117.1 60 
1196.065 1122.521 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y9. (Heavy) 117.1 58 
1194.053 1122.521 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y9. (Light) 117.1 58 
644.428 1057.692 30 CER1.TPASQGVILPIK.+2y10. (Heavy) 75.8 32.6 
640.403 1053.667 30 CER1.TPASQGVILPIK.+2y10. (Light) 75.8 32.6 
644.428 714.543 30 CER1.TPASQGVILPIK.+2y6. (Heavy) 75.8 32.6 
640.403 710.517 30 CER1.TPASQGVILPIK.+2y6. (Light) 75.8 32.6 
644.428 771.564 30 CER1.TPASQGVILPIK.+2y7. (Heavy) 75.8 32.6 
640.403 767.539 30 CER1.TPASQGVILPIK.+2y7. (Light) 75.8 32.6 
644.428 899.623 30 CER1.TPASQGVILPIK.+2y8. (Heavy) 75.8 29.6 
640.403 895.598 30 CER1.TPASQGVILPIK.+2y8. (Light) 75.8 29.6 
644.428 986.655 30 CER1.TPASQGVILPIK.+2y9. (Heavy) 75.8 32.6 
640.403 982.63 30 CER1.TPASQGVILPIK.+2y9. (Light) 75.8 32.6 
599.981 661.321 31 CER1.TVPFSQTITHEGCEK.+3y11+2. (Heavy) 73.3 30 
597.298 659.309 31 CER1.TVPFSQTITHEGCEK.+3y11+2. (Light) 73.3 30 
599.981 734.856 31 CER1.TVPFSQTITHEGCEK.+3y12+2. (Heavy) 73.3 25 
597.298 732.843 31 CER1.TVPFSQTITHEGCEK.+3y12+2. (Light) 73.3 25 
599.981 783.382 31 CER1.TVPFSQTITHEGCEK.+3y13+2. (Heavy) 73.3 22 
597.298 781.369 31 CER1.TVPFSQTITHEGCEK.+3y13+2. (Light) 73.3 22 
599.981 892.413 31 CER1.TVPFSQTITHEGCEK.+3y7. (Heavy) 73.3 30 
597.298 888.388 31 CER1.TVPFSQTITHEGCEK.+3y7. (Light) 73.3 30 
599.981 1106.545 31 CER1.TVPFSQTITHEGCEK.+3y9. (Heavy) 73.3 30 
597.298 1102.52 31 CER1.TVPFSQTITHEGCEK.+3y9. (Light) 73.3 30 
671.394 1210.655 33.1 CER1.VVVQNNLCFGK.+2y10. (Heavy) 77.7 30.2 
667.368 1206.63 33.1 CER1.VVVQNNLCFGK.+2y10. (Light) 77.7 30.2 
671.394 770.417 33.1 CER1.VVVQNNLCFGK.+2y6. (Heavy) 77.7 30.2 
667.368 766.392 33.1 CER1.VVVQNNLCFGK.+2y6. (Light) 77.7 30.2 
671.394 884.46 33.1 CER1.VVVQNNLCFGK.+2y7. (Heavy) 77.7 31.2 
667.368 880.435 33.1 CER1.VVVQNNLCFGK.+2y7. (Light) 77.7 31.2 
671.394 1012.518 33.1 CER1.VVVQNNLCFGK.+2y8. (Heavy) 77.7 29.2 
667.368 1008.493 33.1 CER1.VVVQNNLCFGK.+2y8. (Light) 77.7 29.2 
671.394 1111.587 33.1 CER1.VVVQNNLCFGK.+2y9. (Heavy) 77.7 30.2 
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667.368 1107.562 33.1 CER1.VVVQNNLCFGK.+2y9. (Light) 77.7 30.2 
692.034 779.508 39.8 CTNB1.HAVVNLINYQDDAELATR.+3b7. (Heavy) 80.8 26.2 
690.692 775.482 39.8 CTNB1.HAVVNLINYQDDAELATR.+3b7. (Light) 80.8 26.2 
692.034 893.551 39.8 CTNB1.HAVVNLINYQDDAELATR.+3b8. (Heavy) 80.8 27.2 
690.692 889.525 39.8 CTNB1.HAVVNLINYQDDAELATR.+3b8. (Light) 80.8 27.2 
692.034 1295.586 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y11. (Heavy) 80.8 25.2 
690.692 1295.586 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y11. (Light) 80.8 25.2 
692.034 890.421 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y8. (Heavy) 80.8 30.2 
690.692 890.421 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y8. (Light) 80.8 30.2 
692.034 1018.48 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y9. (Heavy) 80.8 29.2 
690.692 1018.48 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y9. (Light) 80.8 29.2 
725.424 1058.567 27.8 CTNB1.LLNDEDQVVVNK.+2b9. (Heavy) 81.7 35.3 
721.398 1054.542 27.8 CTNB1.LLNDEDQVVVNK.+2b9. (Light) 81.7 35.3 
725.424 1191.615 27.8 CTNB1.LLNDEDQVVVNK.+2y10. (Heavy) 81.7 33.3 
721.398 1187.59 27.8 CTNB1.LLNDEDQVVVNK.+2y10. (Light) 81.7 33.3 
725.424 833.503 27.8 CTNB1.LLNDEDQVVVNK.+2y7. (Heavy) 81.7 35.3 
721.398 829.478 27.8 CTNB1.LLNDEDQVVVNK.+2y7. (Light) 81.7 35.3 
725.424 962.545 27.8 CTNB1.LLNDEDQVVVNK.+2y8. (Heavy) 81.7 35.3 
721.398 958.52 27.8 CTNB1.LLNDEDQVVVNK.+2y8. (Light) 81.7 35.3 
725.424 1077.572 27.8 CTNB1.LLNDEDQVVVNK.+2y9. (Heavy) 81.7 34.3 
721.398 1073.547 27.8 CTNB1.LLNDEDQVVVNK.+2y9. (Light) 81.7 34.3 
757.419 1082.599 55 CTNB1.NEGVATYAAAVLFR.+2y10. (Heavy) 85.2 35 
755.407 1082.599 55 CTNB1.NEGVATYAAAVLFR.+2y10. (Light) 85.2 35 
757.419 1181.668 55 CTNB1.NEGVATYAAAVLFR.+2y11. (Heavy) 85.2 38 
755.407 1181.668 55 CTNB1.NEGVATYAAAVLFR.+2y11. (Light) 85.2 38 
757.419 1238.689 55 CTNB1.NEGVATYAAAVLFR.+2y12. (Heavy) 85.2 38 
755.407 1238.689 55 CTNB1.NEGVATYAAAVLFR.+2y12. (Light) 85.2 38 
757.419 910.515 55 CTNB1.NEGVATYAAAVLFR.+2y8. (Heavy) 85.2 37 
755.407 910.515 55 CTNB1.NEGVATYAAAVLFR.+2y8. (Light) 85.2 37 
757.419 1011.562 55 CTNB1.NEGVATYAAAVLFR.+2y9. (Heavy) 85.2 39 
755.407 1011.562 55 CTNB1.NEGVATYAAAVLFR.+2y9. (Light) 85.2 39 
390.856 550.267 27.6 DKK1.DHHQASNSSR.+3b4. (Heavy) 58.8 22.9 
389.515 546.242 27.6 DKK1.DHHQASNSSR.+3b4. (Light) 58.8 22.9 
390.856 463.226 27.6 DKK1.DHHQASNSSR.+3y4. (Heavy) 58.8 20.9 
389.515 463.226 27.6 DKK1.DHHQASNSSR.+3y4. (Light) 58.8 20.9 
390.856 550.258 27.6 DKK1.DHHQASNSSR.+3y5. (Heavy) 58.8 20.9 
389.515 550.258 27.6 DKK1.DHHQASNSSR.+3y5. (Light) 58.8 20.9 
390.856 621.295 27.6 DKK1.DHHQASNSSR.+3y6. (Heavy) 58.8 20.9 
389.515 621.295 27.6 DKK1.DHHQASNSSR.+3y6. (Light) 58.8 20.9 
390.856 443.71 27.6 DKK1.DHHQASNSSR.+3y8+2. (Heavy) 58.8 19.9 
389.515 443.71 27.6 DKK1.DHHQASNSSR.+3y8+2. (Light) 58.8 19.9 
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522.586 625.273 27 DKK1.NGICVSSDQNHFR.+3y10+2. (Heavy) 68.4 21 
521.244 625.273 27 DKK1.NGICVSSDQNHFR.+3y10+2. (Light) 68.4 21 
522.586 681.815 27 DKK1.NGICVSSDQNHFR.+3y11+2. (Heavy) 68.4 21 
521.244 681.815 27 DKK1.NGICVSSDQNHFR.+3y11+2. (Light) 68.4 21 
522.586 903.407 27 DKK1.NGICVSSDQNHFR.+3y7. (Heavy) 68.4 28 
521.244 903.407 27 DKK1.NGICVSSDQNHFR.+3y7. (Light) 68.4 28 
522.586 990.439 27 DKK1.NGICVSSDQNHFR.+3y8. (Heavy) 68.4 28 
521.244 990.439 27 DKK1.NGICVSSDQNHFR.+3y8. (Light) 68.4 28 
522.586 545.257 27 DKK1.NGICVSSDQNHFR.+3y9+2. (Heavy) 68.4 23 
521.244 545.257 27 DKK1.NGICVSSDQNHFR.+3y9+2. (Light) 68.4 23 
688.289 1169.45 20.9 DKK1.SSDCASGLCCAR.+2y10. (Heavy) 80.1 31.1 
686.276 1169.45 20.9 DKK1.SSDCASGLCCAR.+2y10. (Light) 80.1 31.1 
688.289 736.323 20.9 DKK1.SSDCASGLCCAR.+2y6. (Heavy) 80.1 33.1 
686.276 736.323 20.9 DKK1.SSDCASGLCCAR.+2y6. (Light) 80.1 33.1 
688.289 823.355 20.9 DKK1.SSDCASGLCCAR.+2y7. (Heavy) 80.1 33.1 
686.276 823.355 20.9 DKK1.SSDCASGLCCAR.+2y7. (Light) 80.1 33.1 
688.289 894.392 20.9 DKK1.SSDCASGLCCAR.+2y8. (Heavy) 80.1 36.1 
686.276 894.392 20.9 DKK1.SSDCASGLCCAR.+2y8. (Light) 80.1 36.1 
688.289 1054.423 20.9 DKK1.SSDCASGLCCAR.+2y9. (Heavy) 80.1 33.1 
686.276 1054.423 20.9 DKK1.SSDCASGLCCAR.+2y9. (Light) 80.1 33.1 
651.328 1069.476 17 DVL1.LSSSTEQSTSSR.+2y10. (Heavy) 77.4 33.9 
649.315 1069.476 17 DVL1.LSSSTEQSTSSR.+2y10. (Light) 77.4 33.9 
651.328 665.321 17 DVL1.LSSSTEQSTSSR.+2y6. (Heavy) 77.4 34.9 
649.315 665.321 17 DVL1.LSSSTEQSTSSR.+2y6. (Light) 77.4 34.9 
651.328 794.364 17 DVL1.LSSSTEQSTSSR.+2y7. (Heavy) 77.4 35.9 
649.315 794.364 17 DVL1.LSSSTEQSTSSR.+2y7. (Light) 77.4 35.9 
651.328 895.412 17 DVL1.LSSSTEQSTSSR.+2y8. (Heavy) 77.4 33.9 
649.315 895.412 17 DVL1.LSSSTEQSTSSR.+2y8. (Light) 77.4 33.9 
651.328 982.444 17 DVL1.LSSSTEQSTSSR.+2y9. (Heavy) 77.4 34.9 
649.315 982.444 17 DVL1.LSSSTEQSTSSR.+2y9. (Light) 77.4 34.9 
487.964 608.859 26.2 DVL1.NVLSNRPVHAYK.+3y10+2. (Heavy) 65.1 21.5 
485.281 606.846 26.2 DVL1.NVLSNRPVHAYK.+3y10+2. (Light) 65.1 21.5 
487.964 658.393 26.2 DVL1.NVLSNRPVHAYK.+3y11+2. (Heavy) 65.1 23.5 
485.281 656.38 26.2 DVL1.NVLSNRPVHAYK.+3y11+2. (Light) 65.1 23.5 
487.964 746.45 26.2 DVL1.NVLSNRPVHAYK.+3y6. (Heavy) 65.1 21.5 
485.281 742.425 26.2 DVL1.NVLSNRPVHAYK.+3y6. (Light) 65.1 21.5 
487.964 508.801 26.2 DVL1.NVLSNRPVHAYK.+3y8+2. (Heavy) 65.1 25.5 
485.281 506.788 26.2 DVL1.NVLSNRPVHAYK.+3y8+2. (Light) 65.1 25.5 
487.964 552.317 26.2 DVL1.NVLSNRPVHAYK.+3y9+2. (Heavy) 65.1 23.5 
485.281 550.304 26.2 DVL1.NVLSNRPVHAYK.+3y9+2. (Light) 65.1 23.5 
608.015 1173.693 26 DVL1.SQASATAPGLPPPHPTTK.+3y11. (Heavy) 73.9 29.3 
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605.332 1169.668 26 DVL1.SQASATAPGLPPPHPTTK.+3y11. (Light) 73.9 29.3 
608.015 752.427 26 DVL1.SQASATAPGLPPPHPTTK.+3y15+2. (Heavy) 73.9 23.3 
605.332 750.414 26 DVL1.SQASATAPGLPPPHPTTK.+3y15+2. (Light) 73.9 23.3 
608.015 787.946 26 DVL1.SQASATAPGLPPPHPTTK.+3y16+2. (Heavy) 73.9 22.3 
605.332 785.933 26 DVL1.SQASATAPGLPPPHPTTK.+3y16+2. (Light) 73.9 22.3 
608.015 809.482 26 DVL1.SQASATAPGLPPPHPTTK.+3y7. (Heavy) 73.9 30.3 
605.332 805.457 26 DVL1.SQASATAPGLPPPHPTTK.+3y7. (Light) 73.9 30.3 
608.015 906.535 26 DVL1.SQASATAPGLPPPHPTTK.+3y8. (Heavy) 73.9 28.3 
605.332 902.509 26 DVL1.SQASATAPGLPPPHPTTK.+3y8. (Light) 73.9 28.3 
621.389 984.603 29.5 FRAT1.APGPLAAAVPADK.+2y10. (Heavy) 74.1 30.3 
617.364 980.578 29.5 FRAT1.APGPLAAAVPADK.+2y10. (Light) 74.1 30.3 
621.389 1041.624 29.5 FRAT1.APGPLAAAVPADK.+2y11. (Heavy) 74.1 30.3 
617.364 1037.599 29.5 FRAT1.APGPLAAAVPADK.+2y11. (Light) 74.1 30.3 
621.389 632.392 29.5 FRAT1.APGPLAAAVPADK.+2y6. (Heavy) 74.1 33.3 
617.364 628.366 29.5 FRAT1.APGPLAAAVPADK.+2y6. (Light) 74.1 33.3 
621.389 703.429 29.5 FRAT1.APGPLAAAVPADK.+2y7. (Heavy) 74.1 33.3 
617.364 699.404 29.5 FRAT1.APGPLAAAVPADK.+2y7. (Light) 74.1 33.3 
621.389 774.466 29.5 FRAT1.APGPLAAAVPADK.+2y8. (Heavy) 74.1 34.3 
617.364 770.441 29.5 FRAT1.APGPLAAAVPADK.+2y8. (Light) 74.1 34.3 
752.01 1116.729 50.3 FRAT1.LLQQLVLSGNLIK.+2y10. (Heavy) 83.6 35.8 
747.984 1112.704 50.3 FRAT1.LLQQLVLSGNLIK.+2y10. (Light) 83.6 35.8 
752.01 1244.787 50.3 FRAT1.LLQQLVLSGNLIK.+2y11. (Heavy) 83.6 36.8 
747.984 1240.762 50.3 FRAT1.LLQQLVLSGNLIK.+2y11. (Light) 83.6 36.8 
752.01 776.518 50.3 FRAT1.LLQQLVLSGNLIK.+2y7. (Heavy) 83.6 32.8 
747.984 772.493 50.3 FRAT1.LLQQLVLSGNLIK.+2y7. (Light) 83.6 32.8 
752.01 875.586 50.3 FRAT1.LLQQLVLSGNLIK.+2y8. (Heavy) 83.6 37.8 
747.984 871.561 50.3 FRAT1.LLQQLVLSGNLIK.+2y8. (Light) 83.6 37.8 
752.01 988.67 50.3 FRAT1.LLQQLVLSGNLIK.+2y9. (Heavy) 83.6 38.8 
747.984 984.645 50.3 FRAT1.LLQQLVLSGNLIK.+2y9. (Light) 83.6 38.8 
660.675 1100.55 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3b10. (Heavy) 77.7 27.9 
657.991 1096.524 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3b10. (Light) 77.7 27.9 
660.675 940.519 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3b9. (Heavy) 77.7 30.9 
657.991 936.494 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3b9. (Light) 77.7 30.9 
660.675 781.399 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y7. (Heavy) 77.7 27.9 
657.991 777.374 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y7. (Light) 77.7 27.9 
660.675 880.467 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y8. (Heavy) 77.7 27.9 
657.991 876.442 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y8. (Light) 77.7 27.9 
660.675 1040.498 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y9. (Heavy) 77.7 27.9 
657.991 1036.473 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y9. (Light) 77.7 27.9 
547.78 576.308 22.7 FZD1.GGFPGGAGASER.+2b7. (Heavy) 69.9 22 
545.767 572.283 22.7 FZD1.GGFPGGAGASER.+2b7. (Light) 69.9 22 
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547.78 590.289 22.7 FZD1.GGFPGGAGASER.+2y6. (Heavy) 69.9 31 
545.767 590.289 22.7 FZD1.GGFPGGAGASER.+2y6. (Light) 69.9 31 
547.78 647.311 22.7 FZD1.GGFPGGAGASER.+2y7. (Heavy) 69.9 31 
545.767 647.311 22.7 FZD1.GGFPGGAGASER.+2y7. (Light) 69.9 31 
547.78 704.332 22.7 FZD1.GGFPGGAGASER.+2y8. (Heavy) 69.9 31 
545.767 704.332 22.7 FZD1.GGFPGGAGASER.+2y8. (Light) 69.9 31 
547.78 801.385 22.7 FZD1.GGFPGGAGASER.+2y9. (Heavy) 69.9 25 
545.767 801.385 22.7 FZD1.GGFPGGAGASER.+2y9. (Light) 69.9 25 
544.307 658.353 42.2 FZD1.VPSYLNYHFLGEK.+3y10+2. (Heavy) 69.2 26.3 
541.624 656.34 42.2 FZD1.VPSYLNYHFLGEK.+3y10+2. (Light) 69.2 26.3 
544.307 701.869 42.2 FZD1.VPSYLNYHFLGEK.+3y11+2. (Heavy) 69.2 23.3 
541.624 699.856 42.2 FZD1.VPSYLNYHFLGEK.+3y11+2. (Light) 69.2 23.3 
544.307 750.395 42.2 FZD1.VPSYLNYHFLGEK.+3y12+2. (Heavy) 69.2 23.3 
541.624 748.383 42.2 FZD1.VPSYLNYHFLGEK.+3y12+2. (Light) 69.2 23.3 
544.307 625.386 42.2 FZD1.VPSYLNYHFLGEK.+3y5. (Heavy) 69.2 28.3 
541.624 621.361 42.2 FZD1.VPSYLNYHFLGEK.+3y5. (Light) 69.2 28.3 
544.307 1039.551 42.2 FZD1.VPSYLNYHFLGEK.+3y8. (Heavy) 69.2 27.3 
541.624 1035.526 42.2 FZD1.VPSYLNYHFLGEK.+3y8. (Light) 69.2 27.3 
739.919 1133.635 24.5 GLI3.GQQEQPEGTTLVK.+2y10. (Heavy) 82.7 33.1 
735.894 1129.61 24.5 GLI3.GQQEQPEGTTLVK.+2y10. (Light) 82.7 33.1 
739.919 1261.694 24.5 GLI3.GQQEQPEGTTLVK.+2y11. (Heavy) 82.7 32.1 
735.894 1257.668 24.5 GLI3.GQQEQPEGTTLVK.+2y11. (Light) 82.7 32.1 
739.919 779.481 24.5 GLI3.GQQEQPEGTTLVK.+2y7. (Heavy) 82.7 40.1 
735.894 775.456 24.5 GLI3.GQQEQPEGTTLVK.+2y7. (Light) 82.7 40.1 
739.919 876.534 24.5 GLI3.GQQEQPEGTTLVK.+2y8. (Heavy) 82.7 34.1 
735.894 872.509 24.5 GLI3.GQQEQPEGTTLVK.+2y8. (Light) 82.7 34.1 
739.919 1004.592 24.5 GLI3.GQQEQPEGTTLVK.+2y9. (Heavy) 82.7 32.1 
735.894 1000.567 24.5 GLI3.GQQEQPEGTTLVK.+2y9. (Light) 82.7 32.1 
486.952 762.448 28 GLI3.IKPDEDLPSPGAR.+3b6. (Heavy) 65.1 21.5 
484.268 754.398 28 GLI3.IKPDEDLPSPGAR.+3b6. (Light) 65.1 21.5 
486.952 875.532 28 GLI3.IKPDEDLPSPGAR.+3b7. (Heavy) 65.1 17.5 
484.268 867.482 28 GLI3.IKPDEDLPSPGAR.+3b7. (Light) 65.1 17.5 
486.952 577.278 28 GLI3.IKPDEDLPSPGAR.+3y11+2. (Heavy) 65.1 17.5 
484.268 577.278 28 GLI3.IKPDEDLPSPGAR.+3y11+2. (Light) 65.1 17.5 
486.952 584.315 28 GLI3.IKPDEDLPSPGAR.+3y6. (Heavy) 65.1 21.5 
484.268 584.315 28 GLI3.IKPDEDLPSPGAR.+3y6. (Light) 65.1 21.5 
486.952 812.426 28 GLI3.IKPDEDLPSPGAR.+3y8. (Heavy) 65.1 18.5 
484.268 812.426 28 GLI3.IKPDEDLPSPGAR.+3y8. (Light) 65.1 18.5 
774.438 1116.637 44.3 GLI3.TSPNSLVTILNNSR.+2y10. (Heavy) 86.4 43 
772.426 1116.637 44.3 GLI3.TSPNSLVTILNNSR.+2y10. (Light) 86.4 43 
774.438 1230.68 44.3 GLI3.TSPNSLVTILNNSR.+2y11. (Heavy) 86.4 43 
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772.426 1230.68 44.3 GLI3.TSPNSLVTILNNSR.+2y11. (Light) 86.4 43 
774.438 817.453 44.3 GLI3.TSPNSLVTILNNSR.+2y7. (Heavy) 86.4 42 
772.426 817.453 44.3 GLI3.TSPNSLVTILNNSR.+2y7. (Light) 86.4 42 
774.438 916.521 44.3 GLI3.TSPNSLVTILNNSR.+2y8. (Heavy) 86.4 41 
772.426 916.521 44.3 GLI3.TSPNSLVTILNNSR.+2y8. (Light) 86.4 41 
774.438 1029.605 44.3 GLI3.TSPNSLVTILNNSR.+2y9. (Heavy) 86.4 43 
772.426 1029.605 44.3 GLI3.TSPNSLVTILNNSR.+2y9. (Light) 86.4 43 
663.751 1116.681 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y10. (Heavy) 77.2 24.7 
659.726 1112.656 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y10. (Light) 77.2 24.7 
663.751 865.039 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y15+2. (Heavy) 77.2 23.7 
659.726 861.014 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y15+2. (Light) 77.2 23.7 
663.751 775.486 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y7. (Heavy) 77.2 24.7 
659.726 771.461 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y7. (Light) 77.2 24.7 
663.751 890.513 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y8. (Heavy) 77.2 22.7 
659.726 886.488 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y8. (Light) 77.2 22.7 
663.751 1003.597 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y9. (Heavy) 77.2 22.7 
659.726 999.572 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y9. (Light) 77.2 22.7 
712.687 977.428 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y10. (Heavy) 82.3 33.8 
711.345 977.428 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y10. (Light) 82.3 33.8 
712.687 1078.476 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y11. (Heavy) 82.3 30.8 
711.345 1078.476 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y11. (Light) 82.3 30.8 
712.687 748.322 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y7. (Heavy) 82.3 26.8 
711.345 748.322 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y7. (Light) 82.3 26.8 
712.687 835.354 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y8. (Heavy) 82.3 26.8 
711.345 835.354 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y8. (Light) 82.3 26.8 
712.687 906.391 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y9. (Heavy) 82.3 29.8 
711.345 906.391 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y9. (Light) 82.3 29.8 
751.945 1087.608 37.1 GSK3B.VIGNGSFGVVYQAK.+2y10. (Heavy) 83.6 33.8 
747.919 1083.583 37.1 GSK3B.VIGNGSFGVVYQAK.+2y10. (Light) 83.6 33.8 
751.945 1258.673 37.1 GSK3B.VIGNGSFGVVYQAK.+2y12. (Heavy) 83.6 33.8 
747.919 1254.648 37.1 GSK3B.VIGNGSFGVVYQAK.+2y12. (Light) 83.6 33.8 
751.945 796.487 37.1 GSK3B.VIGNGSFGVVYQAK.+2y7. (Heavy) 83.6 35.8 
747.919 792.461 37.1 GSK3B.VIGNGSFGVVYQAK.+2y7. (Light) 83.6 35.8 
751.945 943.555 37.1 GSK3B.VIGNGSFGVVYQAK.+2y8. (Heavy) 83.6 33.8 
747.919 939.53 37.1 GSK3B.VIGNGSFGVVYQAK.+2y8. (Light) 83.6 33.8 
751.945 1030.587 37.1 GSK3B.VIGNGSFGVVYQAK.+2y9. (Heavy) 83.6 33.8 
747.919 1026.562 37.1 GSK3B.VIGNGSFGVVYQAK.+2y9. (Light) 83.6 33.8 
772.39 1164.531 30 HES1.FLSTCEGVNTEVR.+2y10. (Heavy) 86.3 36.8 
770.377 1164.531 30 HES1.FLSTCEGVNTEVR.+2y10. (Light) 86.3 36.8 
772.39 1251.563 30 HES1.FLSTCEGVNTEVR.+2y11. (Heavy) 86.3 36.8 
770.377 1251.563 30 HES1.FLSTCEGVNTEVR.+2y11. (Light) 86.3 36.8 
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772.39 774.41 30 HES1.FLSTCEGVNTEVR.+2y7. (Heavy) 86.3 41.8 
770.377 774.41 30 HES1.FLSTCEGVNTEVR.+2y7. (Light) 86.3 41.8 
772.39 903.453 30 HES1.FLSTCEGVNTEVR.+2y8. (Heavy) 86.3 40.8 
770.377 903.453 30 HES1.FLSTCEGVNTEVR.+2y8. (Light) 86.3 40.8 
772.39 1063.484 30 HES1.FLSTCEGVNTEVR.+2y9. (Heavy) 86.3 39.8 
770.377 1063.484 30 HES1.FLSTCEGVNTEVR.+2y9. (Light) 86.3 39.8 
498.302 507.307 8 HES1.LGSQAGEAAK.+2y5. (Heavy) 65.1 27.3 
494.277 503.282 8 HES1.LGSQAGEAAK.+2y5. (Light) 65.1 27.3 
498.302 578.345 8 HES1.LGSQAGEAAK.+2y6. (Heavy) 65.1 25.3 
494.277 574.32 8 HES1.LGSQAGEAAK.+2y6. (Light) 65.1 25.3 
498.302 706.403 8 HES1.LGSQAGEAAK.+2y7. (Heavy) 65.1 23.3 
494.277 702.378 8 HES1.LGSQAGEAAK.+2y7. (Light) 65.1 23.3 
498.302 793.435 8 HES1.LGSQAGEAAK.+2y8. (Heavy) 65.1 23.3 
494.277 789.41 8 HES1.LGSQAGEAAK.+2y8. (Light) 65.1 23.3 
498.302 850.457 8 HES1.LGSQAGEAAK.+2y9. (Heavy) 65.1 25.3 
494.277 846.432 8 HES1.LGSQAGEAAK.+2y9. (Light) 65.1 25.3 
722.412 1318.782 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y12. (Heavy) 81.4 33.5 
718.386 1310.731 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y12. (Light) 81.4 33.5 
722.412 781.455 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y15+2. (Heavy) 81.4 32.5 
718.386 777.43 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y15+2. (Light) 81.4 32.5 
722.412 879.516 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y17+2. (Heavy) 81.4 27.5 
718.386 875.491 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y17+2. (Light) 81.4 27.5 
722.412 923.032 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y18+2. (Heavy) 81.4 27.5 
718.386 919.007 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y18+2. (Light) 81.4 27.5 
722.412 966.548 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y19+2. (Heavy) 81.4 27.5 
718.386 962.523 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y19+2. (Light) 81.4 27.5 
417.577 524.78 26.2 HEY1.LGSAHPEAPALR.+3y10+2. (Heavy) 60.8 18.7 
416.235 524.78 26.2 HEY1.LGSAHPEAPALR.+3y10+2. (Light) 60.8 18.7 
417.577 553.291 26.2 HEY1.LGSAHPEAPALR.+3y11+2. (Heavy) 60.8 19.7 
416.235 553.291 26.2 HEY1.LGSAHPEAPALR.+3y11+2. (Light) 60.8 19.7 
417.577 527.33 26.2 HEY1.LGSAHPEAPALR.+3y5. (Heavy) 60.8 24.7 
416.235 527.33 26.2 HEY1.LGSAHPEAPALR.+3y5. (Light) 60.8 24.7 
417.577 753.425 26.2 HEY1.LGSAHPEAPALR.+3y7. (Heavy) 60.8 24.7 
416.235 753.425 26.2 HEY1.LGSAHPEAPALR.+3y7. (Light) 60.8 24.7 
417.577 445.746 26.2 HEY1.LGSAHPEAPALR.+3y8+2. (Heavy) 60.8 22.7 
416.235 445.746 26.2 HEY1.LGSAHPEAPALR.+3y8+2. (Light) 60.8 22.7 
478.598 810.477 24.2 HEY1.LVSHLNNYASQR.+3b7. (Heavy) 65.2 21.6 
477.256 806.452 24.2 HEY1.LVSHLNNYASQR.+3b7. (Light) 65.2 21.6 
478.598 595.289 24.2 HEY1.LVSHLNNYASQR.+3y10+2. (Heavy) 65.2 18.6 
477.256 595.289 24.2 HEY1.LVSHLNNYASQR.+3y10+2. (Light) 65.2 18.6 
478.598 644.823 24.2 HEY1.LVSHLNNYASQR.+3y11+2. (Heavy) 65.2 21.6 
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477.256 644.823 24.2 HEY1.LVSHLNNYASQR.+3y11+2. (Light) 65.2 21.6 
478.598 624.31 24.2 HEY1.LVSHLNNYASQR.+3y5. (Heavy) 65.2 22.6 
477.256 624.31 24.2 HEY1.LVSHLNNYASQR.+3y5. (Light) 65.2 22.6 
478.598 965.48 24.2 HEY1.LVSHLNNYASQR.+3y8. (Heavy) 65.2 25.6 
477.256 965.48 24.2 HEY1.LVSHLNNYASQR.+3y8. (Light) 65.2 25.6 
847.469 1072.527 58 HEY1.YLSIIEGLDASDPLR.+2y10. (Heavy) 91.7 40.1 
845.457 1072.527 58 HEY1.YLSIIEGLDASDPLR.+2y10. (Light) 91.7 40.1 
847.469 1185.611 58 HEY1.YLSIIEGLDASDPLR.+2y11. (Heavy) 91.7 38.1 
845.457 1185.611 58 HEY1.YLSIIEGLDASDPLR.+2y11. (Light) 91.7 38.1 
847.469 1385.727 58 HEY1.YLSIIEGLDASDPLR.+2y13. (Heavy) 91.7 39.1 
845.457 1385.727 58 HEY1.YLSIIEGLDASDPLR.+2y13. (Light) 91.7 39.1 
847.469 886.463 58 HEY1.YLSIIEGLDASDPLR.+2y8. (Heavy) 91.7 39.1 
845.457 886.463 58 HEY1.YLSIIEGLDASDPLR.+2y8. (Light) 91.7 39.1 
847.469 943.484 58 HEY1.YLSIIEGLDASDPLR.+2y9. (Heavy) 91.7 39.1 
845.457 943.484 58 HEY1.YLSIIEGLDASDPLR.+2y9. (Light) 91.7 39.1 
561.801 589.33 27.8 INHBA.EGSDLSVVER.+2y5. (Heavy) 70.9 28.8 
559.788 589.33 27.8 INHBA.EGSDLSVVER.+2y5. (Light) 70.9 28.8 
561.801 702.414 27.8 INHBA.EGSDLSVVER.+2y6. (Heavy) 70.9 30.8 
559.788 702.414 27.8 INHBA.EGSDLSVVER.+2y6. (Light) 70.9 30.8 
561.801 817.441 27.8 INHBA.EGSDLSVVER.+2y7. (Heavy) 70.9 27.8 
559.788 817.441 27.8 INHBA.EGSDLSVVER.+2y7. (Light) 70.9 27.8 
561.801 904.473 27.8 INHBA.EGSDLSVVER.+2y8. (Heavy) 70.9 28.8 
559.788 904.473 27.8 INHBA.EGSDLSVVER.+2y8. (Light) 70.9 28.8 
561.801 961.495 27.8 INHBA.EGSDLSVVER.+2y9. (Heavy) 70.9 30.8 
559.788 961.495 27.8 INHBA.EGSDLSVVER.+2y9. (Light) 70.9 30.8 
654.008 767.398 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3b7. (Heavy) 77.2 29.7 
651.325 763.373 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3b7. (Light) 77.2 29.7 
654.008 925.468 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3b9. (Heavy) 77.2 27.7 
651.325 921.442 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3b9. (Light) 77.2 27.7 
654.008 706.428 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y6. (Heavy) 77.2 24.7 
651.325 702.403 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y6. (Light) 77.2 24.7 
654.008 777.465 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y7. (Heavy) 77.2 26.7 
651.325 773.44 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y7. (Light) 77.2 26.7 
654.008 906.508 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y8. (Heavy) 77.2 26.7 
651.325 902.483 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y8. (Light) 77.2 26.7 
491.817 588.391 30 INHBA.SELLLSEK.+2b5. (Heavy) 64.6 21.9 
487.792 584.365 30 INHBA.SELLLSEK.+2b5. (Light) 64.6 21.9 
491.817 508.328 30 INHBA.SELLLSEK.+2y4. (Heavy) 64.6 24.9 
487.792 504.303 30 INHBA.SELLLSEK.+2y4. (Light) 64.6 24.9 
491.817 621.412 30 INHBA.SELLLSEK.+2y5. (Heavy) 64.6 25.9 
487.792 617.387 30 INHBA.SELLLSEK.+2y5. (Light) 64.6 25.9 
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491.817 734.496 30 INHBA.SELLLSEK.+2y6. (Heavy) 64.6 22.9 
487.792 730.471 30 INHBA.SELLLSEK.+2y6. (Light) 64.6 22.9 
491.817 863.539 30 INHBA.SELLLSEK.+2y7. (Heavy) 64.6 21.9 
487.792 859.513 30 INHBA.SELLLSEK.+2y7. (Light) 64.6 21.9 
640.882 679.408 30 LFTY1.EHLGPLASGAHK.+2b6. (Heavy) 75.5 22.7 
636.857 675.382 30 LFTY1.EHLGPLASGAHK.+2b6. (Light) 75.5 22.7 
640.882 444.287 30 LFTY1.EHLGPLASGAHK.+2y4. (Heavy) 75.5 22.7 
636.857 440.262 30 LFTY1.EHLGPLASGAHK.+2y4. (Light) 75.5 22.7 
640.882 531.319 30 LFTY1.EHLGPLASGAHK.+2y5. (Heavy) 75.5 22.7 
636.857 527.294 30 LFTY1.EHLGPLASGAHK.+2y5. (Light) 75.5 22.7 
640.882 602.356 30 LFTY1.EHLGPLASGAHK.+2y6. (Heavy) 75.5 22.7 
636.857 598.331 30 LFTY1.EHLGPLASGAHK.+2y6. (Light) 75.5 22.7 
640.882 435.261 30 LFTY1.EHLGPLASGAHK.+2y9+2. (Heavy) 75.5 24.7 
636.857 433.248 30 LFTY1.EHLGPLASGAHK.+2y9+2. (Light) 75.5 24.7 
734.445 783.455 44 LFTY1.LPPNSELVQAVLR.+2b7. (Heavy) 83.5 33.7 
732.433 779.43 44 LFTY1.LPPNSELVQAVLR.+2b7. (Light) 83.5 33.7 
734.445 1128.637 44 LFTY1.LPPNSELVQAVLR.+2y10. (Heavy) 83.5 41.7 
732.433 1128.637 44 LFTY1.LPPNSELVQAVLR.+2y10. (Light) 83.5 41.7 
734.445 798.52 44 LFTY1.LPPNSELVQAVLR.+2y7. (Heavy) 83.5 41.7 
732.433 798.52 44 LFTY1.LPPNSELVQAVLR.+2y7. (Light) 83.5 41.7 
734.445 927.562 44 LFTY1.LPPNSELVQAVLR.+2y8. (Heavy) 83.5 41.7 
732.433 927.562 44 LFTY1.LPPNSELVQAVLR.+2y8. (Light) 83.5 41.7 
734.445 1014.594 44 LFTY1.LPPNSELVQAVLR.+2y9. (Heavy) 83.5 41.7 
732.433 1014.594 44 LFTY1.LPPNSELVQAVLR.+2y9. (Light) 83.5 41.7 
656.916 1152.71 40.5 LFTY1.QPLLLQVSVQR.+2y10. (Heavy) 77.8 37.3 
654.904 1152.71 40.5 LFTY1.QPLLLQVSVQR.+2y10. (Light) 77.8 37.3 
656.916 716.405 40.5 LFTY1.QPLLLQVSVQR.+2y6. (Heavy) 77.8 30.3 
654.904 716.405 40.5 LFTY1.QPLLLQVSVQR.+2y6. (Light) 77.8 30.3 
656.916 829.489 40.5 LFTY1.QPLLLQVSVQR.+2y7. (Heavy) 77.8 33.3 
654.904 829.489 40.5 LFTY1.QPLLLQVSVQR.+2y7. (Light) 77.8 33.3 
656.916 942.573 40.5 LFTY1.QPLLLQVSVQR.+2y8. (Heavy) 77.8 37.3 
654.904 942.573 40.5 LFTY1.QPLLLQVSVQR.+2y8. (Light) 77.8 37.3 
656.916 1055.657 40.5 LFTY1.QPLLLQVSVQR.+2y9. (Heavy) 77.8 37.3 
654.904 1055.657 40.5 LFTY1.QPLLLQVSVQR.+2y9. (Light) 77.8 37.3 
456.273 504.271 3.3 NANOG.NSNGVTQK.+2b5. (Heavy) 62 19.9 
452.248 500.246 3.3 NANOG.NSNGVTQK.+2b5. (Light) 62 19.9 
456.273 507.344 3.3 NANOG.NSNGVTQK.+2y4. (Heavy) 62 19.9 
452.248 503.319 3.3 NANOG.NSNGVTQK.+2y4. (Light) 62 19.9 
456.273 564.365 3.3 NANOG.NSNGVTQK.+2y5. (Heavy) 62 19.9 
452.248 560.34 3.3 NANOG.NSNGVTQK.+2y5. (Light) 62 19.9 
456.273 678.408 3.3 NANOG.NSNGVTQK.+2y6. (Heavy) 62 19.9 
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452.248 674.383 3.3 NANOG.NSNGVTQK.+2y6. (Light) 62 19.9 
456.273 765.44 3.3 NANOG.NSNGVTQK.+2y7. (Heavy) 62 19.9 
452.248 761.415 3.3 NANOG.NSNGVTQK.+2y7. (Light) 62 19.9 
836.437 1205.594 41.8 NANOG.TVFSSTQLCVLNDR.+2y10. (Heavy) 90.9 41.5 
834.425 1205.594 41.8 NANOG.TVFSSTQLCVLNDR.+2y10. (Light) 90.9 41.5 
836.437 1292.626 41.8 NANOG.TVFSSTQLCVLNDR.+2y11. (Heavy) 90.9 39.5 
834.425 1292.626 41.8 NANOG.TVFSSTQLCVLNDR.+2y11. (Light) 90.9 39.5 
836.437 889.456 41.8 NANOG.TVFSSTQLCVLNDR.+2y7. (Heavy) 90.9 37.5 
834.425 889.456 41.8 NANOG.TVFSSTQLCVLNDR.+2y7. (Light) 90.9 37.5 
836.437 1017.515 41.8 NANOG.TVFSSTQLCVLNDR.+2y8. (Heavy) 90.9 39.5 
834.425 1017.515 41.8 NANOG.TVFSSTQLCVLNDR.+2y8. (Light) 90.9 39.5 
836.437 1118.562 41.8 NANOG.TVFSSTQLCVLNDR.+2y9. (Heavy) 90.9 39.5 
834.425 1118.562 41.8 NANOG.TVFSSTQLCVLNDR.+2y9. (Light) 90.9 39.5 
789.102 1196.719 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y10. (Heavy) 87.1 33.7 
786.419 1192.694 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y10. (Light) 87.1 33.7 
789.102 1325.761 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y11. (Heavy) 87.1 32.7 
786.419 1321.736 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y11. (Light) 87.1 32.7 
789.102 928.99 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y15+2. (Heavy) 87.1 25.7 
786.419 926.977 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y15+2. (Light) 87.1 25.7 
789.102 1029.048 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y17+2. (Heavy) 87.1 25.7 
786.419 1027.035 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y17+2. (Light) 87.1 25.7 
789.102 1083.635 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y9. (Heavy) 87.1 32.7 
786.419 1079.609 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y9. (Light) 87.1 32.7 
958 1242.655 46 NODAL.GQPSSPSPLAYMLSLYR.+2y10. (Heavy) 99.8 52 
955.988 1242.655 46 NODAL.GQPSSPSPLAYMLSLYR.+2y10. (Light) 99.8 52 
958 1329.687 46 NODAL.GQPSSPSPLAYMLSLYR.+2y11. (Heavy) 99.8 45 
955.988 1329.687 46 NODAL.GQPSSPSPLAYMLSLYR.+2y11. (Light) 99.8 45 
958 1426.74 46 NODAL.GQPSSPSPLAYMLSLYR.+2y12. (Heavy) 99.8 46 
955.988 1426.74 46 NODAL.GQPSSPSPLAYMLSLYR.+2y12. (Light) 99.8 46 
958 1513.772 46 NODAL.GQPSSPSPLAYMLSLYR.+2y13. (Heavy) 99.8 46 
955.988 1513.772 46 NODAL.GQPSSPSPLAYMLSLYR.+2y13. (Light) 99.8 46 
958 1032.518 46 NODAL.GQPSSPSPLAYMLSLYR.+2y8. (Heavy) 99.8 54 
955.988 1032.518 46 NODAL.GQPSSPSPLAYMLSLYR.+2y8. (Light) 99.8 54 
787.447 1183.578 30 NODAL.TKPLSMLYVDNGR.+2y10. (Heavy) 86.2 42.3 
783.421 1183.578 30 NODAL.TKPLSMLYVDNGR.+2y10. (Light) 86.2 42.3 
787.447 1280.63 30 NODAL.TKPLSMLYVDNGR.+2y11. (Heavy) 86.2 37.3 
783.421 1280.63 30 NODAL.TKPLSMLYVDNGR.+2y11. (Light) 86.2 37.3 
787.447 836.426 30 NODAL.TKPLSMLYVDNGR.+2y7. (Heavy) 86.2 42.3 
783.421 836.426 30 NODAL.TKPLSMLYVDNGR.+2y7. (Light) 86.2 42.3 
787.447 983.461 30 NODAL.TKPLSMLYVDNGR.+2y8. (Heavy) 86.2 41.3 
783.421 983.461 30 NODAL.TKPLSMLYVDNGR.+2y8. (Light) 86.2 41.3 
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787.447 1070.494 30 NODAL.TKPLSMLYVDNGR.+2y9. (Heavy) 86.2 42.3 
783.421 1070.494 30 NODAL.TKPLSMLYVDNGR.+2y9. (Light) 86.2 42.3 
591.827 606.358 31 NODAL.VPSTCCAPVK.+2y5. (Heavy) 71.9 32.6 
587.802 602.333 31 NODAL.VPSTCCAPVK.+2y5. (Light) 71.9 32.6 
591.827 766.389 31 NODAL.VPSTCCAPVK.+2y6. (Heavy) 71.9 30.6 
587.802 762.364 31 NODAL.VPSTCCAPVK.+2y6. (Light) 71.9 30.6 
591.827 867.436 31 NODAL.VPSTCCAPVK.+2y7. (Heavy) 71.9 31.6 
587.802 863.411 31 NODAL.VPSTCCAPVK.+2y7. (Light) 71.9 31.6 
591.827 954.469 31 NODAL.VPSTCCAPVK.+2y8. (Heavy) 71.9 29.6 
587.802 950.443 31 NODAL.VPSTCCAPVK.+2y8. (Light) 71.9 29.6 
591.827 1051.521 31 NODAL.VPSTCCAPVK.+2y9. (Heavy) 71.9 29.6 
587.802 1047.496 31 NODAL.VPSTCCAPVK.+2y9. (Light) 71.9 29.6 
686.342 1211.529 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y10. (Heavy) 80.4 33 
685.001 1211.529 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y10. (Light) 80.4 33 
686.342 712.344 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y12+2. (Heavy) 80.4 30 
685.001 712.344 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y12+2. (Light) 80.4 30 
686.342 761.878 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y13+2. (Heavy) 80.4 29 
685.001 761.878 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y13+2. (Light) 80.4 29 
686.342 810.405 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y14+2. (Heavy) 80.4 27 
685.001 810.405 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y14+2. (Light) 80.4 27 
686.342 874.926 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y15+2. (Heavy) 80.4 25 
685.001 874.926 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y15+2. (Light) 80.4 25 
655.866 646.315 42.3 NOTC1.GSIVYLEIDNR.+2y5. (Heavy) 77.8 27.2 
653.854 646.315 42.3 NOTC1.GSIVYLEIDNR.+2y5. (Light) 77.8 27.2 
655.866 759.4 42.3 NOTC1.GSIVYLEIDNR.+2y6. (Heavy) 77.8 28.2 
653.854 759.4 42.3 NOTC1.GSIVYLEIDNR.+2y6. (Light) 77.8 28.2 
655.866 922.463 42.3 NOTC1.GSIVYLEIDNR.+2y7. (Heavy) 77.8 30.2 
653.854 922.463 42.3 NOTC1.GSIVYLEIDNR.+2y7. (Light) 77.8 30.2 
655.866 1021.531 42.3 NOTC1.GSIVYLEIDNR.+2y8. (Heavy) 77.8 29.2 
653.854 1021.531 42.3 NOTC1.GSIVYLEIDNR.+2y8. (Light) 77.8 29.2 
655.866 1134.615 42.3 NOTC1.GSIVYLEIDNR.+2y9. (Heavy) 77.8 32.2 
653.854 1134.615 42.3 NOTC1.GSIVYLEIDNR.+2y9. (Light) 77.8 32.2 
824.939 1287.68 45 NOTC1.NGGTCDLLTLTEYK.+2y10. (Heavy) 88.9 35.9 
820.914 1283.655 45 NOTC1.NGGTCDLLTLTEYK.+2y10. (Light) 88.9 35.9 
824.939 1388.728 45 NOTC1.NGGTCDLLTLTEYK.+2y11. (Heavy) 88.9 36.9 
820.914 1384.703 45 NOTC1.NGGTCDLLTLTEYK.+2y11. (Light) 88.9 36.9 
824.939 899.539 45 NOTC1.NGGTCDLLTLTEYK.+2y7. (Heavy) 88.9 36.9 
820.914 895.513 45 NOTC1.NGGTCDLLTLTEYK.+2y7. (Light) 88.9 36.9 
824.939 1012.623 45 NOTC1.NGGTCDLLTLTEYK.+2y8. (Heavy) 88.9 38.9 
820.914 1008.598 45 NOTC1.NGGTCDLLTLTEYK.+2y8. (Light) 88.9 38.9 
824.939 1127.65 45 NOTC1.NGGTCDLLTLTEYK.+2y9. (Heavy) 88.9 38.9 
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820.914 1123.625 45 NOTC1.NGGTCDLLTLTEYK.+2y9. (Light) 88.9 38.9 
365.565 463.322 26.2 P53.LGFLHSGTAK.+3b4. (Heavy) 56.2 15.8 
362.882 459.297 26.2 P53.LGFLHSGTAK.+3b4. (Light) 56.2 15.8 
365.565 495.307 26.2 P53.LGFLHSGTAK.+3y5. (Heavy) 56.2 17.8 
362.882 491.282 26.2 P53.LGFLHSGTAK.+3y5. (Light) 56.2 17.8 
365.565 632.366 26.2 P53.LGFLHSGTAK.+3y6. (Heavy) 56.2 19.8 
362.882 628.341 26.2 P53.LGFLHSGTAK.+3y6. (Light) 56.2 19.8 
365.565 446.763 26.2 P53.LGFLHSGTAK.+3y8+2. (Heavy) 56.2 16.8 
362.882 444.751 26.2 P53.LGFLHSGTAK.+3y8+2. (Light) 56.2 16.8 
365.565 475.274 26.2 P53.LGFLHSGTAK.+3y9+2. (Heavy) 56.2 16.8 
362.882 473.261 26.2 P53.LGFLHSGTAK.+3y9+2. (Light) 56.2 16.8 
700.749 839.602 54.4 P53.RPILTIITLEDSSGNLLGR.+3b7. (Heavy) 81.4 32.5 
699.407 835.576 54.4 P53.RPILTIITLEDSSGNLLGR.+3b7. (Light) 81.4 32.5 
700.749 1047.506 54.4 P53.RPILTIITLEDSSGNLLGR.+3y10. (Heavy) 81.4 30.5 
699.407 1047.506 54.4 P53.RPILTIITLEDSSGNLLGR.+3y10. (Light) 81.4 30.5 
700.749 716.405 54.4 P53.RPILTIITLEDSSGNLLGR.+3y7. (Heavy) 81.4 28.5 
699.407 716.405 54.4 P53.RPILTIITLEDSSGNLLGR.+3y7. (Light) 81.4 28.5 
700.749 803.437 54.4 P53.RPILTIITLEDSSGNLLGR.+3y8. (Heavy) 81.4 30.5 
699.407 803.437 54.4 P53.RPILTIITLEDSSGNLLGR.+3y8. (Light) 81.4 30.5 
700.749 918.464 54.4 P53.RPILTIITLEDSSGNLLGR.+3y9. (Heavy) 81.4 30.5 
699.407 918.464 54.4 P53.RPILTIITLEDSSGNLLGR.+3y9. (Light) 81.4 30.5 
702.886 831.385 28.5 P53.SVTCTYSPALNK.+2b7. (Heavy) 80 29 
698.861 827.36 28.5 P53.SVTCTYSPALNK.+2b7. (Light) 80 29 
702.886 1186.607 28.5 P53.SVTCTYSPALNK.+2y10. (Heavy) 80 31 
698.861 1182.582 28.5 P53.SVTCTYSPALNK.+2y10. (Light) 80 31 
702.886 824.481 28.5 P53.SVTCTYSPALNK.+2y7. (Heavy) 80 29 
698.861 820.456 28.5 P53.SVTCTYSPALNK.+2y7. (Light) 80 29 
702.886 925.529 28.5 P53.SVTCTYSPALNK.+2y8. (Heavy) 80 31 
698.861 921.504 28.5 P53.SVTCTYSPALNK.+2y8. (Light) 80 31 
702.886 1085.56 28.5 P53.SVTCTYSPALNK.+2y9. (Heavy) 80 31 
698.861 1081.535 28.5 P53.SVTCTYSPALNK.+2y9. (Light) 80 31 
573.854 968.539 44 PO5F1.FEALQLSFK.+2b8. (Heavy) 70.6 25.6 
569.829 964.514 44 PO5F1.FEALQLSFK.+2b8. (Light) 70.6 25.6 
573.854 654.412 44 PO5F1.FEALQLSFK.+2y5. (Heavy) 70.6 24.6 
569.829 650.387 44 PO5F1.FEALQLSFK.+2y5. (Light) 70.6 24.6 
573.854 767.496 44 PO5F1.FEALQLSFK.+2y6. (Heavy) 70.6 25.6 
569.829 763.471 44 PO5F1.FEALQLSFK.+2y6. (Light) 70.6 25.6 
573.854 838.533 44 PO5F1.FEALQLSFK.+2y7. (Heavy) 70.6 24.6 
569.829 834.508 44 PO5F1.FEALQLSFK.+2y7. (Light) 70.6 24.6 
573.854 967.576 44 PO5F1.FEALQLSFK.+2y8. (Heavy) 70.6 27.6 
569.829 963.551 44 PO5F1.FEALQLSFK.+2y8. (Light) 70.6 27.6 
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747.4 1219.61 23 PO5F1.LEQNPEESQDIK.+2y10. (Heavy) 83.3 33.5 
743.375 1215.585 23 PO5F1.LEQNPEESQDIK.+2y10. (Light) 83.3 33.5 
747.4 751.413 23 PO5F1.LEQNPEESQDIK.+2y6. (Heavy) 83.3 39.5 
743.375 747.388 23 PO5F1.LEQNPEESQDIK.+2y6. (Light) 83.3 39.5 
747.4 880.456 23 PO5F1.LEQNPEESQDIK.+2y7. (Heavy) 83.3 39.5 
743.375 876.431 23 PO5F1.LEQNPEESQDIK.+2y7. (Light) 83.3 39.5 
747.4 977.509 23 PO5F1.LEQNPEESQDIK.+2y8. (Heavy) 83.3 35.5 
743.375 973.484 23 PO5F1.LEQNPEESQDIK.+2y8. (Light) 83.3 35.5 
747.4 1091.552 23 PO5F1.LEQNPEESQDIK.+2y9. (Heavy) 83.3 35.5 
743.375 1087.527 23 PO5F1.LEQNPEESQDIK.+2y9. (Light) 83.3 35.5 
1028.001 1293.641 34.1 PO5F1.WVEEADNNENLQEICK.+2y10. (Heavy) 103.7 48.5 
1023.975 1289.615 34.1 PO5F1.WVEEADNNENLQEICK.+2y10. (Light) 103.7 48.5 
1028.001 1408.667 34.1 PO5F1.WVEEADNNENLQEICK.+2y11. (Heavy) 103.7 47.5 
1023.975 1404.642 34.1 PO5F1.WVEEADNNENLQEICK.+2y11. (Light) 103.7 47.5 
1028.001 1479.705 34.1 PO5F1.WVEEADNNENLQEICK.+2y12. (Heavy) 103.7 47.5 
1023.975 1475.679 34.1 PO5F1.WVEEADNNENLQEICK.+2y12. (Light) 103.7 47.5 
1028.001 1065.555 34.1 PO5F1.WVEEADNNENLQEICK.+2y8. (Heavy) 103.7 47.5 
1023.975 1061.53 34.1 PO5F1.WVEEADNNENLQEICK.+2y8. (Light) 103.7 47.5 
1028.001 1179.598 34.1 PO5F1.WVEEADNNENLQEICK.+2y9. (Heavy) 103.7 48.5 
1023.975 1175.573 34.1 PO5F1.WVEEADNNENLQEICK.+2y9. (Light) 103.7 48.5 
752.937 1064.573 31.7 PTC1.LPTPSPEPPPSVVR.+2y10. (Heavy) 84.8 42.7 
750.925 1064.573 31.7 PTC1.LPTPSPEPPPSVVR.+2y10. (Light) 84.8 42.7 
752.937 1161.626 31.7 PTC1.LPTPSPEPPPSVVR.+2y11. (Heavy) 84.8 40.7 
750.925 1161.626 31.7 PTC1.LPTPSPEPPPSVVR.+2y11. (Light) 84.8 40.7 
752.937 1262.674 31.7 PTC1.LPTPSPEPPPSVVR.+2y12. (Heavy) 84.8 40.7 
750.925 1262.674 31.7 PTC1.LPTPSPEPPPSVVR.+2y12. (Light) 84.8 40.7 
752.937 880.489 31.7 PTC1.LPTPSPEPPPSVVR.+2y8. (Heavy) 84.8 42.7 
750.925 880.489 31.7 PTC1.LPTPSPEPPPSVVR.+2y8. (Light) 84.8 42.7 
752.937 977.541 31.7 PTC1.LPTPSPEPPPSVVR.+2y9. (Heavy) 84.8 42.7 
750.925 977.541 31.7 PTC1.LPTPSPEPPPSVVR.+2y9. (Light) 84.8 42.7 
704.671 786.384 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y13+2. (Heavy) 81.7 32.6 
703.329 786.384 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y13+2. (Light) 81.7 32.6 
704.671 843.897 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y14+2. (Heavy) 81.7 29.6 
703.329 843.897 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y14+2. (Light) 81.7 29.6 
704.671 925.429 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y15+2. (Heavy) 81.7 29.6 
703.329 925.429 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y15+2. (Light) 81.7 29.6 
704.671 837.41 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y7. (Heavy) 81.7 33.6 
703.329 837.41 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y7. (Light) 81.7 33.6 
704.671 1000.473 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y8. (Heavy) 81.7 33.6 
703.329 1000.473 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y8. (Light) 81.7 33.6 
661.365 679.87 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y12+2. (Heavy) 77.8 26.9 
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658.681 677.857 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y12+2. (Light) 77.8 26.9 
661.365 729.404 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y13+2. (Heavy) 77.8 27.9 
658.681 727.392 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y13+2. (Light) 77.8 27.9 
661.365 793.925 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y14+2. (Heavy) 77.8 26.9 
658.681 791.913 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y14+2. (Light) 77.8 26.9 
661.365 843.46 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y15+2. (Heavy) 77.8 26.9 
658.681 841.447 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y15+2. (Light) 77.8 26.9 
661.365 808.446 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y7. (Heavy) 77.8 23.9 
658.681 804.421 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y7. (Light) 77.8 23.9 
662.032 690.851 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y12+2. (Heavy) 77.8 31.9 
659.349 690.851 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y12+2. (Light) 77.8 31.9 
662.032 770.926 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y13+2. (Heavy) 77.8 26.9 
659.349 768.914 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y13+2. (Light) 77.8 26.9 
662.032 821.45 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y14+2. (Heavy) 77.8 24.9 
659.349 819.438 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y14+2. (Light) 77.8 24.9 
662.032 902.982 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y15+2. (Heavy) 77.8 27.9 
659.349 900.969 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y15+2. (Light) 77.8 27.9 
662.032 799.431 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y7. (Heavy) 77.8 28.9 
659.349 799.431 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y7. (Light) 77.8 28.9 
626.662 795.892 45.3 SFRP1.SEAIIEHLCASEFALR.+3b14+2. (Heavy) 76 26.2 
625.321 793.88 45.3 SFRP1.SEAIIEHLCASEFALR.+3b14+2. (Light) 76 26.2 
626.662 666.822 45.3 SFRP1.SEAIIEHLCASEFALR.+3y11+2. (Heavy) 76 26.2 
625.321 666.822 45.3 SFRP1.SEAIIEHLCASEFALR.+3y11+2. (Light) 76 26.2 
626.662 723.364 45.3 SFRP1.SEAIIEHLCASEFALR.+3y12+2. (Heavy) 76 25.2 
625.321 723.364 45.3 SFRP1.SEAIIEHLCASEFALR.+3y12+2. (Light) 76 25.2 
626.662 953.451 45.3 SFRP1.SEAIIEHLCASEFALR.+3y8. (Heavy) 76 31.2 
625.321 953.451 45.3 SFRP1.SEAIIEHLCASEFALR.+3y8. (Light) 76 31.2 
626.662 1066.535 45.3 SFRP1.SEAIIEHLCASEFALR.+3y9. (Heavy) 76 30.2 
625.321 1066.535 45.3 SFRP1.SEAIIEHLCASEFALR.+3y9. (Light) 76 30.2 
413.263 429.312 31.2 SFRP1.SQYLLTAIHK.+3y3. (Heavy) 59.7 22.2 
410.58 425.287 31.2 SFRP1.SQYLLTAIHK.+3y3. (Light) 59.7 22.2 
413.263 500.349 31.2 SFRP1.SQYLLTAIHK.+3y4. (Heavy) 59.7 20.2 
410.58 496.324 31.2 SFRP1.SQYLLTAIHK.+3y4. (Light) 59.7 20.2 
413.263 601.397 31.2 SFRP1.SQYLLTAIHK.+3y5. (Heavy) 59.7 19.2 
410.58 597.372 31.2 SFRP1.SQYLLTAIHK.+3y5. (Light) 59.7 19.2 
413.263 714.481 31.2 SFRP1.SQYLLTAIHK.+3y6. (Heavy) 59.7 19.2 
410.58 710.456 31.2 SFRP1.SQYLLTAIHK.+3y6. (Light) 59.7 19.2 
413.263 495.818 31.2 SFRP1.SQYLLTAIHK.+3y8+2. (Heavy) 59.7 16.2 
410.58 493.805 31.2 SFRP1.SQYLLTAIHK.+3y8+2. (Light) 59.7 16.2 
938.096 1168.633 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y10. (Heavy) 97.9 30.2 
935.413 1164.608 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y10. (Light) 97.9 30.2 
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938.096 1281.717 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y11. (Heavy) 97.9 36.2 
935.413 1277.692 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y11. (Light) 97.9 36.2 
938.096 1038.473 41.5 
SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y17+2. 
(Heavy) 97.9 34.2 
935.413 1036.46 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y17+2. (Light) 97.9 34.2 
938.096 983.553 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y8. (Heavy) 97.9 33.2 
935.413 979.528 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y8. (Light) 97.9 33.2 
938.096 1054.59 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y9. (Heavy) 97.9 30.2 
935.413 1050.565 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y9. (Light) 97.9 30.2 
882.514 1133.669 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y10. (Heavy) 93.1 40.8 
878.489 1129.644 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y10. (Light) 93.1 40.8 
882.514 1261.728 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y11. (Heavy) 93.1 39.8 
878.489 1257.702 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y11. (Light) 93.1 39.8 
882.514 934.573 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y7. (Heavy) 93.1 38.8 
878.489 930.548 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y7. (Light) 93.1 38.8 
882.514 1005.61 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y8. (Heavy) 93.1 39.8 
878.489 1001.585 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y8. (Light) 93.1 39.8 
882.514 1062.632 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y9. (Heavy) 93.1 41.8 
878.489 1058.607 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y9. (Light) 93.1 41.8 
444.931 594.323 30.1 SFRP2.LPNLLGHETMK.+3y10+2. (Heavy) 62 20 
442.248 592.311 30.1 SFRP2.LPNLLGHETMK.+3y10+2. (Light) 62 20 
444.931 556.295 30.1 SFRP2.LPNLLGHETMK.+3y4. (Heavy) 62 25 
442.248 552.27 30.1 SFRP2.LPNLLGHETMK.+3y4. (Light) 62 25 
444.931 750.375 30.1 SFRP2.LPNLLGHETMK.+3y6. (Heavy) 62 24 
442.248 746.35 30.1 SFRP2.LPNLLGHETMK.+3y6. (Light) 62 24 
444.931 863.459 30.1 SFRP2.LPNLLGHETMK.+3y7. (Heavy) 62 23 
442.248 859.434 30.1 SFRP2.LPNLLGHETMK.+3y7. (Light) 62 23 
444.931 545.797 30.1 SFRP2.LPNLLGHETMK.+3y9+2. (Heavy) 62 20 
442.248 543.784 30.1 SFRP2.LPNLLGHETMK.+3y9+2. (Light) 62 20 
814.463 1252.687 47.5 SHH.ELTPNYNPDIIFK.+2y10. (Heavy) 88.2 35.3 
810.438 1248.662 47.5 SHH.ELTPNYNPDIIFK.+2y10. (Light) 88.2 35.3 
814.463 1353.735 47.5 SHH.ELTPNYNPDIIFK.+2y11. (Heavy) 88.2 36.3 
810.438 1349.71 47.5 SHH.ELTPNYNPDIIFK.+2y11. (Light) 88.2 36.3 
814.463 878.528 47.5 SHH.ELTPNYNPDIIFK.+2y7. (Heavy) 88.2 35.3 
810.438 874.503 47.5 SHH.ELTPNYNPDIIFK.+2y7. (Light) 88.2 35.3 
814.463 1041.592 47.5 SHH.ELTPNYNPDIIFK.+2y8. (Heavy) 88.2 40.3 
810.438 1037.567 47.5 SHH.ELTPNYNPDIIFK.+2y8. (Light) 88.2 40.3 
814.463 1155.635 47.5 SHH.ELTPNYNPDIIFK.+2y9. (Heavy) 88.2 41.3 
810.438 1151.609 47.5 SHH.ELTPNYNPDIIFK.+2y9. (Light) 88.2 41.3 
660.427 966.609 33.5 SHH.LAHALLAALAPAR.+2y10. (Heavy) 78.1 36.5 
658.414 966.609 33.5 SHH.LAHALLAALAPAR.+2y10. (Light) 78.1 36.5 
660.427 1103.668 33.5 SHH.LAHALLAALAPAR.+2y11. (Heavy) 78.1 35.5 
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658.414 1103.668 33.5 SHH.LAHALLAALAPAR.+2y11. (Light) 78.1 35.5 
660.427 669.404 33.5 SHH.LAHALLAALAPAR.+2y7. (Heavy) 78.1 35.5 
658.414 669.404 33.5 SHH.LAHALLAALAPAR.+2y7. (Light) 78.1 35.5 
660.427 782.488 33.5 SHH.LAHALLAALAPAR.+2y8. (Heavy) 78.1 35.5 
658.414 782.488 33.5 SHH.LAHALLAALAPAR.+2y8. (Light) 78.1 35.5 
660.427 895.572 33.5 SHH.LAHALLAALAPAR.+2y9. (Heavy) 78.1 35.5 
658.414 895.572 33.5 SHH.LAHALLAALAPAR.+2y9. (Light) 78.1 35.5 
652.003 780.874 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3b15+2. (Heavy) 77.1 30.6 
649.319 778.862 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3b15+2. (Light) 77.1 30.6 
652.003 658.859 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y13+2. (Heavy) 77.1 30.6 
649.319 656.846 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y13+2. (Light) 77.1 30.6 
652.003 707.385 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y14+2. (Heavy) 77.1 28.6 
649.319 705.373 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y14+2. (Light) 77.1 28.6 
652.003 780.92 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y15+2. (Heavy) 77.1 30.6 
649.319 778.907 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y15+2. (Light) 77.1 30.6 
652.003 901.504 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y8. (Heavy) 77.1 31.6 
649.319 897.479 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y8. (Light) 77.1 31.6 
928.526 1045.655 49 SMO.DYVLCQANVTIGLPTK.+2y10. (Heavy) 96.5 41.8 
924.5 1041.63 49 SMO.DYVLCQANVTIGLPTK.+2y10. (Light) 96.5 41.8 
928.526 1173.714 49 SMO.DYVLCQANVTIGLPTK.+2y11. (Heavy) 96.5 41.8 
924.5 1169.689 49 SMO.DYVLCQANVTIGLPTK.+2y11. (Light) 96.5 41.8 
928.526 1333.745 49 SMO.DYVLCQANVTIGLPTK.+2y12. (Heavy) 96.5 41.8 
924.5 1329.719 49 SMO.DYVLCQANVTIGLPTK.+2y12. (Light) 96.5 41.8 
928.526 1446.829 49 SMO.DYVLCQANVTIGLPTK.+2y13. (Heavy) 96.5 41.8 
924.5 1442.804 49 SMO.DYVLCQANVTIGLPTK.+2y13. (Light) 96.5 41.8 
928.526 974.618 49 SMO.DYVLCQANVTIGLPTK.+2y9. (Heavy) 96.5 41.8 
924.5 970.593 49 SMO.DYVLCQANVTIGLPTK.+2y9. (Light) 96.5 41.8 
762.892 1144.578 31 SMO.FNSSGQCEVPLVR.+2y10. (Heavy) 85.6 39.3 
760.88 1144.578 31 SMO.FNSSGQCEVPLVR.+2y10. (Light) 85.6 39.3 
762.892 1231.61 31 SMO.FNSSGQCEVPLVR.+2y11. (Heavy) 85.6 36.3 
760.88 1231.61 31 SMO.FNSSGQCEVPLVR.+2y11. (Light) 85.6 36.3 
762.892 872.466 31 SMO.FNSSGQCEVPLVR.+2y7. (Heavy) 85.6 39.3 
760.88 872.466 31 SMO.FNSSGQCEVPLVR.+2y7. (Light) 85.6 39.3 
762.892 1000.524 31 SMO.FNSSGQCEVPLVR.+2y8. (Heavy) 85.6 38.3 
760.88 1000.524 31 SMO.FNSSGQCEVPLVR.+2y8. (Light) 85.6 38.3 
762.892 1057.546 31 SMO.FNSSGQCEVPLVR.+2y9. (Heavy) 85.6 41.3 
760.88 1057.546 31 SMO.FNSSGQCEVPLVR.+2y9. (Light) 85.6 41.3 
616.32 913.449 16.9 SMO.GAASSGNATGPGPR.+2y10. (Heavy) 74.9 30 
614.307 913.449 16.9 SMO.GAASSGNATGPGPR.+2y10. (Light) 74.9 30 
616.32 1000.481 16.9 SMO.GAASSGNATGPGPR.+2y11. (Heavy) 74.9 31 
614.307 1000.481 16.9 SMO.GAASSGNATGPGPR.+2y11. (Light) 74.9 31 
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616.32 1071.518 16.9 SMO.GAASSGNATGPGPR.+2y12. (Heavy) 74.9 32 
614.307 1071.518 16.9 SMO.GAASSGNATGPGPR.+2y12. (Light) 74.9 32 
616.32 769.395 16.9 SMO.GAASSGNATGPGPR.+2y8. (Heavy) 74.9 31 
614.307 769.395 16.9 SMO.GAASSGNATGPGPR.+2y8. (Light) 74.9 31 
616.32 826.417 16.9 SMO.GAASSGNATGPGPR.+2y9. (Heavy) 74.9 31 
614.307 826.417 16.9 SMO.GAASSGNATGPGPR.+2y9. (Light) 74.9 31 
749.914 951.541 28 SUFU.GIETDGSNLSGVSAK.+2y10. (Heavy) 83.4 33.7 
745.888 947.516 28 SUFU.GIETDGSNLSGVSAK.+2y10. (Light) 83.4 33.7 
749.914 1066.568 28 SUFU.GIETDGSNLSGVSAK.+2y11. (Heavy) 83.4 33.7 
745.888 1062.543 28 SUFU.GIETDGSNLSGVSAK.+2y11. (Light) 83.4 33.7 
749.914 1167.615 28 SUFU.GIETDGSNLSGVSAK.+2y12. (Heavy) 83.4 33.7 
745.888 1163.59 28 SUFU.GIETDGSNLSGVSAK.+2y12. (Light) 83.4 33.7 
749.914 1296.658 28 SUFU.GIETDGSNLSGVSAK.+2y13. (Heavy) 83.4 33.7 
745.888 1292.633 28 SUFU.GIETDGSNLSGVSAK.+2y13. (Light) 83.4 33.7 
749.914 807.487 28 SUFU.GIETDGSNLSGVSAK.+2y8. (Heavy) 83.4 33.7 
745.888 803.462 28 SUFU.GIETDGSNLSGVSAK.+2y8. (Light) 83.4 33.7 
646.066 1115.727 38.8 SUFU.GLEINSKPVLPPINPQR.+3b10. (Heavy) 76.7 23.4 
643.382 1107.677 38.8 SUFU.GLEINSKPVLPPINPQR.+3b10. (Light) 76.7 23.4 
646.066 746.451 38.8 SUFU.GLEINSKPVLPPINPQR.+3y13+2. (Heavy) 76.7 23.4 
643.382 744.438 38.8 SUFU.GLEINSKPVLPPINPQR.+3y13+2. (Light) 76.7 23.4 
646.066 802.993 38.8 SUFU.GLEINSKPVLPPINPQR.+3y14+2. (Heavy) 76.7 24.4 
643.382 800.98 38.8 SUFU.GLEINSKPVLPPINPQR.+3y14+2. (Light) 76.7 24.4 
646.066 724.41 38.8 SUFU.GLEINSKPVLPPINPQR.+3y6. (Heavy) 76.7 30.4 
643.382 724.41 38.8 SUFU.GLEINSKPVLPPINPQR.+3y6. (Light) 76.7 30.4 
646.066 821.463 38.8 SUFU.GLEINSKPVLPPINPQR.+3y7. (Heavy) 76.7 24.4 
643.382 821.463 38.8 SUFU.GLEINSKPVLPPINPQR.+3y7. (Light) 76.7 24.4 
745.034 976.467 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3b9. (Heavy) 84.7 30.8 
743.692 972.442 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3b9. (Light) 84.7 30.8 
745.034 812.43 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y6. (Heavy) 84.7 28.8 
743.692 812.43 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y6. (Light) 84.7 28.8 
745.034 869.452 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y7. (Heavy) 84.7 30.8 
743.692 869.452 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y7. (Light) 84.7 30.8 
745.034 1016.52 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y8. (Heavy) 84.7 30.8 
743.692 1016.52 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y8. (Light) 84.7 30.8 
745.034 1073.542 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y9. (Heavy) 84.7 33.8 
743.692 1073.542 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y9. (Light) 84.7 33.8 
614.321 746.407 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y12+2. (Heavy) 75.1 23.8 
612.979 746.407 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y12+2. (Light) 75.1 23.8 
614.321 789.923 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y13+2. (Heavy) 75.1 21.8 
612.979 789.923 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y13+2. (Light) 75.1 21.8 
614.321 847.436 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y14+2. (Heavy) 75.1 26.8 
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612.979 847.436 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y14+2. (Light) 75.1 26.8 
614.321 838.489 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y7. (Heavy) 75.1 30.8 
612.979 838.489 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y7. (Light) 75.1 30.8 
614.321 1095.591 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y9. (Heavy) 75.1 30.8 
612.979 1095.591 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y9. (Light) 75.1 30.8 
812.967 1195.706 69 TDGF1.FSYSVIWIMAISK.+2y10. (Heavy) 88 40.2 
808.941 1191.681 69 TDGF1.FSYSVIWIMAISK.+2y10. (Light) 88 40.2 
812.967 1358.769 69 TDGF1.FSYSVIWIMAISK.+2y11. (Heavy) 88 40.2 
808.941 1354.744 69 TDGF1.FSYSVIWIMAISK.+2y11. (Light) 88 40.2 
812.967 896.521 69 TDGF1.FSYSVIWIMAISK.+2y7. (Heavy) 88 39.8 
808.941 892.496 69 TDGF1.FSYSVIWIMAISK.+2y7. (Light) 88 39.8 
812.967 1009.605 69 TDGF1.FSYSVIWIMAISK.+2y8. (Heavy) 88 40.2 
808.941 1005.58 69 TDGF1.FSYSVIWIMAISK.+2y8. (Light) 88 40.2 
812.967 1108.674 69 TDGF1.FSYSVIWIMAISK.+2y9. (Heavy) 88 37.8 
808.941 1104.649 69 TDGF1.FSYSVIWIMAISK.+2y9. (Light) 88 37.8 
500.292 570.344 23.5 TDGF1.TPELPPSAR.+2b5. (Heavy) 66.4 23.3 
498.28 566.318 23.5 TDGF1.TPELPPSAR.+2b5. (Light) 66.4 23.3 
500.292 527.294 23.5 TDGF1.TPELPPSAR.+2y5. (Heavy) 66.4 27.3 
498.28 527.294 23.5 TDGF1.TPELPPSAR.+2y5. (Light) 66.4 27.3 
500.292 640.378 23.5 TDGF1.TPELPPSAR.+2y6. (Heavy) 66.4 27.3 
498.28 640.378 23.5 TDGF1.TPELPPSAR.+2y6. (Light) 66.4 27.3 
500.292 769.42 23.5 TDGF1.TPELPPSAR.+2y7. (Heavy) 66.4 27.3 
498.28 769.42 23.5 TDGF1.TPELPPSAR.+2y7. (Light) 66.4 27.3 
500.292 866.473 23.5 TDGF1.TPELPPSAR.+2y8. (Heavy) 66.4 28.3 
498.28 866.473 23.5 TDGF1.TPELPPSAR.+2y8. (Light) 66.4 28.3 
713.422 1136.643 44.4 WIF1.ASVVQVGFPCLGK.+2y10. (Heavy) 80.8 32.6 
709.397 1132.618 44.4 WIF1.ASVVQVGFPCLGK.+2y10. (Light) 80.8 32.6 
713.422 753.427 44.4 WIF1.ASVVQVGFPCLGK.+2y6. (Heavy) 80.8 29.6 
709.397 749.401 44.4 WIF1.ASVVQVGFPCLGK.+2y6. (Light) 80.8 29.6 
713.422 810.448 44.4 WIF1.ASVVQVGFPCLGK.+2y7. (Heavy) 80.8 29.6 
709.397 806.423 44.4 WIF1.ASVVQVGFPCLGK.+2y7. (Light) 80.8 29.6 
713.422 909.516 44.4 WIF1.ASVVQVGFPCLGK.+2y8. (Heavy) 80.8 30.6 
709.397 905.491 44.4 WIF1.ASVVQVGFPCLGK.+2y8. (Light) 80.8 30.6 
713.422 1037.575 44.4 WIF1.ASVVQVGFPCLGK.+2y9. (Heavy) 80.8 29.6 
709.397 1033.55 44.4 WIF1.ASVVQVGFPCLGK.+2y9. (Light) 80.8 29.6 
728.307 910.37 29.5 WIF1.TCQQAECPGGCR.+2b7. (Heavy) 83 36.3 
726.295 906.344 29.5 WIF1.TCQQAECPGGCR.+2b7. (Light) 83 36.3 
728.307 1162.473 29.5 WIF1.TCQQAECPGGCR.+2y10. (Heavy) 83 37.3 
726.295 1162.473 29.5 WIF1.TCQQAECPGGCR.+2y10. (Light) 83 37.3 
728.307 835.319 29.5 WIF1.TCQQAECPGGCR.+2y7. (Heavy) 83 38.3 
726.295 835.319 29.5 WIF1.TCQQAECPGGCR.+2y7. (Light) 83 38.3 
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728.307 906.356 29.5 WIF1.TCQQAECPGGCR.+2y8. (Heavy) 83 36.3 
726.295 906.356 29.5 WIF1.TCQQAECPGGCR.+2y8. (Light) 83 36.3 
728.307 1034.414 29.5 WIF1.TCQQAECPGGCR.+2y9. (Heavy) 83 38.3 
726.295 1034.414 29.5 WIF1.TCQQAECPGGCR.+2y9. (Light) 83 38.3 
913.044 1134.655 73 WIF1.VLIGFEEDILIVSEGK.+2y10. (Heavy) 95.3 43 
909.019 1130.63 73 WIF1.VLIGFEEDILIVSEGK.+2y10. (Light) 95.3 43 
913.044 1263.698 73 WIF1.VLIGFEEDILIVSEGK.+2y11. (Heavy) 95.3 46 
909.019 1259.673 73 WIF1.VLIGFEEDILIVSEGK.+2y11. (Light) 95.3 46 
913.044 1410.766 73 WIF1.VLIGFEEDILIVSEGK.+2y12. (Heavy) 95.3 46 
909.019 1406.741 73 WIF1.VLIGFEEDILIVSEGK.+2y12. (Light) 95.3 46 
913.044 1467.788 73 WIF1.VLIGFEEDILIVSEGK.+2y13. (Heavy) 95.3 43 
909.019 1463.763 73 WIF1.VLIGFEEDILIVSEGK.+2y13. (Light) 95.3 43 
913.044 1005.613 73 WIF1.VLIGFEEDILIVSEGK.+2y9. (Heavy) 95.3 47 
909.019 1001.588 73 WIF1.VLIGFEEDILIVSEGK.+2y9. (Light) 95.3 47 
1079.968 1239.491 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y10. (Heavy) 108.7 53.4 
1077.955 1239.491 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y10. (Light) 108.7 53.4 
1079.968 1352.576 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y11. (Heavy) 108.7 52.4 
1077.955 1352.576 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y11. (Light) 108.7 52.4 
1079.968 1423.613 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y12. (Heavy) 108.7 51.4 
1077.955 1423.613 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y12. (Light) 108.7 51.4 
1079.968 1067.443 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y8. (Heavy) 108.7 53.4 
1077.955 1067.443 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y8. (Light) 108.7 53.4 
1079.968 1124.465 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y9. (Heavy) 108.7 60.4 
1077.955 1124.465 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y9. (Light) 108.7 60.4 
670.703 1085.57 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y11. (Heavy) 79.2 32.5 
669.362 1085.57 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y11. (Light) 79.2 32.5 
670.703 708.883 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y14+2. (Heavy) 79.2 24.5 
669.362 708.883 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y14+2. (Light) 79.2 24.5 
670.703 765.425 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y15+2. (Heavy) 79.2 24.5 
669.362 765.425 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y15+2. (Light) 79.2 24.5 
670.703 838.96 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y16+2. (Heavy) 79.2 27.5 
669.362 838.96 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y16+2. (Light) 79.2 27.5 
670.703 874.478 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y17+2. (Heavy) 79.2 24.5 
669.362 874.478 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y17+2. (Light) 79.2 24.5 
618.016 1060.575 36 WNT1.QNPGILHSVSGGLQSAVR.+3y11. (Heavy) 75.4 25.9 
616.674 1060.575 36 WNT1.QNPGILHSVSGGLQSAVR.+3y11. (Light) 75.4 25.9 
618.016 655.862 36 WNT1.QNPGILHSVSGGLQSAVR.+3y13+2. (Heavy) 75.4 25.9 
616.674 655.862 36 WNT1.QNPGILHSVSGGLQSAVR.+3y13+2. (Light) 75.4 25.9 
618.016 789.442 36 WNT1.QNPGILHSVSGGLQSAVR.+3y16+2. (Heavy) 75.4 25.9 
616.674 789.442 36 WNT1.QNPGILHSVSGGLQSAVR.+3y16+2. (Light) 75.4 25.9 
618.016 787.442 36 WNT1.QNPGILHSVSGGLQSAVR.+3y8. (Heavy) 75.4 25.9 
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616.674 787.442 36 WNT1.QNPGILHSVSGGLQSAVR.+3y8. (Light) 75.4 25.9 
618.016 874.474 36 WNT1.QNPGILHSVSGGLQSAVR.+3y9. (Heavy) 75.4 25.9 
616.674 874.474 36 WNT1.QNPGILHSVSGGLQSAVR.+3y9. (Light) 75.4 25.9 
422.539 486.243 29 WNT2.CHGVSGSCTLR.+3b4. (Heavy) 61.1 19.8 
421.197 482.218 29 WNT2.CHGVSGSCTLR.+3b4. (Light) 61.1 19.8 
422.539 630.297 29 WNT2.CHGVSGSCTLR.+3b6. (Heavy) 61.1 19.8 
421.197 626.271 29 WNT2.CHGVSGSCTLR.+3b6. (Light) 61.1 19.8 
422.539 717.329 29 WNT2.CHGVSGSCTLR.+3b7. (Heavy) 61.1 21.8 
421.197 713.304 29 WNT2.CHGVSGSCTLR.+3b7. (Light) 61.1 21.8 
422.539 549.281 29 WNT2.CHGVSGSCTLR.+3y4. (Heavy) 61.1 19.8 
421.197 549.281 29 WNT2.CHGVSGSCTLR.+3y4. (Light) 61.1 19.8 
422.539 636.313 29 WNT2.CHGVSGSCTLR.+3y5. (Heavy) 61.1 23.8 
421.197 636.313 29 WNT2.CHGVSGSCTLR.+3y5. (Light) 61.1 23.8 
604.956 746.857 30.5 WNT2.CQDCLEALDVHTCK.+3y12+2. (Heavy) 73.7 25.2 
602.272 744.845 30.5 WNT2.CQDCLEALDVHTCK.+3y12+2. (Light) 73.7 25.2 
604.956 791.402 30.5 WNT2.CQDCLEALDVHTCK.+3y6. (Heavy) 73.7 30.2 
602.272 787.377 30.5 WNT2.CQDCLEALDVHTCK.+3y6. (Light) 73.7 30.2 
604.956 904.486 30.5 WNT2.CQDCLEALDVHTCK.+3y7. (Heavy) 73.7 30.2 
602.272 900.461 30.5 WNT2.CQDCLEALDVHTCK.+3y7. (Light) 73.7 30.2 
604.956 975.523 30.5 WNT2.CQDCLEALDVHTCK.+3y8. (Heavy) 73.7 30.2 
602.272 971.498 30.5 WNT2.CQDCLEALDVHTCK.+3y8. (Light) 73.7 30.2 
604.956 1104.566 30.5 WNT2.CQDCLEALDVHTCK.+3y9. (Heavy) 73.7 30.2 
602.272 1100.541 30.5 WNT2.CQDCLEALDVHTCK.+3y9. (Light) 73.7 30.2 
1010.556 1020.584 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y10. (Heavy) 103.6 52.4 
1008.544 1020.584 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y10. (Light) 103.6 52.4 
1010.556 1107.616 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y11. (Heavy) 103.6 52.4 
1008.544 1107.616 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y11. (Light) 103.6 52.4 
1010.556 1220.7 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y12. (Heavy) 103.6 51.4 
1008.544 1220.7 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y12. (Light) 103.6 51.4 
1010.556 1291.737 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y13. (Heavy) 103.6 51.4 
1008.544 1291.737 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y13. (Light) 103.6 51.4 
1010.556 1454.8 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y14. (Heavy) 103.6 50.4 
1008.544 1454.8 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y14. (Light) 103.6 50.4 
646.024 978.537 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y10. (Heavy) 77.4 31.8 
644.683 978.537 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y10. (Light) 77.4 31.8 
646.024 593.341 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y5. (Heavy) 77.4 26.8 
644.683 593.341 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y5. (Light) 77.4 26.8 
646.024 664.378 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y6. (Heavy) 77.4 26.8 
644.683 664.378 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y6. (Light) 77.4 26.8 
646.024 763.446 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y7. (Heavy) 77.4 25.8 
644.683 763.446 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y7. (Light) 77.4 25.8 
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646.024 820.468 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y8. (Heavy) 77.4 23.8 
644.683 820.468 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y8. (Light) 77.4 23.8 
483.252 651.804 27.6 WNT3A.IGIQECQHQFR.+3y10+2. (Heavy) 65.6 22.7 
481.91 651.804 27.6 WNT3A.IGIQECQHQFR.+3y10+2. (Light) 65.6 22.7 
483.252 587.305 27.6 WNT3A.IGIQECQHQFR.+3y4. (Heavy) 65.6 26.7 
481.91 587.305 27.6 WNT3A.IGIQECQHQFR.+3y4. (Light) 65.6 26.7 
483.252 502.722 27.6 WNT3A.IGIQECQHQFR.+3y7+2. (Heavy) 65.6 22.7 
481.91 502.722 27.6 WNT3A.IGIQECQHQFR.+3y7+2. (Light) 65.6 22.7 
483.252 566.751 27.6 WNT3A.IGIQECQHQFR.+3y8+2. (Heavy) 65.6 21.7 
481.91 566.751 27.6 WNT3A.IGIQECQHQFR.+3y8+2. (Light) 65.6 21.7 
483.252 623.293 27.6 WNT3A.IGIQECQHQFR.+3y9+2. (Heavy) 65.6 21.7 
481.91 623.293 27.6 WNT3A.IGIQECQHQFR.+3y9+2. (Light) 65.6 21.7 
809.85 1139.493 21.9 WNT3A.SCAEGTAAICGCSSR.+2y11. (Heavy) 89 42 
807.837 1139.493 21.9 WNT3A.SCAEGTAAICGCSSR.+2y11. (Light) 89 42 
809.85 1268.536 21.9 WNT3A.SCAEGTAAICGCSSR.+2y12. (Heavy) 89 40 
807.837 1268.536 21.9 WNT3A.SCAEGTAAICGCSSR.+2y12. (Light) 89 40 
809.85 839.35 21.9 WNT3A.SCAEGTAAICGCSSR.+2y7. (Heavy) 89 41 
807.837 839.35 21.9 WNT3A.SCAEGTAAICGCSSR.+2y7. (Light) 89 41 
809.85 910.387 21.9 WNT3A.SCAEGTAAICGCSSR.+2y8. (Heavy) 89 42 
807.837 910.387 21.9 WNT3A.SCAEGTAAICGCSSR.+2y8. (Light) 89 42 
809.85 981.424 21.9 WNT3A.SCAEGTAAICGCSSR.+2y9. (Heavy) 89 42 
807.837 981.424 21.9 WNT3A.SCAEGTAAICGCSSR.+2y9. (Light) 89 42 
997.003 1078.531 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y11. (Heavy) 102.6 48.2 
994.991 1078.531 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y11. (Light) 102.6 48.2 
997.003 1177.599 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y12. (Heavy) 102.6 47.2 
994.991 1177.599 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y12. (Light) 102.6 47.2 
997.003 1248.636 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y13. (Heavy) 102.6 49.2 
994.991 1248.636 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y13. (Light) 102.6 49.2 
997.003 1411.7 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y14. (Heavy) 102.6 50.2 
994.991 1411.7 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y14. (Light) 102.6 50.2 
997.003 1512.748 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y15. (Heavy) 102.6 48.2 
994.991 1512.748 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y15. (Light) 102.6 48.2 
1260.107 1221.557 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y10. (Heavy) 121.8 61.6 
1258.094 1221.557 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y10. (Light) 121.8 61.6 
1260.107 1384.62 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y11. (Heavy) 121.8 61.6 
1258.094 1384.62 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y11. (Light) 121.8 61.6 
1260.107 1483.689 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y12. (Heavy) 121.8 61.6 
1258.094 1483.689 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y12. (Light) 121.8 61.6 
1260.107 993.446 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y8. (Heavy) 121.8 63.6 
1258.094 993.446 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y8. (Light) 121.8 63.6 
1260.107 1108.473 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y9. (Heavy) 121.8 61.6 
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1258.094 1108.473 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y9. (Light) 121.8 61.6 
619.817 963.485 3.4 WNT5A.NESTGSLGTQGR.+2y10. (Heavy) 75.1 29.2 
617.805 963.485 3.4 WNT5A.NESTGSLGTQGR.+2y10. (Light) 75.1 29.2 
619.817 631.352 3.4 WNT5A.NESTGSLGTQGR.+2y6. (Heavy) 75.1 30.2 
617.805 631.352 3.4 WNT5A.NESTGSLGTQGR.+2y6. (Light) 75.1 30.2 
619.817 718.384 3.4 WNT5A.NESTGSLGTQGR.+2y7. (Heavy) 75.1 32.2 
617.805 718.384 3.4 WNT5A.NESTGSLGTQGR.+2y7. (Light) 75.1 32.2 
619.817 775.406 3.4 WNT5A.NESTGSLGTQGR.+2y8. (Heavy) 75.1 30.2 
617.805 775.406 3.4 WNT5A.NESTGSLGTQGR.+2y8. (Light) 75.1 30.2 
619.817 876.453 3.4 WNT5A.NESTGSLGTQGR.+2y9. (Heavy) 75.1 30.2 
617.805 876.453 3.4 WNT5A.NESTGSLGTQGR.+2y9. (Light) 75.1 30.2 
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Appendix B. Peak areas for transitions detected in scheduled SRM analysis of 
dimethyl labeled H9 cell lysates.  
Precursor 
m/z 
Fragment 
m/z RT (min) Target Protein, Peptide, Fragment Ion, Label 
Mean Peak 
Area 
Standard 
Deviation 
of Mean 
Peak Area 
582.795 476.246 29.1 ACTB.GYSFTTTAER.+2y4. (Heavy) 23811 9660 
580.783 476.246 29.1 ACTB.GYSFTTTAER.+2y4. (Light) 20860 9751 
582.795 577.294 29.1 ACTB.GYSFTTTAER.+2y5. (Heavy) 45451 21443 
580.783 577.294 29.1 ACTB.GYSFTTTAER.+2y5. (Light) 41523 20064 
582.795 678.342 29.1 ACTB.GYSFTTTAER.+2y6. (Heavy) 58962 19614 
580.783 678.342 29.1 ACTB.GYSFTTTAER.+2y6. (Light) 90647 52141 
582.795 825.41 29.1 ACTB.GYSFTTTAER.+2y7. (Heavy) 34110 14261 
580.783 825.41 29.1 ACTB.GYSFTTTAER.+2y7. (Light) 54495 27176 
582.795 912.442 29.1 ACTB.GYSFTTTAER.+2y8. (Heavy) 107325 46509 
580.783 912.442 29.1 ACTB.GYSFTTTAER.+2y8. (Light) 182880 102798 
911.978 1298.67 47.1 ACTB.SYELPDGQVITIGNER.+2y12. (Heavy) 4373888 435867 
909.965 1298.67 47.1 ACTB.SYELPDGQVITIGNER.+2y12. (Light) 125124 12764 
911.978 649.839 47.1 ACTB.SYELPDGQVITIGNER.+2y12+2. (Heavy) 5911726 716353 
909.965 649.839 47.1 ACTB.SYELPDGQVITIGNER.+2y12+2. (Light) 129708 19544 
911.978 706.381 47.1 ACTB.SYELPDGQVITIGNER.+2y13+2. (Heavy) 109338 11575 
909.965 706.381 47.1 ACTB.SYELPDGQVITIGNER.+2y13+2. (Light) 150754 24616 
911.978 475.226 47.1 ACTB.SYELPDGQVITIGNER.+2y4. (Heavy) 917033 77457 
909.965 475.226 47.1 ACTB.SYELPDGQVITIGNER.+2y4. (Light) 968609 105112 
911.978 689.358 47.1 ACTB.SYELPDGQVITIGNER.+2y6. (Heavy) 720522 64175 
909.965 689.358 47.1 ACTB.SYELPDGQVITIGNER.+2y6. (Light) 935067 97949 
1009.592 1323.818 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y12. (Heavy) 245131 60316 
1005.567 1319.793 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y12. (Light) 312709 56804 
1009.592 908.511 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y16+2. (Heavy) 140185 35906 
1005.567 906.499 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y16+2. (Light) 173856 29472 
1009.592 600.402 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y5. (Heavy) 96814 19724 
1005.567 596.377 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y5. (Light) 118033 25860 
1009.592 671.439 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y6. (Heavy) 56786 14922 
1005.567 667.414 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y6. (Light) 75427 14720 
1009.592 901.529 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y8. (Heavy) 58846 14697 
1005.567 897.504 38.1 ACTB.VAPEEHPVLLTEAPLNPK.+2y8. (Light) 86260 17821 
669.362 914.459 53.2 AKT1.FYGAEIVSALDYLHSEK.+3b16+2. (Heavy) 6205 3392 
666.679 912.446 53.2 AKT1.FYGAEIVSALDYLHSEK.+3b16+2. (Light) 8179 4550 
669.362 1194.63 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y10. (Heavy) 3605 2013 
666.679 1190.605 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y10. (Light) 14104 15996 
669.362 1293.699 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y11. (Heavy) 411 237 
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666.679 1289.674 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y11. (Light) 605 616 
669.362 832.446 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y15+2. (Heavy) 7607 7444 
666.679 830.433 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y15+2. (Light) 32736 24227 
669.362 913.977 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y16+2. (Heavy) 2765 1162 
666.679 911.965 53.2 AKT1.FYGAEIVSALDYLHSEK.+3y16+2. (Light) 3574 1579 
1239.575 1209.538 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y10. (Heavy) 601 355 
1237.563 1209.538 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y10. (Light) 3940 5865 
1239.575 1306.591 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y11. (Heavy) 891 890 
1237.563 1306.591 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y11. (Light) 538 479 
1239.575 1377.628 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y12. (Heavy) 543 400 
1237.563 1377.628 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y12. (Light) 449 189 
1239.575 1490.712 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y13. (Heavy) 356 359 
1237.563 1490.712 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y13. (Light) 252 161 
1239.575 1080.496 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y9. (Heavy) 414 253 
1237.563 1080.496 50.3 AKT1.TFCGTPEYLAPEVLEDNDYGR.+2y9. (Light) 435 212 
426.221 646.35 27.6 AKT1.TFHVETPEER.+3b5. (Heavy) 5773 7659 
424.879 642.325 27.6 AKT1.TFHVETPEER.+3b5. (Light) 4753 4376 
426.221 747.397 27.6 AKT1.TFHVETPEER.+3b6. (Heavy) 771 583 
424.879 743.372 27.6 AKT1.TFHVETPEER.+3b6. (Light) 1345 990 
426.221 433.204 27.6 AKT1.TFHVETPEER.+3y3. (Heavy) 7046 6515 
424.879 433.204 27.6 AKT1.TFHVETPEER.+3y3. (Light) 4928 4548 
426.221 530.257 27.6 AKT1.TFHVETPEER.+3y4. (Heavy) 6113 3868 
424.879 530.257 27.6 AKT1.TFHVETPEER.+3y4. (Light) 2624 2512 
426.221 631.305 27.6 AKT1.TFHVETPEER.+3y5. (Heavy) 1956 2250 
424.879 631.305 27.6 AKT1.TFHVETPEER.+3y5. (Light) 4015 4018 
1030.466 1196.507 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y10. (Heavy) 1374 742 
1028.453 1196.507 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y10. (Light) 1327 621 
1030.466 1311.534 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y11. (Heavy) 1069 760 
1028.453 1311.534 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y11. (Light) 1628 901 
1030.466 1424.618 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y12. (Heavy) 654 488 
1028.453 1424.618 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y12. (Light) 816 441 
1030.466 934.411 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y8. (Heavy) 2492 1472 
1028.453 934.411 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y8. (Light) 2526 1487 
1030.466 1049.438 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y9. (Heavy) 772 746 
1028.453 1049.438 46.8 APC.NDSLSSLDFDDDDVDLSR.+2y9. (Light) 695 420 
496.597 578.291 31.5 APC.NVSSLIATNEDHR.+3y10+2. (Heavy) 8510 5124 
495.255 578.291 31.5 APC.NVSSLIATNEDHR.+3y10+2. (Light) 31302 24792 
496.597 621.807 31.5 APC.NVSSLIATNEDHR.+3y11+2. (Heavy) 3275 2009 
495.255 621.807 31.5 APC.NVSSLIATNEDHR.+3y11+2. (Light) 2559 993 
496.597 771.338 31.5 APC.NVSSLIATNEDHR.+3y6. (Heavy) 19947 21637 
495.255 771.338 31.5 APC.NVSSLIATNEDHR.+3y6. (Light) 2710 2669 
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496.597 842.375 31.5 APC.NVSSLIATNEDHR.+3y7. (Heavy) 1143 560 
495.255 842.375 31.5 APC.NVSSLIATNEDHR.+3y7. (Light) 3538 3360 
496.597 955.459 31.5 APC.NVSSLIATNEDHR.+3y8. (Heavy) 594 659 
495.255 955.459 31.5 APC.NVSSLIATNEDHR.+3y8. (Light) 731 574 
612.984 1206.623 28.7 APC.SAEDPVSEVPAVSQHPR.+3y11. (Heavy) 2275 2453 
611.643 1206.623 28.7 APC.SAEDPVSEVPAVSQHPR.+3y11. (Light) 2316 #N/A 
612.984 701.875 28.7 APC.SAEDPVSEVPAVSQHPR.+3y13+2. (Heavy) 8985 7192 
611.643 701.875 28.7 APC.SAEDPVSEVPAVSQHPR.+3y13+2. (Light) 30922 26156 
612.984 759.389 28.7 APC.SAEDPVSEVPAVSQHPR.+3y14+2. (Heavy) 4149 2378 
611.643 759.389 28.7 APC.SAEDPVSEVPAVSQHPR.+3y14+2. (Light) 8030 4773 
612.984 823.91 28.7 APC.SAEDPVSEVPAVSQHPR.+3y15+2. (Heavy) 2063 827 
611.643 823.91 28.7 APC.SAEDPVSEVPAVSQHPR.+3y15+2. (Light) 3126 2280 
612.984 891.48 28.7 APC.SAEDPVSEVPAVSQHPR.+3y8. (Heavy) 1986 1392 
611.643 891.48 28.7 APC.SAEDPVSEVPAVSQHPR.+3y8. (Light) 8862 7501 
683.997 783.381 33.1 AXN1.DAHEENPESILDEHVQR.+3y13+2. (Heavy) 1073 1041 
682.656 783.381 33.1 AXN1.DAHEENPESILDEHVQR.+3y13+2. (Light) 1328 1045 
683.997 783.374 33.1 AXN1.DAHEENPESILDEHVQR.+3y6. (Heavy) 1932 838 
682.656 783.374 33.1 AXN1.DAHEENPESILDEHVQR.+3y6. (Light) 1149 682 
683.997 896.458 33.1 AXN1.DAHEENPESILDEHVQR.+3y7. (Heavy) 3681 5087 
682.656 896.458 33.1 AXN1.DAHEENPESILDEHVQR.+3y7. (Light) 1675 2111 
683.997 1009.543 33.1 AXN1.DAHEENPESILDEHVQR.+3y8. (Heavy) 2397 1688 
682.656 1009.543 33.1 AXN1.DAHEENPESILDEHVQR.+3y8. (Light) 1337 725 
683.997 1096.575 33.1 AXN1.DAHEENPESILDEHVQR.+3y9. (Heavy) 1989 1253 
682.656 1096.575 33.1 AXN1.DAHEENPESILDEHVQR.+3y9. (Light) 723 702 
596.313 624.354 33.6 AXN1.SDIYLEYTR.+2b5. (Heavy) 1548 1088 
594.301 620.329 33.6 AXN1.SDIYLEYTR.+2b5. (Light) 5071 5355 
596.313 568.273 33.6 AXN1.SDIYLEYTR.+2y4. (Heavy) 3836 2482 
594.301 568.273 33.6 AXN1.SDIYLEYTR.+2y4. (Light) 6692 6520 
596.313 681.357 33.6 AXN1.SDIYLEYTR.+2y5. (Heavy) 1137 1105 
594.301 681.357 33.6 AXN1.SDIYLEYTR.+2y5. (Light) 44080 37595 
596.313 844.42 33.6 AXN1.SDIYLEYTR.+2y6. (Heavy) 1333 915 
594.301 844.42 33.6 AXN1.SDIYLEYTR.+2y6. (Light) 2983 2700 
596.313 957.504 33.6 AXN1.SDIYLEYTR.+2y7. (Heavy) 868 783 
594.301 957.504 33.6 AXN1.SDIYLEYTR.+2y7. (Light) 1852 1783 
829.368 1164.55 29.4 CDN1A.DCDALMAGCIQEAR.+2y10. (Heavy) 1799 1044 
827.355 1164.55 29.4 CDN1A.DCDALMAGCIQEAR.+2y10. (Light) 1824 673 
829.368 1235.587 29.4 CDN1A.DCDALMAGCIQEAR.+2y11. (Heavy) 733 637 
827.355 1235.587 29.4 CDN1A.DCDALMAGCIQEAR.+2y11. (Light) 1067 814 
829.368 833.393 29.4 CDN1A.DCDALMAGCIQEAR.+2y7. (Heavy) 878 654 
827.355 833.393 29.4 CDN1A.DCDALMAGCIQEAR.+2y7. (Light) 1274 587 
829.368 904.431 29.4 CDN1A.DCDALMAGCIQEAR.+2y8. (Heavy) 1254 990 
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827.355 904.431 29.4 CDN1A.DCDALMAGCIQEAR.+2y8. (Light) 1299 973 
829.368 1051.466 29.4 CDN1A.DCDALMAGCIQEAR.+2y9. (Heavy) 3852 2105 
827.355 1051.466 29.4 CDN1A.DCDALMAGCIQEAR.+2y9. (Light) 6697 4008 
1196.065 1219.574 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y10. (Heavy) 200 99 
1194.053 1219.574 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y10. (Light) 175 114 
1196.065 1320.622 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y11. (Heavy) 199 126 
1194.053 1320.622 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y11. (Light) 222 157 
1196.065 1449.664 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y12. (Heavy) 228 214 
1194.053 1449.664 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y12. (Light) 184 105 
1196.065 1009.437 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y8. (Heavy) 204 98 
1194.053 1009.437 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y8. (Light) 385 293 
1196.065 1122.521 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y9. (Heavy) 211 117 
1194.053 1122.521 67.9 CDN1A.WNFDFVTETPLEGDFAWER.+2y9. (Light) 296 276 
644.428 1057.692 30 CER1.TPASQGVILPIK.+2y10. (Heavy) 1817 1347 
640.403 1053.667 30 CER1.TPASQGVILPIK.+2y10. (Light) 1758 917 
644.428 714.543 30 CER1.TPASQGVILPIK.+2y6. (Heavy) 5763 3257 
640.403 710.517 30 CER1.TPASQGVILPIK.+2y6. (Light) 6497 3613 
644.428 771.564 30 CER1.TPASQGVILPIK.+2y7. (Heavy) 3270 2395 
640.403 767.539 30 CER1.TPASQGVILPIK.+2y7. (Light) 8900 7083 
644.428 899.623 30 CER1.TPASQGVILPIK.+2y8. (Heavy) 2588 1305 
640.403 895.598 30 CER1.TPASQGVILPIK.+2y8. (Light) 155549 217025 
644.428 986.655 30 CER1.TPASQGVILPIK.+2y9. (Heavy) 2316 994 
640.403 982.63 30 CER1.TPASQGVILPIK.+2y9. (Light) 2401 2865 
599.981 661.321 31 CER1.TVPFSQTITHEGCEK.+3y11+2. (Heavy) 3012 1224 
597.298 659.309 31 CER1.TVPFSQTITHEGCEK.+3y11+2. (Light) 27629 31691 
599.981 734.856 31 CER1.TVPFSQTITHEGCEK.+3y12+2. (Heavy) 6757 7123 
597.298 732.843 31 CER1.TVPFSQTITHEGCEK.+3y12+2. (Light) 18320 21479 
599.981 783.382 31 CER1.TVPFSQTITHEGCEK.+3y13+2. (Heavy) 9495 6430 
597.298 781.369 31 CER1.TVPFSQTITHEGCEK.+3y13+2. (Light) 13878 8324 
599.981 892.413 31 CER1.TVPFSQTITHEGCEK.+3y7. (Heavy) 3640 1743 
597.298 888.388 31 CER1.TVPFSQTITHEGCEK.+3y7. (Light) 5604 4415 
599.981 1106.545 31 CER1.TVPFSQTITHEGCEK.+3y9. (Heavy) 674 407 
597.298 1102.52 31 CER1.TVPFSQTITHEGCEK.+3y9. (Light) 1904 1257 
671.394 1210.655 33.1 CER1.VVVQNNLCFGK.+2y10. (Heavy) 18732 25749 
667.368 1206.63 33.1 CER1.VVVQNNLCFGK.+2y10. (Light) 10319 11324 
671.394 770.417 33.1 CER1.VVVQNNLCFGK.+2y6. (Heavy) 3229 1890 
667.368 766.392 33.1 CER1.VVVQNNLCFGK.+2y6. (Light) 2365 1287 
671.394 884.46 33.1 CER1.VVVQNNLCFGK.+2y7. (Heavy) 2268 1141 
667.368 880.435 33.1 CER1.VVVQNNLCFGK.+2y7. (Light) 1185 972 
671.394 1012.518 33.1 CER1.VVVQNNLCFGK.+2y8. (Heavy) 700 585 
667.368 1008.493 33.1 CER1.VVVQNNLCFGK.+2y8. (Light) 1537 1627 
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671.394 1111.587 33.1 CER1.VVVQNNLCFGK.+2y9. (Heavy) 1431 1297 
667.368 1107.562 33.1 CER1.VVVQNNLCFGK.+2y9. (Light) 1193 768 
692.034 779.508 39.8 CTNB1.HAVVNLINYQDDAELATR.+3b7. (Heavy) 37010 9418 
690.692 775.482 39.8 CTNB1.HAVVNLINYQDDAELATR.+3b7. (Light) 22185 5583 
692.034 893.551 39.8 CTNB1.HAVVNLINYQDDAELATR.+3b8. (Heavy) 15112 4977 
690.692 889.525 39.8 CTNB1.HAVVNLINYQDDAELATR.+3b8. (Light) 12683 4037 
692.034 1295.586 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y11. (Heavy) 11808 1711 
690.692 1295.586 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y11. (Light) 11236 1801 
692.034 890.421 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y8. (Heavy) 21974 5749 
690.692 890.421 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y8. (Light) 20260 4445 
692.034 1018.48 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y9. (Heavy) 12219 3428 
690.692 1018.48 39.8 CTNB1.HAVVNLINYQDDAELATR.+3y9. (Light) 10287 3178 
725.424 1058.567 27.8 CTNB1.LLNDEDQVVVNK.+2b9. (Heavy) 2003 2923 
721.398 1054.542 27.8 CTNB1.LLNDEDQVVVNK.+2b9. (Light) 1118 924 
725.424 1191.615 27.8 CTNB1.LLNDEDQVVVNK.+2y10. (Heavy) 2951 3346 
721.398 1187.59 27.8 CTNB1.LLNDEDQVVVNK.+2y10. (Light) 3525 4927 
725.424 833.503 27.8 CTNB1.LLNDEDQVVVNK.+2y7. (Heavy) 1491 1588 
721.398 829.478 27.8 CTNB1.LLNDEDQVVVNK.+2y7. (Light) 1317 751 
725.424 962.545 27.8 CTNB1.LLNDEDQVVVNK.+2y8. (Heavy) 1113 1013 
721.398 958.52 27.8 CTNB1.LLNDEDQVVVNK.+2y8. (Light) 1125 1115 
725.424 1077.572 27.8 CTNB1.LLNDEDQVVVNK.+2y9. (Heavy) 1140 1134 
721.398 1073.547 27.8 CTNB1.LLNDEDQVVVNK.+2y9. (Light) 1459 783 
757.419 1082.599 55 CTNB1.NEGVATYAAAVLFR.+2y10. (Heavy) 4078 1853 
755.407 1082.599 55 CTNB1.NEGVATYAAAVLFR.+2y10. (Light) 2840 1553 
757.419 1181.668 55 CTNB1.NEGVATYAAAVLFR.+2y11. (Heavy) 81653 19636 
755.407 1181.668 55 CTNB1.NEGVATYAAAVLFR.+2y11. (Light) 5213 2900 
757.419 1238.689 55 CTNB1.NEGVATYAAAVLFR.+2y12. (Heavy) 173870 34095 
755.407 1238.689 55 CTNB1.NEGVATYAAAVLFR.+2y12. (Light) 5790 2424 
757.419 910.515 55 CTNB1.NEGVATYAAAVLFR.+2y8. (Heavy) 4979 1507 
755.407 910.515 55 CTNB1.NEGVATYAAAVLFR.+2y8. (Light) 5809 2598 
757.419 1011.562 55 CTNB1.NEGVATYAAAVLFR.+2y9. (Heavy) 2888 1492 
755.407 1011.562 55 CTNB1.NEGVATYAAAVLFR.+2y9. (Light) 2343 1257 
390.856 550.267 27.6 DKK1.DHHQASNSSR.+3b4. (Heavy) 3224 3061 
389.515 546.242 27.6 DKK1.DHHQASNSSR.+3b4. (Light) 4578 3510 
390.856 463.226 27.6 DKK1.DHHQASNSSR.+3y4. (Heavy) 4102 2730 
389.515 463.226 27.6 DKK1.DHHQASNSSR.+3y4. (Light) 15484 13706 
390.856 550.258 27.6 DKK1.DHHQASNSSR.+3y5. (Heavy) 3578 3632 
389.515 550.258 27.6 DKK1.DHHQASNSSR.+3y5. (Light) 2527 1485 
390.856 621.295 27.6 DKK1.DHHQASNSSR.+3y6. (Heavy) 1630 1059 
389.515 621.295 27.6 DKK1.DHHQASNSSR.+3y6. (Light) 2441 1169 
390.856 443.71 27.6 DKK1.DHHQASNSSR.+3y8+2. (Heavy) 24542 35315 
161 
 
 
 
389.515 443.71 27.6 DKK1.DHHQASNSSR.+3y8+2. (Light) 11286 11556 
522.586 625.273 27 DKK1.NGICVSSDQNHFR.+3y10+2. (Heavy) 1576 1109 
521.244 625.273 27 DKK1.NGICVSSDQNHFR.+3y10+2. (Light) 5900 5832 
522.586 681.815 27 DKK1.NGICVSSDQNHFR.+3y11+2. (Heavy) 1517 636 
521.244 681.815 27 DKK1.NGICVSSDQNHFR.+3y11+2. (Light) 2154 2521 
522.586 903.407 27 DKK1.NGICVSSDQNHFR.+3y7. (Heavy) 953 468 
521.244 903.407 27 DKK1.NGICVSSDQNHFR.+3y7. (Light) 1512 1150 
522.586 990.439 27 DKK1.NGICVSSDQNHFR.+3y8. (Heavy) 681 535 
521.244 990.439 27 DKK1.NGICVSSDQNHFR.+3y8. (Light) 992 145 
522.586 545.257 27 DKK1.NGICVSSDQNHFR.+3y9+2. (Heavy) 1832 1741 
521.244 545.257 27 DKK1.NGICVSSDQNHFR.+3y9+2. (Light) 4294 4877 
688.289 1169.45 20.9 DKK1.SSDCASGLCCAR.+2y10. (Heavy) #N/A #N/A 
686.276 1169.45 20.9 DKK1.SSDCASGLCCAR.+2y10. (Light) 37 3 
688.289 736.323 20.9 DKK1.SSDCASGLCCAR.+2y6. (Heavy) 75 50 
686.276 736.323 20.9 DKK1.SSDCASGLCCAR.+2y6. (Light) 55 28 
688.289 823.355 20.9 DKK1.SSDCASGLCCAR.+2y7. (Heavy) 65 52 
686.276 823.355 20.9 DKK1.SSDCASGLCCAR.+2y7. (Light) 70 27 
688.289 894.392 20.9 DKK1.SSDCASGLCCAR.+2y8. (Heavy) 105 #N/A 
686.276 894.392 20.9 DKK1.SSDCASGLCCAR.+2y8. (Light) 79 56 
688.289 1054.423 20.9 DKK1.SSDCASGLCCAR.+2y9. (Heavy) #N/A #N/A 
686.276 1054.423 20.9 DKK1.SSDCASGLCCAR.+2y9. (Light) 62 32 
651.328 1069.476 17 DVL1.LSSSTEQSTSSR.+2y10. (Heavy) #N/A #N/A 
649.315 1069.476 17 DVL1.LSSSTEQSTSSR.+2y10. (Light) #N/A #N/A 
651.328 665.321 17 DVL1.LSSSTEQSTSSR.+2y6. (Heavy) 35 12 
649.315 665.321 17 DVL1.LSSSTEQSTSSR.+2y6. (Light) 41 10 
651.328 794.364 17 DVL1.LSSSTEQSTSSR.+2y7. (Heavy) #N/A #N/A 
649.315 794.364 17 DVL1.LSSSTEQSTSSR.+2y7. (Light) 20 3 
651.328 895.412 17 DVL1.LSSSTEQSTSSR.+2y8. (Heavy) 22 0 
649.315 895.412 17 DVL1.LSSSTEQSTSSR.+2y8. (Light) 21 2 
651.328 982.444 17 DVL1.LSSSTEQSTSSR.+2y9. (Heavy) #N/A #N/A 
649.315 982.444 17 DVL1.LSSSTEQSTSSR.+2y9. (Light) 22 #N/A 
487.964 608.859 26.2 DVL1.NVLSNRPVHAYK.+3y10+2. (Heavy) 5974 3412 
485.281 606.846 26.2 DVL1.NVLSNRPVHAYK.+3y10+2. (Light) 6844 7199 
487.964 658.393 26.2 DVL1.NVLSNRPVHAYK.+3y11+2. (Heavy) 2865 2546 
485.281 656.38 26.2 DVL1.NVLSNRPVHAYK.+3y11+2. (Light) 2714 2276 
487.964 746.45 26.2 DVL1.NVLSNRPVHAYK.+3y6. (Heavy) 1544 1041 
485.281 742.425 26.2 DVL1.NVLSNRPVHAYK.+3y6. (Light) 2485 4118 
487.964 508.801 26.2 DVL1.NVLSNRPVHAYK.+3y8+2. (Heavy) 4612 7189 
485.281 506.788 26.2 DVL1.NVLSNRPVHAYK.+3y8+2. (Light) 1640 1786 
487.964 552.317 26.2 DVL1.NVLSNRPVHAYK.+3y9+2. (Heavy) 7451 8767 
485.281 550.304 26.2 DVL1.NVLSNRPVHAYK.+3y9+2. (Light) 103705 181753 
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608.015 1173.693 26 DVL1.SQASATAPGLPPPHPTTK.+3y11. (Heavy) 110 155 
605.332 1169.668 26 DVL1.SQASATAPGLPPPHPTTK.+3y11. (Light) 89 162 
608.015 752.427 26 DVL1.SQASATAPGLPPPHPTTK.+3y15+2. (Heavy) 1308 795 
605.332 750.414 26 DVL1.SQASATAPGLPPPHPTTK.+3y15+2. (Light) 1235 1177 
608.015 787.946 26 DVL1.SQASATAPGLPPPHPTTK.+3y16+2. (Heavy) 324 269 
605.332 785.933 26 DVL1.SQASATAPGLPPPHPTTK.+3y16+2. (Light) 719 968 
608.015 809.482 26 DVL1.SQASATAPGLPPPHPTTK.+3y7. (Heavy) 679 611 
605.332 805.457 26 DVL1.SQASATAPGLPPPHPTTK.+3y7. (Light) 20453 25104 
608.015 906.535 26 DVL1.SQASATAPGLPPPHPTTK.+3y8. (Heavy) 762 409 
605.332 902.509 26 DVL1.SQASATAPGLPPPHPTTK.+3y8. (Light) 605 393 
621.389 984.603 29.5 FRAT1.APGPLAAAVPADK.+2y10. (Heavy) 2204 2133 
617.364 980.578 29.5 FRAT1.APGPLAAAVPADK.+2y10. (Light) 1704 1894 
621.389 1041.624 29.5 FRAT1.APGPLAAAVPADK.+2y11. (Heavy) 1881 1213 
617.364 1037.599 29.5 FRAT1.APGPLAAAVPADK.+2y11. (Light) 5260 4523 
621.389 632.392 29.5 FRAT1.APGPLAAAVPADK.+2y6. (Heavy) 6542 6977 
617.364 628.366 29.5 FRAT1.APGPLAAAVPADK.+2y6. (Light) 9810 8637 
621.389 703.429 29.5 FRAT1.APGPLAAAVPADK.+2y7. (Heavy) 15762 9784 
617.364 699.404 29.5 FRAT1.APGPLAAAVPADK.+2y7. (Light) 4177 2696 
621.389 774.466 29.5 FRAT1.APGPLAAAVPADK.+2y8. (Heavy) 4519 2564 
617.364 770.441 29.5 FRAT1.APGPLAAAVPADK.+2y8. (Light) 3347 2473 
752.01 1116.729 50.3 FRAT1.LLQQLVLSGNLIK.+2y10. (Heavy) 1763 1766 
747.984 1112.704 50.3 FRAT1.LLQQLVLSGNLIK.+2y10. (Light) 8911 8347 
752.01 1244.787 50.3 FRAT1.LLQQLVLSGNLIK.+2y11. (Heavy) 1174 585 
747.984 1240.762 50.3 FRAT1.LLQQLVLSGNLIK.+2y11. (Light) 14337 25305 
752.01 776.518 50.3 FRAT1.LLQQLVLSGNLIK.+2y7. (Heavy) 2066 1174 
747.984 772.493 50.3 FRAT1.LLQQLVLSGNLIK.+2y7. (Light) 4067 2018 
752.01 875.586 50.3 FRAT1.LLQQLVLSGNLIK.+2y8. (Heavy) 1817 1154 
747.984 871.561 50.3 FRAT1.LLQQLVLSGNLIK.+2y8. (Light) 4430 3051 
752.01 988.67 50.3 FRAT1.LLQQLVLSGNLIK.+2y9. (Heavy) 1266 836 
747.984 984.645 50.3 FRAT1.LLQQLVLSGNLIK.+2y9. (Light) 2014 1481 
660.675 1100.55 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3b10. (Heavy) 680 349 
657.991 1096.524 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3b10. (Light) 1376 580 
660.675 940.519 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3b9. (Heavy) 2526 1924 
657.991 936.494 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3b9. (Light) 5015 4757 
660.675 781.399 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y7. (Heavy) 2154 1591 
657.991 777.374 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y7. (Light) 2005 1348 
660.675 880.467 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y8. (Heavy) 1901 1331 
657.991 876.442 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y8. (Light) 1566 994 
660.675 1040.498 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y9. (Heavy) 1385 1073 
657.991 1036.473 30.4 FZD1.FPVHGAGELCVGQNTSDK.+3y9. (Light) 1724 852 
547.78 576.308 22.7 FZD1.GGFPGGAGASER.+2b7. (Heavy) 439 599 
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545.767 572.283 22.7 FZD1.GGFPGGAGASER.+2b7. (Light) 262 186 
547.78 590.289 22.7 FZD1.GGFPGGAGASER.+2y6. (Heavy) 225 228 
545.767 590.289 22.7 FZD1.GGFPGGAGASER.+2y6. (Light) 186 97 
547.78 647.311 22.7 FZD1.GGFPGGAGASER.+2y7. (Heavy) 519 645 
545.767 647.311 22.7 FZD1.GGFPGGAGASER.+2y7. (Light) 3399 3623 
547.78 704.332 22.7 FZD1.GGFPGGAGASER.+2y8. (Heavy) 522 409 
545.767 704.332 22.7 FZD1.GGFPGGAGASER.+2y8. (Light) 631 661 
547.78 801.385 22.7 FZD1.GGFPGGAGASER.+2y9. (Heavy) 167 #N/A 
545.767 801.385 22.7 FZD1.GGFPGGAGASER.+2y9. (Light) 965 788 
544.307 658.353 42.2 FZD1.VPSYLNYHFLGEK.+3y10+2. (Heavy) 4042 2908 
541.624 656.34 42.2 FZD1.VPSYLNYHFLGEK.+3y10+2. (Light) 5971 2623 
544.307 701.869 42.2 FZD1.VPSYLNYHFLGEK.+3y11+2. (Heavy) 3701 2230 
541.624 699.856 42.2 FZD1.VPSYLNYHFLGEK.+3y11+2. (Light) 12139 1722 
544.307 750.395 42.2 FZD1.VPSYLNYHFLGEK.+3y12+2. (Heavy) 6180 2558 
541.624 748.383 42.2 FZD1.VPSYLNYHFLGEK.+3y12+2. (Light) 81899 14524 
544.307 625.386 42.2 FZD1.VPSYLNYHFLGEK.+3y5. (Heavy) 4372 2398 
541.624 621.361 42.2 FZD1.VPSYLNYHFLGEK.+3y5. (Light) 6978 3550 
544.307 1039.551 42.2 FZD1.VPSYLNYHFLGEK.+3y8. (Heavy) 951 475 
541.624 1035.526 42.2 FZD1.VPSYLNYHFLGEK.+3y8. (Light) 488 241 
739.919 1133.635 24.5 GLI3.GQQEQPEGTTLVK.+2y10. (Heavy) 168 13 
735.894 1129.61 24.5 GLI3.GQQEQPEGTTLVK.+2y10. (Light) 414 326 
739.919 1261.694 24.5 GLI3.GQQEQPEGTTLVK.+2y11. (Heavy) 155 30 
735.894 1257.668 24.5 GLI3.GQQEQPEGTTLVK.+2y11. (Light) 161 #N/A 
739.919 779.481 24.5 GLI3.GQQEQPEGTTLVK.+2y7. (Heavy) 497 251 
735.894 775.456 24.5 GLI3.GQQEQPEGTTLVK.+2y7. (Light) 298 166 
739.919 876.534 24.5 GLI3.GQQEQPEGTTLVK.+2y8. (Heavy) 404 343 
735.894 872.509 24.5 GLI3.GQQEQPEGTTLVK.+2y8. (Light) 368 251 
739.919 1004.592 24.5 GLI3.GQQEQPEGTTLVK.+2y9. (Heavy) 1362 1645 
735.894 1000.567 24.5 GLI3.GQQEQPEGTTLVK.+2y9. (Light) 247 133 
486.952 762.448 28 GLI3.IKPDEDLPSPGAR.+3b6. (Heavy) 2414 1846 
484.268 754.398 28 GLI3.IKPDEDLPSPGAR.+3b6. (Light) 4925 3112 
486.952 875.532 28 GLI3.IKPDEDLPSPGAR.+3b7. (Heavy) 819 535 
484.268 867.482 28 GLI3.IKPDEDLPSPGAR.+3b7. (Light) 1520 1207 
486.952 577.278 28 GLI3.IKPDEDLPSPGAR.+3y11+2. (Heavy) 5315 3681 
484.268 577.278 28 GLI3.IKPDEDLPSPGAR.+3y11+2. (Light) 6321 5971 
486.952 584.315 28 GLI3.IKPDEDLPSPGAR.+3y6. (Heavy) 6794 3590 
484.268 584.315 28 GLI3.IKPDEDLPSPGAR.+3y6. (Light) 15094 12531 
486.952 812.426 28 GLI3.IKPDEDLPSPGAR.+3y8. (Heavy) 1107 1117 
484.268 812.426 28 GLI3.IKPDEDLPSPGAR.+3y8. (Light) 2091 1446 
774.438 1116.637 44.3 GLI3.TSPNSLVTILNNSR.+2y10. (Heavy) 602 130 
772.426 1116.637 44.3 GLI3.TSPNSLVTILNNSR.+2y10. (Light) 1751 1282 
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774.438 1230.68 44.3 GLI3.TSPNSLVTILNNSR.+2y11. (Heavy) 468 213 
772.426 1230.68 44.3 GLI3.TSPNSLVTILNNSR.+2y11. (Light) 320 220 
774.438 817.453 44.3 GLI3.TSPNSLVTILNNSR.+2y7. (Heavy) 1293 941 
772.426 817.453 44.3 GLI3.TSPNSLVTILNNSR.+2y7. (Light) 1293 374 
774.438 916.521 44.3 GLI3.TSPNSLVTILNNSR.+2y8. (Heavy) 1053 928 
772.426 916.521 44.3 GLI3.TSPNSLVTILNNSR.+2y8. (Light) 847 485 
774.438 1029.605 44.3 GLI3.TSPNSLVTILNNSR.+2y9. (Heavy) 438 253 
772.426 1029.605 44.3 GLI3.TSPNSLVTILNNSR.+2y9. (Light) 480 299 
663.751 1116.681 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y10. (Heavy) 1139 2072 
659.726 1112.656 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y10. (Light) 863 540 
663.751 865.039 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y15+2. (Heavy) 2469 1251 
659.726 861.014 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y15+2. (Light) 1676 1226 
663.751 775.486 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y7. (Heavy) 9639 6552 
659.726 771.461 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y7. (Light) 2971 1875 
663.751 890.513 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y8. (Heavy) 4419 2516 
659.726 886.488 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y8. (Light) 2605 1947 
663.751 1003.597 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y9. (Heavy) 2333 1797 
659.726 999.572 50.6 GSK3B.DIKPQNLLLDPDTAVLK.+3y9. (Light) 2465 1198 
712.687 977.428 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y10. (Heavy) 643 457 
711.345 977.428 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y10. (Light) 519 470 
712.687 1078.476 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y11. (Heavy) 82 #N/A 
711.345 1078.476 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y11. (Light) 498 99 
712.687 748.322 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y7. (Heavy) 244 207 
711.345 748.322 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y7. (Light) 195 91 
712.687 835.354 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y8. (Heavy) 197 242 
711.345 835.354 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y8. (Light) 229 160 
712.687 906.391 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y9. (Heavy) 185 57 
711.345 906.391 23 GSK3B.IQAAASTPTNATAASDANTGDR.+3y9. (Light) 329 213 
751.945 1087.608 37.1 GSK3B.VIGNGSFGVVYQAK.+2y10. (Heavy) 1541 1209 
747.919 1083.583 37.1 GSK3B.VIGNGSFGVVYQAK.+2y10. (Light) 17113 10383 
751.945 1258.673 37.1 GSK3B.VIGNGSFGVVYQAK.+2y12. (Heavy) 1557 988 
747.919 1254.648 37.1 GSK3B.VIGNGSFGVVYQAK.+2y12. (Light) 838 322 
751.945 796.487 37.1 GSK3B.VIGNGSFGVVYQAK.+2y7. (Heavy) 1217 933 
747.919 792.461 37.1 GSK3B.VIGNGSFGVVYQAK.+2y7. (Light) 1043 708 
751.945 943.555 37.1 GSK3B.VIGNGSFGVVYQAK.+2y8. (Heavy) 1646 1283 
747.919 939.53 37.1 GSK3B.VIGNGSFGVVYQAK.+2y8. (Light) 900 667 
751.945 1030.587 37.1 GSK3B.VIGNGSFGVVYQAK.+2y9. (Heavy) 3715 2345 
747.919 1026.562 37.1 GSK3B.VIGNGSFGVVYQAK.+2y9. (Light) 1042 768 
772.39 1164.531 30 HES1.FLSTCEGVNTEVR.+2y10. (Heavy) 1002 794 
770.377 1164.531 30 HES1.FLSTCEGVNTEVR.+2y10. (Light) 1166 975 
772.39 1251.563 30 HES1.FLSTCEGVNTEVR.+2y11. (Heavy) 3239 2704 
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770.377 1251.563 30 HES1.FLSTCEGVNTEVR.+2y11. (Light) 2395 2193 
772.39 774.41 30 HES1.FLSTCEGVNTEVR.+2y7. (Heavy) 2338 1232 
770.377 774.41 30 HES1.FLSTCEGVNTEVR.+2y7. (Light) 4047 3788 
772.39 903.453 30 HES1.FLSTCEGVNTEVR.+2y8. (Heavy) 2129 1563 
770.377 903.453 30 HES1.FLSTCEGVNTEVR.+2y8. (Light) 3082 2842 
772.39 1063.484 30 HES1.FLSTCEGVNTEVR.+2y9. (Heavy) 1070 984 
770.377 1063.484 30 HES1.FLSTCEGVNTEVR.+2y9. (Light) 2689 1908 
498.302 507.307 8 HES1.LGSQAGEAAK.+2y5. (Heavy) 11 #N/A 
494.277 503.282 8 HES1.LGSQAGEAAK.+2y5. (Light) 16 7 
498.302 578.345 8 HES1.LGSQAGEAAK.+2y6. (Heavy) 11 #N/A 
494.277 574.32 8 HES1.LGSQAGEAAK.+2y6. (Light) 16 8 
498.302 706.403 8 HES1.LGSQAGEAAK.+2y7. (Heavy) 18 6 
494.277 702.378 8 HES1.LGSQAGEAAK.+2y7. (Light) #N/A #N/A 
498.302 793.435 8 HES1.LGSQAGEAAK.+2y8. (Heavy) 11 0 
494.277 789.41 8 HES1.LGSQAGEAAK.+2y8. (Light) 11 0 
498.302 850.457 8 HES1.LGSQAGEAAK.+2y9. (Heavy) 41 37 
494.277 846.432 8 HES1.LGSQAGEAAK.+2y9. (Light) 64 51 
722.412 1318.782 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y12. (Heavy) 464 272 
718.386 1310.731 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y12. (Light) 5139 7363 
722.412 781.455 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y15+2. (Heavy) 1610 1018 
718.386 777.43 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y15+2. (Light) 2120 1791 
722.412 879.516 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y17+2. (Heavy) 6225 6103 
718.386 875.491 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y17+2. (Light) 7550 10137 
722.412 923.032 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y18+2. (Heavy) 771 579 
718.386 919.007 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y18+2. (Light) 650 157 
722.412 966.548 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y19+2. (Heavy) 610 229 
718.386 962.523 27.1 HES1.NSSSPVAATPASVNTTPDKPK.+3y19+2. (Light) 871 439 
417.577 524.78 26.2 HEY1.LGSAHPEAPALR.+3y10+2. (Heavy) 2100 1501 
416.235 524.78 26.2 HEY1.LGSAHPEAPALR.+3y10+2. (Light) 1382 1327 
417.577 553.291 26.2 HEY1.LGSAHPEAPALR.+3y11+2. (Heavy) 2954 1657 
416.235 553.291 26.2 HEY1.LGSAHPEAPALR.+3y11+2. (Light) 1795 1192 
417.577 527.33 26.2 HEY1.LGSAHPEAPALR.+3y5. (Heavy) 1247 153 
416.235 527.33 26.2 HEY1.LGSAHPEAPALR.+3y5. (Light) 2971 2697 
417.577 753.425 26.2 HEY1.LGSAHPEAPALR.+3y7. (Heavy) 612 209 
416.235 753.425 26.2 HEY1.LGSAHPEAPALR.+3y7. (Light) 1019 585 
417.577 445.746 26.2 HEY1.LGSAHPEAPALR.+3y8+2. (Heavy) 5511 3587 
416.235 445.746 26.2 HEY1.LGSAHPEAPALR.+3y8+2. (Light) 10660 10262 
478.598 810.477 24.2 HEY1.LVSHLNNYASQR.+3b7. (Heavy) 205 89 
477.256 806.452 24.2 HEY1.LVSHLNNYASQR.+3b7. (Light) 353 193 
478.598 595.289 24.2 HEY1.LVSHLNNYASQR.+3y10+2. (Heavy) 356 284 
477.256 595.289 24.2 HEY1.LVSHLNNYASQR.+3y10+2. (Light) 945 949 
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478.598 644.823 24.2 HEY1.LVSHLNNYASQR.+3y11+2. (Heavy) 695 324 
477.256 644.823 24.2 HEY1.LVSHLNNYASQR.+3y11+2. (Light) 1432 1078 
478.598 624.31 24.2 HEY1.LVSHLNNYASQR.+3y5. (Heavy) 847 506 
477.256 624.31 24.2 HEY1.LVSHLNNYASQR.+3y5. (Light) 1186 1423 
478.598 965.48 24.2 HEY1.LVSHLNNYASQR.+3y8. (Heavy) 281 224 
477.256 965.48 24.2 HEY1.LVSHLNNYASQR.+3y8. (Light) 412 283 
847.469 1072.527 58 HEY1.YLSIIEGLDASDPLR.+2y10. (Heavy) 4484 2722 
845.457 1072.527 58 HEY1.YLSIIEGLDASDPLR.+2y10. (Light) 1389 598 
847.469 1185.611 58 HEY1.YLSIIEGLDASDPLR.+2y11. (Heavy) 970 579 
845.457 1185.611 58 HEY1.YLSIIEGLDASDPLR.+2y11. (Light) 1078 525 
847.469 1385.727 58 HEY1.YLSIIEGLDASDPLR.+2y13. (Heavy) 692 428 
845.457 1385.727 58 HEY1.YLSIIEGLDASDPLR.+2y13. (Light) 792 506 
847.469 886.463 58 HEY1.YLSIIEGLDASDPLR.+2y8. (Heavy) 983 820 
845.457 886.463 58 HEY1.YLSIIEGLDASDPLR.+2y8. (Light) 1021 641 
847.469 943.484 58 HEY1.YLSIIEGLDASDPLR.+2y9. (Heavy) 2060 1433 
845.457 943.484 58 HEY1.YLSIIEGLDASDPLR.+2y9. (Light) 941 688 
561.801 589.33 27.8 INHBA.EGSDLSVVER.+2y5. (Heavy) 3940 2890 
559.788 589.33 27.8 INHBA.EGSDLSVVER.+2y5. (Light) 14650 9092 
561.801 702.414 27.8 INHBA.EGSDLSVVER.+2y6. (Heavy) 66474 41149 
559.788 702.414 27.8 INHBA.EGSDLSVVER.+2y6. (Light) 43850 25604 
561.801 817.441 27.8 INHBA.EGSDLSVVER.+2y7. (Heavy) 1766 852 
559.788 817.441 27.8 INHBA.EGSDLSVVER.+2y7. (Light) 1641 1308 
561.801 904.473 27.8 INHBA.EGSDLSVVER.+2y8. (Heavy) 2034 1226 
559.788 904.473 27.8 INHBA.EGSDLSVVER.+2y8. (Light) 2448 1639 
561.801 961.495 27.8 INHBA.EGSDLSVVER.+2y9. (Heavy) 2072 1726 
559.788 961.495 27.8 INHBA.EGSDLSVVER.+2y9. (Light) 2658 1800 
654.008 767.398 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3b7. (Heavy) 8974 10135 
651.325 763.373 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3b7. (Light) 14986 16127 
654.008 925.468 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3b9. (Heavy) 1749 1036 
651.325 921.442 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3b9. (Light) 2077 1769 
654.008 706.428 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y6. (Heavy) 4974 8265 
651.325 702.403 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y6. (Light) 5673 5106 
654.008 777.465 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y7. (Heavy) 2987 2424 
651.325 773.44 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y7. (Light) 3105 1106 
654.008 906.508 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y8. (Heavy) 1777 852 
651.325 902.483 29.2 INHBA.HPQGSLDTGEEAEEVGLK.+3y8. (Light) 1621 1144 
491.817 588.391 30 INHBA.SELLLSEK.+2b5. (Heavy) 7133 4569 
487.792 584.365 30 INHBA.SELLLSEK.+2b5. (Light) 25824 33718 
491.817 508.328 30 INHBA.SELLLSEK.+2y4. (Heavy) 10791 8208 
487.792 504.303 30 INHBA.SELLLSEK.+2y4. (Light) 8500 7563 
491.817 621.412 30 INHBA.SELLLSEK.+2y5. (Heavy) 11239 9245 
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487.792 617.387 30 INHBA.SELLLSEK.+2y5. (Light) 24206 18452 
491.817 734.496 30 INHBA.SELLLSEK.+2y6. (Heavy) 9327 16701 
487.792 730.471 30 INHBA.SELLLSEK.+2y6. (Light) 12454 9613 
491.817 863.539 30 INHBA.SELLLSEK.+2y7. (Heavy) 1653 1163 
487.792 859.513 30 INHBA.SELLLSEK.+2y7. (Light) 2041 1582 
640.882 679.408 30 LFTY1.EHLGPLASGAHK.+2b6. (Heavy) 2870 2288 
636.857 675.382 30 LFTY1.EHLGPLASGAHK.+2b6. (Light) 5085 2969 
640.882 444.287 30 LFTY1.EHLGPLASGAHK.+2y4. (Heavy) 5674 4523 
636.857 440.262 30 LFTY1.EHLGPLASGAHK.+2y4. (Light) 27378 22316 
640.882 531.319 30 LFTY1.EHLGPLASGAHK.+2y5. (Heavy) 2409 1161 
636.857 527.294 30 LFTY1.EHLGPLASGAHK.+2y5. (Light) 3056 2446 
640.882 602.356 30 LFTY1.EHLGPLASGAHK.+2y6. (Heavy) 6018 3794 
636.857 598.331 30 LFTY1.EHLGPLASGAHK.+2y6. (Light) 4389 2671 
640.882 435.261 30 LFTY1.EHLGPLASGAHK.+2y9+2. (Heavy) 2309 1939 
636.857 433.248 30 LFTY1.EHLGPLASGAHK.+2y9+2. (Light) 2287 1837 
734.445 783.455 44 LFTY1.LPPNSELVQAVLR.+2b7. (Heavy) 1823 388 
732.433 779.43 44 LFTY1.LPPNSELVQAVLR.+2b7. (Light) 1246 718 
734.445 1128.637 44 LFTY1.LPPNSELVQAVLR.+2y10. (Heavy) 611 352 
732.433 1128.637 44 LFTY1.LPPNSELVQAVLR.+2y10. (Light) 713 355 
734.445 798.52 44 LFTY1.LPPNSELVQAVLR.+2y7. (Heavy) 1409 1070 
732.433 798.52 44 LFTY1.LPPNSELVQAVLR.+2y7. (Light) 1013 794 
734.445 927.562 44 LFTY1.LPPNSELVQAVLR.+2y8. (Heavy) 667 401 
732.433 927.562 44 LFTY1.LPPNSELVQAVLR.+2y8. (Light) 806 573 
734.445 1014.594 44 LFTY1.LPPNSELVQAVLR.+2y9. (Heavy) 640 431 
732.433 1014.594 44 LFTY1.LPPNSELVQAVLR.+2y9. (Light) 1697 2400 
656.916 1152.71 40.5 LFTY1.QPLLLQVSVQR.+2y10. (Heavy) 74917 42010 
654.904 1152.71 40.5 LFTY1.QPLLLQVSVQR.+2y10. (Light) 137282 102665 
656.916 716.405 40.5 LFTY1.QPLLLQVSVQR.+2y6. (Heavy) 5802 4447 
654.904 716.405 40.5 LFTY1.QPLLLQVSVQR.+2y6. (Light) 6719 4542 
656.916 829.489 40.5 LFTY1.QPLLLQVSVQR.+2y7. (Heavy) 2453 1593 
654.904 829.489 40.5 LFTY1.QPLLLQVSVQR.+2y7. (Light) 4873 3155 
656.916 942.573 40.5 LFTY1.QPLLLQVSVQR.+2y8. (Heavy) 2420 1205 
654.904 942.573 40.5 LFTY1.QPLLLQVSVQR.+2y8. (Light) 1049 876 
656.916 1055.657 40.5 LFTY1.QPLLLQVSVQR.+2y9. (Heavy) 7578 4648 
654.904 1055.657 40.5 LFTY1.QPLLLQVSVQR.+2y9. (Light) 1628 1100 
456.273 504.271 3.3 NANOG.NSNGVTQK.+2b5. (Heavy) 216 121 
452.248 500.246 3.3 NANOG.NSNGVTQK.+2b5. (Light) 185 66 
456.273 507.344 3.3 NANOG.NSNGVTQK.+2y4. (Heavy) 323 195 
452.248 503.319 3.3 NANOG.NSNGVTQK.+2y4. (Light) 185 87 
456.273 564.365 3.3 NANOG.NSNGVTQK.+2y5. (Heavy) 149 81 
452.248 560.34 3.3 NANOG.NSNGVTQK.+2y5. (Light) 183 105 
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456.273 678.408 3.3 NANOG.NSNGVTQK.+2y6. (Heavy) 98 51 
452.248 674.383 3.3 NANOG.NSNGVTQK.+2y6. (Light) 171 98 
456.273 765.44 3.3 NANOG.NSNGVTQK.+2y7. (Heavy) 173 76 
452.248 761.415 3.3 NANOG.NSNGVTQK.+2y7. (Light) 529 292 
836.437 1205.594 41.8 NANOG.TVFSSTQLCVLNDR.+2y10. (Heavy) 780 510 
834.425 1205.594 41.8 NANOG.TVFSSTQLCVLNDR.+2y10. (Light) 1038 905 
836.437 1292.626 41.8 NANOG.TVFSSTQLCVLNDR.+2y11. (Heavy) 557 58 
834.425 1292.626 41.8 NANOG.TVFSSTQLCVLNDR.+2y11. (Light) 1109 917 
836.437 889.456 41.8 NANOG.TVFSSTQLCVLNDR.+2y7. (Heavy) 814 264 
834.425 889.456 41.8 NANOG.TVFSSTQLCVLNDR.+2y7. (Light) 1507 735 
836.437 1017.515 41.8 NANOG.TVFSSTQLCVLNDR.+2y8. (Heavy) 801 802 
834.425 1017.515 41.8 NANOG.TVFSSTQLCVLNDR.+2y8. (Light) 648 334 
836.437 1118.562 41.8 NANOG.TVFSSTQLCVLNDR.+2y9. (Heavy) 1049 1070 
834.425 1118.562 41.8 NANOG.TVFSSTQLCVLNDR.+2y9. (Light) 1189 725 
789.102 1196.719 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y10. (Heavy) 402 152 
786.419 1192.694 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y10. (Light) 430 326 
789.102 1325.761 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y11. (Heavy) 1269 2295 
786.419 1321.736 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y11. (Light) 394 230 
789.102 928.99 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y15+2. (Heavy) 730 483 
786.419 926.977 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y15+2. (Light) 549 273 
789.102 1029.048 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y17+2. (Heavy) 1205 2336 
786.419 1027.035 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y17+2. (Light) 827 609 
789.102 1083.635 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y9. (Heavy) 1304 1255 
786.419 1079.609 58.7 NANOG.YLSLQQMQELSNILNLSYK.+3y9. (Light) 762 648 
958 1242.655 46 NODAL.GQPSSPSPLAYMLSLYR.+2y10. (Heavy) 1112 487 
955.988 1242.655 46 NODAL.GQPSSPSPLAYMLSLYR.+2y10. (Light) 438 312 
958 1329.687 46 NODAL.GQPSSPSPLAYMLSLYR.+2y11. (Heavy) 427 289 
955.988 1329.687 46 NODAL.GQPSSPSPLAYMLSLYR.+2y11. (Light) 409 242 
958 1426.74 46 NODAL.GQPSSPSPLAYMLSLYR.+2y12. (Heavy) 209 95 
955.988 1426.74 46 NODAL.GQPSSPSPLAYMLSLYR.+2y12. (Light) 243 140 
958 1513.772 46 NODAL.GQPSSPSPLAYMLSLYR.+2y13. (Heavy) 126 #N/A 
955.988 1513.772 46 NODAL.GQPSSPSPLAYMLSLYR.+2y13. (Light) 180 66 
958 1032.518 46 NODAL.GQPSSPSPLAYMLSLYR.+2y8. (Heavy) 529 361 
955.988 1032.518 46 NODAL.GQPSSPSPLAYMLSLYR.+2y8. (Light) 384 235 
787.447 1183.578 30 NODAL.TKPLSMLYVDNGR.+2y10. (Heavy) 805 916 
783.421 1183.578 30 NODAL.TKPLSMLYVDNGR.+2y10. (Light) 665 390 
787.447 1280.63 30 NODAL.TKPLSMLYVDNGR.+2y11. (Heavy) #N/A #N/A 
783.421 1280.63 30 NODAL.TKPLSMLYVDNGR.+2y11. (Light) 1646 849 
787.447 836.426 30 NODAL.TKPLSMLYVDNGR.+2y7. (Heavy) 1039 310 
783.421 836.426 30 NODAL.TKPLSMLYVDNGR.+2y7. (Light) 958 749 
787.447 983.461 30 NODAL.TKPLSMLYVDNGR.+2y8. (Heavy) 1830 1628 
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783.421 983.461 30 NODAL.TKPLSMLYVDNGR.+2y8. (Light) 793 501 
787.447 1070.494 30 NODAL.TKPLSMLYVDNGR.+2y9. (Heavy) 1305 1681 
783.421 1070.494 30 NODAL.TKPLSMLYVDNGR.+2y9. (Light) 1262 548 
591.827 606.358 31 NODAL.VPSTCCAPVK.+2y5. (Heavy) 2477 1438 
587.802 602.333 31 NODAL.VPSTCCAPVK.+2y5. (Light) 4482 3417 
591.827 766.389 31 NODAL.VPSTCCAPVK.+2y6. (Heavy) 9100 8185 
587.802 762.364 31 NODAL.VPSTCCAPVK.+2y6. (Light) 3415 2183 
591.827 867.436 31 NODAL.VPSTCCAPVK.+2y7. (Heavy) 2823 2086 
587.802 863.411 31 NODAL.VPSTCCAPVK.+2y7. (Light) 2266 1869 
591.827 954.469 31 NODAL.VPSTCCAPVK.+2y8. (Heavy) 1996 1049 
587.802 950.443 31 NODAL.VPSTCCAPVK.+2y8. (Light) 6317 7662 
591.827 1051.521 31 NODAL.VPSTCCAPVK.+2y9. (Heavy) 5421 5650 
587.802 1047.496 31 NODAL.VPSTCCAPVK.+2y9. (Light) 5625 5442 
686.342 1211.529 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y10. (Heavy) 2436 1951 
685.001 1211.529 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y10. (Light) 13616 17751 
686.342 712.344 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y12+2. (Heavy) 2041 928 
685.001 712.344 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y12+2. (Light) 3591 4895 
686.342 761.878 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y13+2. (Heavy) 1424 787 
685.001 761.878 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y13+2. (Light) 2262 1212 
686.342 810.405 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y14+2. (Heavy) 1447 1070 
685.001 810.405 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y14+2. (Light) 2424 2159 
686.342 874.926 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y15+2. (Heavy) 1125 1062 
685.001 874.926 43.6 NOTC1.FEEPVVLPDLDDQTDHR.+3y15+2. (Light) 1015 800 
655.866 646.315 42.3 NOTC1.GSIVYLEIDNR.+2y5. (Heavy) 64694 29189 
653.854 646.315 42.3 NOTC1.GSIVYLEIDNR.+2y5. (Light) 33977 14088 
655.866 759.4 42.3 NOTC1.GSIVYLEIDNR.+2y6. (Heavy) 3959 2235 
653.854 759.4 42.3 NOTC1.GSIVYLEIDNR.+2y6. (Light) 7049 3457 
655.866 922.463 42.3 NOTC1.GSIVYLEIDNR.+2y7. (Heavy) 2458 1646 
653.854 922.463 42.3 NOTC1.GSIVYLEIDNR.+2y7. (Light) 4593 3409 
655.866 1021.531 42.3 NOTC1.GSIVYLEIDNR.+2y8. (Heavy) 2722 1715 
653.854 1021.531 42.3 NOTC1.GSIVYLEIDNR.+2y8. (Light) 3419 978 
655.866 1134.615 42.3 NOTC1.GSIVYLEIDNR.+2y9. (Heavy) 5156 1662 
653.854 1134.615 42.3 NOTC1.GSIVYLEIDNR.+2y9. (Light) 4289 1593 
824.939 1287.68 45 NOTC1.NGGTCDLLTLTEYK.+2y10. (Heavy) 758 238 
820.914 1283.655 45 NOTC1.NGGTCDLLTLTEYK.+2y10. (Light) 774 844 
824.939 1388.728 45 NOTC1.NGGTCDLLTLTEYK.+2y11. (Heavy) 7735 3748 
820.914 1384.703 45 NOTC1.NGGTCDLLTLTEYK.+2y11. (Light) 583 526 
824.939 899.539 45 NOTC1.NGGTCDLLTLTEYK.+2y7. (Heavy) 2285 1213 
820.914 895.513 45 NOTC1.NGGTCDLLTLTEYK.+2y7. (Light) 2476 1563 
824.939 1012.623 45 NOTC1.NGGTCDLLTLTEYK.+2y8. (Heavy) 2799 2047 
820.914 1008.598 45 NOTC1.NGGTCDLLTLTEYK.+2y8. (Light) 1064 863 
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824.939 1127.65 45 NOTC1.NGGTCDLLTLTEYK.+2y9. (Heavy) 1549 604 
820.914 1123.625 45 NOTC1.NGGTCDLLTLTEYK.+2y9. (Light) 1163 801 
365.565 463.322 26.2 P53.LGFLHSGTAK.+3b4. (Heavy) 3470 1488 
362.882 459.297 26.2 P53.LGFLHSGTAK.+3b4. (Light) 1037 872 
365.565 495.307 26.2 P53.LGFLHSGTAK.+3y5. (Heavy) 1036 869 
362.882 491.282 26.2 P53.LGFLHSGTAK.+3y5. (Light) 731 223 
365.565 632.366 26.2 P53.LGFLHSGTAK.+3y6. (Heavy) 544 432 
362.882 628.341 26.2 P53.LGFLHSGTAK.+3y6. (Light) 1316 1872 
365.565 446.763 26.2 P53.LGFLHSGTAK.+3y8+2. (Heavy) 2646 2655 
362.882 444.751 26.2 P53.LGFLHSGTAK.+3y8+2. (Light) 734 413 
365.565 475.274 26.2 P53.LGFLHSGTAK.+3y9+2. (Heavy) 1086 1109 
362.882 473.261 26.2 P53.LGFLHSGTAK.+3y9+2. (Light) 2938 2165 
700.749 839.602 54.4 P53.RPILTIITLEDSSGNLLGR.+3b7. (Heavy) 1246 866 
699.407 835.576 54.4 P53.RPILTIITLEDSSGNLLGR.+3b7. (Light) 1910 1985 
700.749 1047.506 54.4 P53.RPILTIITLEDSSGNLLGR.+3y10. (Heavy) 2679 2733 
699.407 1047.506 54.4 P53.RPILTIITLEDSSGNLLGR.+3y10. (Light) 1864 1378 
700.749 716.405 54.4 P53.RPILTIITLEDSSGNLLGR.+3y7. (Heavy) 5253 3496 
699.407 716.405 54.4 P53.RPILTIITLEDSSGNLLGR.+3y7. (Light) 1856 1433 
700.749 803.437 54.4 P53.RPILTIITLEDSSGNLLGR.+3y8. (Heavy) 1308 957 
699.407 803.437 54.4 P53.RPILTIITLEDSSGNLLGR.+3y8. (Light) 3577 1871 
700.749 918.464 54.4 P53.RPILTIITLEDSSGNLLGR.+3y9. (Heavy) 6835 2548 
699.407 918.464 54.4 P53.RPILTIITLEDSSGNLLGR.+3y9. (Light) 160536 61571 
702.886 831.385 28.5 P53.SVTCTYSPALNK.+2b7. (Heavy) 1246 866 
698.861 827.36 28.5 P53.SVTCTYSPALNK.+2b7. (Light) 1910 1985 
702.886 1186.607 28.5 P53.SVTCTYSPALNK.+2y10. (Heavy) 2679 2733 
698.861 1182.582 28.5 P53.SVTCTYSPALNK.+2y10. (Light) 1864 1378 
702.886 824.481 28.5 P53.SVTCTYSPALNK.+2y7. (Heavy) 5253 3496 
698.861 820.456 28.5 P53.SVTCTYSPALNK.+2y7. (Light) 1856 1433 
702.886 925.529 28.5 P53.SVTCTYSPALNK.+2y8. (Heavy) 1308 957 
698.861 921.504 28.5 P53.SVTCTYSPALNK.+2y8. (Light) 3577 1871 
702.886 1085.56 28.5 P53.SVTCTYSPALNK.+2y9. (Heavy) 6835 2548 
698.861 1081.535 28.5 P53.SVTCTYSPALNK.+2y9. (Light) 160536 61571 
573.854 968.539 44 PO5F1.FEALQLSFK.+2b8. (Heavy) 2844 1272 
569.829 964.514 44 PO5F1.FEALQLSFK.+2b8. (Light) 15455 5875 
573.854 654.412 44 PO5F1.FEALQLSFK.+2y5. (Heavy) 10167 2837 
569.829 650.387 44 PO5F1.FEALQLSFK.+2y5. (Light) 3611 2333 
573.854 767.496 44 PO5F1.FEALQLSFK.+2y6. (Heavy) 3295 1439 
569.829 763.471 44 PO5F1.FEALQLSFK.+2y6. (Light) 3905 1991 
573.854 838.533 44 PO5F1.FEALQLSFK.+2y7. (Heavy) 4649 2124 
569.829 834.508 44 PO5F1.FEALQLSFK.+2y7. (Light) 7975 2881 
573.854 967.576 44 PO5F1.FEALQLSFK.+2y8. (Heavy) 4567 2301 
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569.829 963.551 44 PO5F1.FEALQLSFK.+2y8. (Light) 49186 7871 
747.4 1219.61 23 PO5F1.LEQNPEESQDIK.+2y10. (Heavy) 82 #N/A 
743.375 1215.585 23 PO5F1.LEQNPEESQDIK.+2y10. (Light) 203 95 
747.4 751.413 23 PO5F1.LEQNPEESQDIK.+2y6. (Heavy) 395 379 
743.375 747.388 23 PO5F1.LEQNPEESQDIK.+2y6. (Light) 470 267 
747.4 880.456 23 PO5F1.LEQNPEESQDIK.+2y7. (Heavy) #N/A #N/A 
743.375 876.431 23 PO5F1.LEQNPEESQDIK.+2y7. (Light) 126 91 
747.4 977.509 23 PO5F1.LEQNPEESQDIK.+2y8. (Heavy) 112 4 
743.375 973.484 23 PO5F1.LEQNPEESQDIK.+2y8. (Light) 130 49 
747.4 1091.552 23 PO5F1.LEQNPEESQDIK.+2y9. (Heavy) 93 #N/A 
743.375 1087.527 23 PO5F1.LEQNPEESQDIK.+2y9. (Light) 139 51 
1028.001 1293.641 34.1 PO5F1.WVEEADNNENLQEICK.+2y10. (Heavy) 453 209 
1023.975 1289.615 34.1 PO5F1.WVEEADNNENLQEICK.+2y10. (Light) 673 333 
1028.001 1408.667 34.1 PO5F1.WVEEADNNENLQEICK.+2y11. (Heavy) 317 363 
1023.975 1404.642 34.1 PO5F1.WVEEADNNENLQEICK.+2y11. (Light) 332 250 
1028.001 1479.705 34.1 PO5F1.WVEEADNNENLQEICK.+2y12. (Heavy) 243 178 
1023.975 1475.679 34.1 PO5F1.WVEEADNNENLQEICK.+2y12. (Light) 469 197 
1028.001 1065.555 34.1 PO5F1.WVEEADNNENLQEICK.+2y8. (Heavy) 572 425 
1023.975 1061.53 34.1 PO5F1.WVEEADNNENLQEICK.+2y8. (Light) 437 274 
1028.001 1179.598 34.1 PO5F1.WVEEADNNENLQEICK.+2y9. (Heavy) 296 176 
1023.975 1175.573 34.1 PO5F1.WVEEADNNENLQEICK.+2y9. (Light) 501 271 
752.937 1064.573 31.7 PTC1.LPTPSPEPPPSVVR.+2y10. (Heavy) 636 333 
750.925 1064.573 31.7 PTC1.LPTPSPEPPPSVVR.+2y10. (Light) 972 731 
752.937 1161.626 31.7 PTC1.LPTPSPEPPPSVVR.+2y11. (Heavy) 920 772 
750.925 1161.626 31.7 PTC1.LPTPSPEPPPSVVR.+2y11. (Light) 809 642 
752.937 1262.674 31.7 PTC1.LPTPSPEPPPSVVR.+2y12. (Heavy) 1130 905 
750.925 1262.674 31.7 PTC1.LPTPSPEPPPSVVR.+2y12. (Light) 1390 1779 
752.937 880.489 31.7 PTC1.LPTPSPEPPPSVVR.+2y8. (Heavy) 1010 874 
750.925 880.489 31.7 PTC1.LPTPSPEPPPSVVR.+2y8. (Light) 1723 1239 
752.937 977.541 31.7 PTC1.LPTPSPEPPPSVVR.+2y9. (Heavy) 4641 4913 
750.925 977.541 31.7 PTC1.LPTPSPEPPPSVVR.+2y9. (Light) 878 634 
704.671 786.384 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y13+2. (Heavy) 2936 1413 
703.329 786.384 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y13+2. (Light) 2819 1727 
704.671 843.897 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y14+2. (Heavy) 1252 658 
703.329 843.897 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y14+2. (Light) 1765 838 
704.671 925.429 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y15+2. (Heavy) 811 472 
703.329 925.429 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y15+2. (Light) 2655 1777 
704.671 837.41 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y7. (Heavy) 1661 1048 
703.329 837.41 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y7. (Light) 871 712 
704.671 1000.473 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y8. (Heavy) 2514 951 
703.329 1000.473 28.2 PTC1.TEYDPHTHVYYTTAEPR.+3y8. (Light) 2617 2253 
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661.365 679.87 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y12+2. (Heavy) 1661 1530 
658.681 677.857 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y12+2. (Light) 3268 2963 
661.365 729.404 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y13+2. (Heavy) 1137 736 
658.681 727.392 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y13+2. (Light) 4284 4965 
661.365 793.925 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y14+2. (Heavy) 1222 720 
658.681 791.913 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y14+2. (Light) 2367 1998 
661.365 843.46 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y15+2. (Heavy) 3618 4172 
658.681 841.447 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y15+2. (Light) 6171 8053 
661.365 808.446 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y7. (Heavy) 1207 587 
658.681 804.421 27.7 PTC1.TYVEVVHQSVAQNSTQK.+3y7. (Light) 2303 1899 
662.032 690.851 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y12+2. (Heavy) 3381 4600 
659.349 690.851 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y12+2. (Light) 1700 1406 
662.032 770.926 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y13+2. (Heavy) 826 577 
659.349 768.914 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y13+2. (Light) 1024 570 
662.032 821.45 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y14+2. (Heavy) 1480 803 
659.349 819.438 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y14+2. (Light) 1579 1145 
662.032 902.982 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y15+2. (Heavy) 917 636 
659.349 900.969 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y15+2. (Light) 2804 2424 
662.032 799.431 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y7. (Heavy) 1349 644 
659.349 799.431 38.1 SFRP1.FYTKPPQCVDIPADLR.+3y7. (Light) 1280 991 
626.662 795.892 45.3 SFRP1.SEAIIEHLCASEFALR.+3b14+2. (Heavy) 3398 3048 
625.321 793.88 45.3 SFRP1.SEAIIEHLCASEFALR.+3b14+2. (Light) 6101 4652 
626.662 666.822 45.3 SFRP1.SEAIIEHLCASEFALR.+3y11+2. (Heavy) 2317 2328 
625.321 666.822 45.3 SFRP1.SEAIIEHLCASEFALR.+3y11+2. (Light) 2360 2108 
626.662 723.364 45.3 SFRP1.SEAIIEHLCASEFALR.+3y12+2. (Heavy) 19293 23448 
625.321 723.364 45.3 SFRP1.SEAIIEHLCASEFALR.+3y12+2. (Light) 16059 18132 
626.662 953.451 45.3 SFRP1.SEAIIEHLCASEFALR.+3y8. (Heavy) 2181 2444 
625.321 953.451 45.3 SFRP1.SEAIIEHLCASEFALR.+3y8. (Light) 2564 2598 
626.662 1066.535 45.3 SFRP1.SEAIIEHLCASEFALR.+3y9. (Heavy) 1365 1593 
625.321 1066.535 45.3 SFRP1.SEAIIEHLCASEFALR.+3y9. (Light) 1602 739 
413.263 429.312 31.2 SFRP1.SQYLLTAIHK.+3y3. (Heavy) 10321 10353 
410.58 425.287 31.2 SFRP1.SQYLLTAIHK.+3y3. (Light) 42335 38654 
413.263 500.349 31.2 SFRP1.SQYLLTAIHK.+3y4. (Heavy) 2076 2261 
410.58 496.324 31.2 SFRP1.SQYLLTAIHK.+3y4. (Light) 15996 8904 
413.263 601.397 31.2 SFRP1.SQYLLTAIHK.+3y5. (Heavy) 2773 1368 
410.58 597.372 31.2 SFRP1.SQYLLTAIHK.+3y5. (Light) 4761 2755 
413.263 714.481 31.2 SFRP1.SQYLLTAIHK.+3y6. (Heavy) 1481 838 
410.58 710.456 31.2 SFRP1.SQYLLTAIHK.+3y6. (Light) 2926 1787 
413.263 495.818 31.2 SFRP1.SQYLLTAIHK.+3y8+2. (Heavy) 5389 3201 
410.58 493.805 31.2 SFRP1.SQYLLTAIHK.+3y8+2. (Light) 5953 4699 
938.096 1168.633 41.5 
SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y10. 
(Heavy) 8428 3038 
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935.413 1164.608 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y10. (Light) 8753 2452 
938.096 1281.717 41.5 
SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y11. 
(Heavy) 646 296 
935.413 1277.692 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y11. (Light) 1790 399 
938.096 1038.473 41.5 
SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y17+2. 
(Heavy) 750 335 
935.413 1036.46 41.5 
SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y17+2. 
(Light) 692 416 
938.096 983.553 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y8. (Heavy) 963 589 
935.413 979.528 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y8. (Light) 979 397 
938.096 1054.59 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y9. (Heavy) 1278 762 
935.413 1050.565 41.5 SFRP2.DSLQCTCEEMNDINAPYLVMGQK.+3y9. (Light) 828 392 
882.514 1133.669 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y10. (Heavy) 3463 3625 
878.489 1129.644 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y10. (Light) 6234 5917 
882.514 1261.728 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y11. (Heavy) 736 388 
878.489 1257.702 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y11. (Light) 3462 2549 
882.514 934.573 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y7. (Heavy) 845 550 
878.489 930.548 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y7. (Light) 4431 5013 
882.514 1005.61 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y8. (Heavy) 1059 960 
878.489 1001.585 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y8. (Light) 3431 2081 
882.514 1062.632 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y9. (Heavy) 2121 1303 
878.489 1058.607 53.6 SFRP2.EVLEQAGAWIPLVMK.+2y9. (Light) 1235 744 
444.931 594.323 30.1 SFRP2.LPNLLGHETMK.+3y10+2. (Heavy) 119515 55316 
442.248 592.311 30.1 SFRP2.LPNLLGHETMK.+3y10+2. (Light) 10624 5882 
444.931 556.295 30.1 SFRP2.LPNLLGHETMK.+3y4. (Heavy) 9164 6349 
442.248 552.27 30.1 SFRP2.LPNLLGHETMK.+3y4. (Light) 9422 5198 
444.931 750.375 30.1 SFRP2.LPNLLGHETMK.+3y6. (Heavy) 17247 9213 
442.248 746.35 30.1 SFRP2.LPNLLGHETMK.+3y6. (Light) 7230 5192 
444.931 863.459 30.1 SFRP2.LPNLLGHETMK.+3y7. (Heavy) 909 658 
442.248 859.434 30.1 SFRP2.LPNLLGHETMK.+3y7. (Light) 1117 964 
444.931 545.797 30.1 SFRP2.LPNLLGHETMK.+3y9+2. (Heavy) 4250 2746 
442.248 543.784 30.1 SFRP2.LPNLLGHETMK.+3y9+2. (Light) 3842 2407 
814.463 1252.687 47.5 SHH.ELTPNYNPDIIFK.+2y10. (Heavy) 610 341 
810.438 1248.662 47.5 SHH.ELTPNYNPDIIFK.+2y10. (Light) 840 589 
814.463 1353.735 47.5 SHH.ELTPNYNPDIIFK.+2y11. (Heavy) 733 577 
810.438 1349.71 47.5 SHH.ELTPNYNPDIIFK.+2y11. (Light) 560 419 
814.463 878.528 47.5 SHH.ELTPNYNPDIIFK.+2y7. (Heavy) 1300 1205 
810.438 874.503 47.5 SHH.ELTPNYNPDIIFK.+2y7. (Light) 781 467 
814.463 1041.592 47.5 SHH.ELTPNYNPDIIFK.+2y8. (Heavy) 1023 569 
810.438 1037.567 47.5 SHH.ELTPNYNPDIIFK.+2y8. (Light) 877 805 
814.463 1155.635 47.5 SHH.ELTPNYNPDIIFK.+2y9. (Heavy) 13883 20771 
810.438 1151.609 47.5 SHH.ELTPNYNPDIIFK.+2y9. (Light) 674 482 
660.427 966.609 33.5 SHH.LAHALLAALAPAR.+2y10. (Heavy) 1848 893 
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658.414 966.609 33.5 SHH.LAHALLAALAPAR.+2y10. (Light) 2123 999 
660.427 1103.668 33.5 SHH.LAHALLAALAPAR.+2y11. (Heavy) 15405 8384 
658.414 1103.668 33.5 SHH.LAHALLAALAPAR.+2y11. (Light) 2559 1472 
660.427 669.404 33.5 SHH.LAHALLAALAPAR.+2y7. (Heavy) 2560 1375 
658.414 669.404 33.5 SHH.LAHALLAALAPAR.+2y7. (Light) 1732 703 
660.427 782.488 33.5 SHH.LAHALLAALAPAR.+2y8. (Heavy) 31412 15568 
658.414 782.488 33.5 SHH.LAHALLAALAPAR.+2y8. (Light) 2673 1469 
660.427 895.572 33.5 SHH.LAHALLAALAPAR.+2y9. (Heavy) 1153 753 
658.414 895.572 33.5 SHH.LAHALLAALAPAR.+2y9. (Light) 1373 343 
652.003 780.874 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3b15+2. (Heavy) 1300 1251 
649.319 778.862 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3b15+2. (Light) 8064 4608 
652.003 658.859 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y13+2. (Heavy) 2686 2732 
649.319 656.846 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y13+2. (Light) 2311 997 
652.003 707.385 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y14+2. (Heavy) 2419 2725 
649.319 705.373 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y14+2. (Light) 18091 11863 
652.003 780.92 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y15+2. (Heavy) 1338 1725 
649.319 778.907 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y15+2. (Light) 6996 5227 
652.003 901.504 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y8. (Heavy) 2715 1944 
649.319 897.479 29.4 SHH.SGGCFPGSATVHLEQGGTK.+3y8. (Light) 2998 1799 
928.526 1045.655 49 SMO.DYVLCQANVTIGLPTK.+2y10. (Heavy) 687 327 
924.5 1041.63 49 SMO.DYVLCQANVTIGLPTK.+2y10. (Light) 626 170 
928.526 1173.714 49 SMO.DYVLCQANVTIGLPTK.+2y11. (Heavy) 441 279 
924.5 1169.689 49 SMO.DYVLCQANVTIGLPTK.+2y11. (Light) 424 136 
928.526 1333.745 49 SMO.DYVLCQANVTIGLPTK.+2y12. (Heavy) 652 229 
924.5 1329.719 49 SMO.DYVLCQANVTIGLPTK.+2y12. (Light) 387 198 
928.526 1446.829 49 SMO.DYVLCQANVTIGLPTK.+2y13. (Heavy) 390 289 
924.5 1442.804 49 SMO.DYVLCQANVTIGLPTK.+2y13. (Light) 1304 997 
928.526 974.618 49 SMO.DYVLCQANVTIGLPTK.+2y9. (Heavy) 574 380 
924.5 970.593 49 SMO.DYVLCQANVTIGLPTK.+2y9. (Light) 1546 1301 
762.892 1144.578 31 SMO.FNSSGQCEVPLVR.+2y10. (Heavy) 997 755 
760.88 1144.578 31 SMO.FNSSGQCEVPLVR.+2y10. (Light) 1366 708 
762.892 1231.61 31 SMO.FNSSGQCEVPLVR.+2y11. (Heavy) 821 821 
760.88 1231.61 31 SMO.FNSSGQCEVPLVR.+2y11. (Light) 2059 1326 
762.892 872.466 31 SMO.FNSSGQCEVPLVR.+2y7. (Heavy) 1499 721 
760.88 872.466 31 SMO.FNSSGQCEVPLVR.+2y7. (Light) 1238 963 
762.892 1000.524 31 SMO.FNSSGQCEVPLVR.+2y8. (Heavy) 1362 748 
760.88 1000.524 31 SMO.FNSSGQCEVPLVR.+2y8. (Light) 641 442 
762.892 1057.546 31 SMO.FNSSGQCEVPLVR.+2y9. (Heavy) 986 956 
760.88 1057.546 31 SMO.FNSSGQCEVPLVR.+2y9. (Light) 1601 1214 
616.32 913.449 16.9 SMO.GAASSGNATGPGPR.+2y10. (Heavy) #N/A #N/A 
614.307 913.449 16.9 SMO.GAASSGNATGPGPR.+2y10. (Light) 41 34 
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616.32 1000.481 16.9 SMO.GAASSGNATGPGPR.+2y11. (Heavy) #N/A #N/A 
614.307 1000.481 16.9 SMO.GAASSGNATGPGPR.+2y11. (Light) 32 22 
616.32 1071.518 16.9 SMO.GAASSGNATGPGPR.+2y12. (Heavy) 68 67 
614.307 1071.518 16.9 SMO.GAASSGNATGPGPR.+2y12. (Light) 65 45 
616.32 769.395 16.9 SMO.GAASSGNATGPGPR.+2y8. (Heavy) #N/A #N/A 
614.307 769.395 16.9 SMO.GAASSGNATGPGPR.+2y8. (Light) 29 12 
616.32 826.417 16.9 SMO.GAASSGNATGPGPR.+2y9. (Heavy) 29 12 
614.307 826.417 16.9 SMO.GAASSGNATGPGPR.+2y9. (Light) #N/A #N/A 
749.914 951.541 28 SUFU.GIETDGSNLSGVSAK.+2y10. (Heavy) 5368 3245 
745.888 947.516 28 SUFU.GIETDGSNLSGVSAK.+2y10. (Light) 2368 2696 
749.914 1066.568 28 SUFU.GIETDGSNLSGVSAK.+2y11. (Heavy) 1574 951 
745.888 1062.543 28 SUFU.GIETDGSNLSGVSAK.+2y11. (Light) 1396 922 
749.914 1167.615 28 SUFU.GIETDGSNLSGVSAK.+2y12. (Heavy) 2264 1510 
745.888 1163.59 28 SUFU.GIETDGSNLSGVSAK.+2y12. (Light) 1354 564 
749.914 1296.658 28 SUFU.GIETDGSNLSGVSAK.+2y13. (Heavy) 1132 691 
745.888 1292.633 28 SUFU.GIETDGSNLSGVSAK.+2y13. (Light) 575 #N/A 
749.914 807.487 28 SUFU.GIETDGSNLSGVSAK.+2y8. (Heavy) 3372 2347 
745.888 803.462 28 SUFU.GIETDGSNLSGVSAK.+2y8. (Light) 2345 1477 
646.066 1115.727 38.8 SUFU.GLEINSKPVLPPINPQR.+3b10. (Heavy) 10225 9258 
643.382 1107.677 38.8 SUFU.GLEINSKPVLPPINPQR.+3b10. (Light) 5824 8164 
646.066 746.451 38.8 SUFU.GLEINSKPVLPPINPQR.+3y13+2. (Heavy) 2798 1680 
643.382 744.438 38.8 SUFU.GLEINSKPVLPPINPQR.+3y13+2. (Light) 6742 6532 
646.066 802.993 38.8 SUFU.GLEINSKPVLPPINPQR.+3y14+2. (Heavy) 1582 896 
643.382 800.98 38.8 SUFU.GLEINSKPVLPPINPQR.+3y14+2. (Light) 2020 964 
646.066 724.41 38.8 SUFU.GLEINSKPVLPPINPQR.+3y6. (Heavy) 5441 4648 
643.382 724.41 38.8 SUFU.GLEINSKPVLPPINPQR.+3y6. (Light) 17332 22087 
646.066 821.463 38.8 SUFU.GLEINSKPVLPPINPQR.+3y7. (Heavy) 2036 1358 
643.382 821.463 38.8 SUFU.GLEINSKPVLPPINPQR.+3y7. (Light) 47486 60552 
745.034 976.467 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3b9. (Heavy) 682 366 
743.692 972.442 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3b9. (Light) 1942 1425 
745.034 812.43 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y6. (Heavy) 2624 2013 
743.692 812.43 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y6. (Light) 1300 718 
745.034 869.452 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y7. (Heavy) 721 639 
743.692 869.452 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y7. (Light) 671 512 
745.034 1016.52 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y8. (Heavy) 1390 1158 
743.692 1016.52 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y8. (Light) 1384 849 
745.034 1073.542 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y9. (Heavy) 722 331 
743.692 1073.542 50.9 SUFU.VHEFTGTDGPSGFGFELTFR.+3y9. (Light) 1044 679 
614.321 746.407 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y12+2. (Heavy) 1308 1193 
612.979 746.407 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y12+2. (Light) 1898 1494 
614.321 789.923 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y13+2. (Heavy) 1447 1309 
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612.979 789.923 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y13+2. (Light) 1523 801 
614.321 847.436 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y14+2. (Heavy) 5918 7002 
612.979 847.436 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y14+2. (Light) 11517 20480 
614.321 838.489 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y7. (Heavy) 2522 1130 
612.979 838.489 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y7. (Light) 6122 8927 
614.321 1095.591 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y9. (Heavy) 4601 3170 
612.979 1095.591 37.6 TDGF1.DDSIWPQEEPAIRPR.+3y9. (Light) 2088 1306 
812.967 1195.706 69 TDGF1.FSYSVIWIMAISK.+2y10. (Heavy) 212 87 
808.941 1191.681 69 TDGF1.FSYSVIWIMAISK.+2y10. (Light) 166 89 
812.967 1358.769 69 TDGF1.FSYSVIWIMAISK.+2y11. (Heavy) 107 68 
808.941 1354.744 69 TDGF1.FSYSVIWIMAISK.+2y11. (Light) 42 14 
812.967 896.521 69 TDGF1.FSYSVIWIMAISK.+2y7. (Heavy) 291 268 
808.941 892.496 69 TDGF1.FSYSVIWIMAISK.+2y7. (Light) 166 112 
812.967 1009.605 69 TDGF1.FSYSVIWIMAISK.+2y8. (Heavy) 255 155 
808.941 1005.58 69 TDGF1.FSYSVIWIMAISK.+2y8. (Light) 175 108 
812.967 1108.674 69 TDGF1.FSYSVIWIMAISK.+2y9. (Heavy) 320 199 
808.941 1104.649 69 TDGF1.FSYSVIWIMAISK.+2y9. (Light) 277 240 
500.292 570.344 23.5 TDGF1.TPELPPSAR.+2b5. (Heavy) 1108 664 
498.28 566.318 23.5 TDGF1.TPELPPSAR.+2b5. (Light) 535 356 
500.292 527.294 23.5 TDGF1.TPELPPSAR.+2y5. (Heavy) 1094 1034 
498.28 527.294 23.5 TDGF1.TPELPPSAR.+2y5. (Light) 437 419 
500.292 640.378 23.5 TDGF1.TPELPPSAR.+2y6. (Heavy) 424 261 
498.28 640.378 23.5 TDGF1.TPELPPSAR.+2y6. (Light) 649 485 
500.292 769.42 23.5 TDGF1.TPELPPSAR.+2y7. (Heavy) 377 214 
498.28 769.42 23.5 TDGF1.TPELPPSAR.+2y7. (Light) 188 118 
500.292 866.473 23.5 TDGF1.TPELPPSAR.+2y8. (Heavy) 143 63 
498.28 866.473 23.5 TDGF1.TPELPPSAR.+2y8. (Light) 251 188 
713.422 1136.643 44.4 WIF1.ASVVQVGFPCLGK.+2y10. (Heavy) 1153 666 
709.397 1132.618 44.4 WIF1.ASVVQVGFPCLGK.+2y10. (Light) 1461 887 
713.422 753.427 44.4 WIF1.ASVVQVGFPCLGK.+2y6. (Heavy) 1657 1123 
709.397 749.401 44.4 WIF1.ASVVQVGFPCLGK.+2y6. (Light) 4692 3615 
713.422 810.448 44.4 WIF1.ASVVQVGFPCLGK.+2y7. (Heavy) 2529 1526 
709.397 806.423 44.4 WIF1.ASVVQVGFPCLGK.+2y7. (Light) 4300 4552 
713.422 909.516 44.4 WIF1.ASVVQVGFPCLGK.+2y8. (Heavy) 779 443 
709.397 905.491 44.4 WIF1.ASVVQVGFPCLGK.+2y8. (Light) 1027 397 
713.422 1037.575 44.4 WIF1.ASVVQVGFPCLGK.+2y9. (Heavy) 3484 3038 
709.397 1033.55 44.4 WIF1.ASVVQVGFPCLGK.+2y9. (Light) 1713 804 
728.307 910.37 29.5 WIF1.TCQQAECPGGCR.+2b7. (Heavy) 2666 1178 
726.295 906.344 29.5 WIF1.TCQQAECPGGCR.+2b7. (Light) 5647 3023 
728.307 1162.473 29.5 WIF1.TCQQAECPGGCR.+2y10. (Heavy) 1308 1111 
726.295 1162.473 29.5 WIF1.TCQQAECPGGCR.+2y10. (Light) 6387 4786 
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728.307 835.319 29.5 WIF1.TCQQAECPGGCR.+2y7. (Heavy) 2004 1409 
726.295 835.319 29.5 WIF1.TCQQAECPGGCR.+2y7. (Light) 4416 3721 
728.307 906.356 29.5 WIF1.TCQQAECPGGCR.+2y8. (Heavy) 2610 1793 
726.295 906.356 29.5 WIF1.TCQQAECPGGCR.+2y8. (Light) 4463 2615 
728.307 1034.414 29.5 WIF1.TCQQAECPGGCR.+2y9. (Heavy) 1935 1516 
726.295 1034.414 29.5 WIF1.TCQQAECPGGCR.+2y9. (Light) 1793 1300 
913.044 1134.655 73 WIF1.VLIGFEEDILIVSEGK.+2y10. (Heavy) 380 292 
909.019 1130.63 73 WIF1.VLIGFEEDILIVSEGK.+2y10. (Light) 236 141 
913.044 1263.698 73 WIF1.VLIGFEEDILIVSEGK.+2y11. (Heavy) 218 180 
909.019 1259.673 73 WIF1.VLIGFEEDILIVSEGK.+2y11. (Light) 211 132 
913.044 1410.766 73 WIF1.VLIGFEEDILIVSEGK.+2y12. (Heavy) 146 87 
909.019 1406.741 73 WIF1.VLIGFEEDILIVSEGK.+2y12. (Light) 98 66 
913.044 1467.788 73 WIF1.VLIGFEEDILIVSEGK.+2y13. (Heavy) 116 73 
909.019 1463.763 73 WIF1.VLIGFEEDILIVSEGK.+2y13. (Light) 101 90 
913.044 1005.613 73 WIF1.VLIGFEEDILIVSEGK.+2y9. (Heavy) 277 229 
909.019 1001.588 73 WIF1.VLIGFEEDILIVSEGK.+2y9. (Light) 218 170 
1079.968 1239.491 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y10. (Heavy) 272 159 
1077.955 1239.491 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y10. (Light) 296 153 
1079.968 1352.576 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y11. (Heavy) 363 269 
1077.955 1352.576 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y11. (Light) 294 208 
1079.968 1423.613 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y12. (Heavy) 243 157 
1077.955 1423.613 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y12. (Light) 248 147 
1079.968 1067.443 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y8. (Heavy) 3569 4746 
1077.955 1067.443 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y8. (Light) 460 255 
1079.968 1124.465 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y9. (Heavy) 271 260 
1077.955 1124.465 38.7 WNT1.ACNSSSPALDGCELLCCGR.+2y9. (Light) 385 328 
670.703 1085.57 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y11. (Heavy) 1244 913 
669.362 1085.57 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y11. (Light) 801 402 
670.703 708.883 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y14+2. (Heavy) 1903 816 
669.362 708.883 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y14+2. (Light) 3578 4492 
670.703 765.425 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y15+2. (Heavy) 12970 18311 
669.362 765.425 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y15+2. (Light) 22196 32111 
670.703 838.96 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y16+2. (Heavy) 1337 582 
669.362 838.96 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y16+2. (Light) 2395 1518 
670.703 874.478 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y17+2. (Heavy) 2273 951 
669.362 874.478 53.4 WNT1.ETAFIFAITSAGVTHSVAR.+3y17+2. (Light) 3529 4428 
618.016 1060.575 36 WNT1.QNPGILHSVSGGLQSAVR.+3y11. (Heavy) 19455 9672 
616.674 1060.575 36 WNT1.QNPGILHSVSGGLQSAVR.+3y11. (Light) 11551 6526 
618.016 655.862 36 WNT1.QNPGILHSVSGGLQSAVR.+3y13+2. (Heavy) 1951 1292 
616.674 655.862 36 WNT1.QNPGILHSVSGGLQSAVR.+3y13+2. (Light) 1609 1076 
618.016 789.442 36 WNT1.QNPGILHSVSGGLQSAVR.+3y16+2. (Heavy) 5901 4378 
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616.674 789.442 36 WNT1.QNPGILHSVSGGLQSAVR.+3y16+2. (Light) 7174 3795 
618.016 787.442 36 WNT1.QNPGILHSVSGGLQSAVR.+3y8. (Heavy) 2981 4815 
616.674 787.442 36 WNT1.QNPGILHSVSGGLQSAVR.+3y8. (Light) 10926 17916 
618.016 874.474 36 WNT1.QNPGILHSVSGGLQSAVR.+3y9. (Heavy) 3163 1694 
616.674 874.474 36 WNT1.QNPGILHSVSGGLQSAVR.+3y9. (Light) 2914 2104 
422.539 486.243 29 WNT2.CHGVSGSCTLR.+3b4. (Heavy) 8003 3935 
421.197 482.218 29 WNT2.CHGVSGSCTLR.+3b4. (Light) 62773 157898 
422.539 630.297 29 WNT2.CHGVSGSCTLR.+3b6. (Heavy) 2582 2064 
421.197 626.271 29 WNT2.CHGVSGSCTLR.+3b6. (Light) 1537 1439 
422.539 717.329 29 WNT2.CHGVSGSCTLR.+3b7. (Heavy) 1052 1631 
421.197 713.304 29 WNT2.CHGVSGSCTLR.+3b7. (Light) 1566 990 
422.539 549.281 29 WNT2.CHGVSGSCTLR.+3y4. (Heavy) 5791 4583 
421.197 549.281 29 WNT2.CHGVSGSCTLR.+3y4. (Light) 2806 1576 
422.539 636.313 29 WNT2.CHGVSGSCTLR.+3y5. (Heavy) 22317 13235 
421.197 636.313 29 WNT2.CHGVSGSCTLR.+3y5. (Light) 1965 1449 
604.956 746.857 30.5 WNT2.CQDCLEALDVHTCK.+3y12+2. (Heavy) 5998 2988 
602.272 744.845 30.5 WNT2.CQDCLEALDVHTCK.+3y12+2. (Light) 4664 3280 
604.956 791.402 30.5 WNT2.CQDCLEALDVHTCK.+3y6. (Heavy) 10899 11394 
602.272 787.377 30.5 WNT2.CQDCLEALDVHTCK.+3y6. (Light) 4463 3458 
604.956 904.486 30.5 WNT2.CQDCLEALDVHTCK.+3y7. (Heavy) 9573 10542 
602.272 900.461 30.5 WNT2.CQDCLEALDVHTCK.+3y7. (Light) 8104 7580 
604.956 975.523 30.5 WNT2.CQDCLEALDVHTCK.+3y8. (Heavy) 1134 917 
602.272 971.498 30.5 WNT2.CQDCLEALDVHTCK.+3y8. (Light) 1345 1099 
604.956 1104.566 30.5 WNT2.CQDCLEALDVHTCK.+3y9. (Heavy) 1007 781 
602.272 1100.541 30.5 WNT2.CQDCLEALDVHTCK.+3y9. (Light) 4244 3994 
1010.556 1020.584 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y10. (Heavy) 143 83 
1008.544 1020.584 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y10. (Light) 145 85 
1010.556 1107.616 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y11. (Heavy) 181 96 
1008.544 1107.616 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y11. (Light) 169 91 
1010.556 1220.7 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y12. (Heavy) 83 65 
1008.544 1220.7 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y12. (Light) 90 62 
1010.556 1291.737 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y13. (Heavy) 151 113 
1008.544 1291.737 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y13. (Light) 105 74 
1010.556 1454.8 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y14. (Heavy) 112 32 
1008.544 1454.8 77.3 WNT2.ESAFVYAISSAGVVFAITR.+2y14. (Light) 162 104 
646.024 978.537 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y10. (Heavy) 2093 903 
644.683 978.537 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y10. (Light) 1717 1328 
646.024 593.341 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y5. (Heavy) 3249 2312 
644.683 593.341 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y5. (Light) 3011 1611 
646.024 664.378 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y6. (Heavy) 2015 1522 
644.683 664.378 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y6. (Light) 3095 1794 
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646.024 763.446 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y7. (Heavy) 3020 1883 
644.683 763.446 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y7. (Light) 2139 1059 
646.024 820.468 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y8. (Heavy) 3815 3093 
644.683 820.468 50.5 WNT3A.ESAFVHAIASAGVAFAVTR.+3y8. (Light) 5634 4016 
483.252 651.804 27.6 WNT3A.IGIQECQHQFR.+3y10+2. (Heavy) 8945 10061 
481.91 651.804 27.6 WNT3A.IGIQECQHQFR.+3y10+2. (Light) 8140 6325 
483.252 587.305 27.6 WNT3A.IGIQECQHQFR.+3y4. (Heavy) 2132 1409 
481.91 587.305 27.6 WNT3A.IGIQECQHQFR.+3y4. (Light) 5848 3726 
483.252 502.722 27.6 WNT3A.IGIQECQHQFR.+3y7+2. (Heavy) 12367 11934 
481.91 502.722 27.6 WNT3A.IGIQECQHQFR.+3y7+2. (Light) 4488 2241 
483.252 566.751 27.6 WNT3A.IGIQECQHQFR.+3y8+2. (Heavy) 2939 2126 
481.91 566.751 27.6 WNT3A.IGIQECQHQFR.+3y8+2. (Light) 7593 6772 
483.252 623.293 27.6 WNT3A.IGIQECQHQFR.+3y9+2. (Heavy) 3353 1732 
481.91 623.293 27.6 WNT3A.IGIQECQHQFR.+3y9+2. (Light) 4619 3912 
809.85 1139.493 21.9 WNT3A.SCAEGTAAICGCSSR.+2y11. (Heavy) 113 #N/A 
807.837 1139.493 21.9 WNT3A.SCAEGTAAICGCSSR.+2y11. (Light) 169 103 
809.85 1268.536 21.9 WNT3A.SCAEGTAAICGCSSR.+2y12. (Heavy) 56 1 
807.837 1268.536 21.9 WNT3A.SCAEGTAAICGCSSR.+2y12. (Light) 2 #N/A 
809.85 839.35 21.9 WNT3A.SCAEGTAAICGCSSR.+2y7. (Heavy) 252 194 
807.837 839.35 21.9 WNT3A.SCAEGTAAICGCSSR.+2y7. (Light) 57 #N/A 
809.85 910.387 21.9 WNT3A.SCAEGTAAICGCSSR.+2y8. (Heavy) 171 57 
807.837 910.387 21.9 WNT3A.SCAEGTAAICGCSSR.+2y8. (Light) 490 508 
809.85 981.424 21.9 WNT3A.SCAEGTAAICGCSSR.+2y9. (Heavy) 339 246 
807.837 981.424 21.9 WNT3A.SCAEGTAAICGCSSR.+2y9. (Light) 9127 11601 
997.003 1078.531 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y11. (Heavy) 562 208 
994.991 1078.531 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y11. (Light) 518 214 
997.003 1177.599 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y12. (Heavy) 445 422 
994.991 1177.599 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y12. (Light) 258 204 
997.003 1248.636 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y13. (Heavy) 380 316 
994.991 1248.636 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y13. (Light) 333 219 
997.003 1411.7 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y14. (Heavy) 409 232 
994.991 1411.7 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y14. (Light) 213 81 
997.003 1512.748 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y15. (Heavy) 206 122 
994.991 1512.748 41.9 WNT5A.ETAFTYAVSAAGVVNAMSR.+2y15. (Light) 129 28 
1260.107 1221.557 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y10. (Heavy) 883 581 
1258.094 1221.557 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y10. (Light) 332 270 
1260.107 1384.62 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y11. (Heavy) 303 207 
1258.094 1384.62 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y11. (Light) 158 91 
1260.107 1483.689 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y12. (Heavy) 212 140 
1258.094 1483.689 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y12. (Light) 354 172 
1260.107 993.446 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y8. (Heavy) 473 266 
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1258.094 993.446 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y8. (Light) 311 244 
1260.107 1108.473 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y9. (Heavy) 372 170 
1258.094 1108.473 48 WNT5A.FNSPTTQDLVYIDPSPDYCVR.+2y9. (Light) 436 257 
619.817 963.485 3.4 WNT5A.NESTGSLGTQGR.+2y10. (Heavy) 71 50 
617.805 963.485 3.4 WNT5A.NESTGSLGTQGR.+2y10. (Light) 185 104 
619.817 631.352 3.4 WNT5A.NESTGSLGTQGR.+2y6. (Heavy) 169 65 
617.805 631.352 3.4 WNT5A.NESTGSLGTQGR.+2y6. (Light) 133 70 
619.817 718.384 3.4 WNT5A.NESTGSLGTQGR.+2y7. (Heavy) 285 267 
617.805 718.384 3.4 WNT5A.NESTGSLGTQGR.+2y7. (Light) 161 99 
619.817 775.406 3.4 WNT5A.NESTGSLGTQGR.+2y8. (Heavy) 114 46 
617.805 775.406 3.4 WNT5A.NESTGSLGTQGR.+2y8. (Light) 241 150 
619.817 876.453 3.4 WNT5A.NESTGSLGTQGR.+2y9. (Heavy) 39 26 
617.805 876.453 3.4 WNT5A.NESTGSLGTQGR.+2y9. (Light) 306 135 
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